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Chapter 1 
1.1. General introduction 
When a micro-organism penetrates the body, defensive mechanisms of the non-specific innate 
immune system come into play, such as soluble chemical factors (bactericidal lysozyme, 
acute phase proteins, interferons), extracellular killing (NK cells, eosinophils), and 
phagocytosis (macrophages, polymorphonuclear neutrophils). This innate immune system is 
supported by the specific acquired immune system which comprises of B- and T-
lymphocytes. These lymphocytes are educated to distinguish between self (host) and non-self 
(foreign) molecules by means of specific receptors on their cell surface and are further 
endowed with specific memory. B lymphocytes, called so because they differentiate in the 
bone marrow, participate in the immune response by producing antibodies that fix to antigen 
by their specific recognition site. These antibodies can mediate different functions, including 
opsonization, complement activation, antibody-dependent cell mediated cytolysis and 
neutrophil, basophil, or eosinophil activation. T cells, designated thus because they 
differentiate in the thymus, control the activation of cells of the innate and acquired immune 
system by producing lymphokines and playa role in killing aberrant cells such as virally 
infected cells and some tumour cells. 
Although we generally benefit from the actions of the immune system, there is an other side 
of the coin. When a diseased organ is replaced by a healthy transplant of another individual 
(not being the recipients identical twin-brother or sister), the cells of this transplant are 
regarded as non-self by the immune system of the recipient. As a result, the recipient's 
immune system will bring all its power into play to get rid of this "intruder". 
To prevent allograft rejection, the immunity of the transplant recipient is reduced with 
immunosuppressive drugs which must be taken throughout the patient's life. The cumulative 
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effects of such immunosuppression, however, include opportunistic infections, cancers, and 
drug specific cytotoxicity. Therefore, a long term goal of transplant immunology is the 
development of immunotherapies that target only those cells that are involved in the rejection 
process. To achieve this goal, an extensive knowledge of the immune response towards the 
allograft is essential. 
Data obtained over the past three decades conclusively demonstrated that T·lymphocytes are 
crucial for allograft rejection. The critical role of T cells in allograft rejection was first 
established by the failure of SCID, neonatally thymectomized and congenitally athymic nude 
rodents to effect rejection (Miller, 1962; Corley and Kindred, 1977; Shelton et ai, 1992). 
Reconstitution experiments showed that T lymphocytes adoptively transferred to above 
rodents or lethally irradiated hosts were sufficient to restore rejection (Dorsch and Roser, 
1974; Hall et ai, 1978A; Shelton et ai, 1992). Furthermore, composite grafts in which 
allogeneic cells were mixed with syngeneic cells before they were engrafted into host animals 
showed that only allogeneic cells were destroyed despite the close proximity of syngeneic 
target cells (reviewed by Rosenberg, 1993). Such exquisite antigen-specificity ruled out the 
involvement of non-specific effector cells such as macrophages, NK cells, or eosinophils and 
implicated that rejection involved lymphocytes. The observation that antibodies were not 
required to destroy the allograft in these studies excluded the requirement for B-cells leaving 
only T cells as potential effector cells. Also supporting the involvement of T lymphocytes 
is the fact that accelerated rejection occurred when a second graft was transplanted into 
recipients that had already rejected a primary graft of the same type. Such accelerated 
rejection points towards the establishment of memory which is provided by lymphocytes 
(Hall et ai, 1977, 1978B). 
Peripheral T-lymphocytes can roughly be divided into two subclasses: helper T lymphocytes 
(HTL) that, upon recognition of antigen-bearing cells, start producing lymphokines which 
induce the proliferation and differentiation of various cells of the innate and acquired immune 
system; and cytotoxic T lymphocytes (CTL) that, upon recognition of antigen-bearing cells, 
bind tightly to these cells. Such interaction triggers the secretion of granules containing 
soluble lytic proteins (perforin and granzymes) leading to the lysis and nuclear degradation 
of the attached target cell. 
Although the relevance of both T cell populations has been examined extensively, obtained 
data have been far from conclusive. What has remained an open and much debated question 
is the extent to which graft destruction can be ascribed to CTL, whose direct cytotoxic 
function appears most suitable, and to what extent this function is due to HTL whose 
production oflymphokines can activate and recruit CTL but also additional effector cells such 
as macrophages and NK cells. 
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1.2. Cytotoxic T lymphocytes 
1.2.1. Involvement In transplant reJedion. 
The dispute on the requirement for CTL in allograft rejection can be ascribed to the large 
variety in experimental settings such as the type of allograft transplanted (Hao et ai, 1987; 
Krieger et ai, 1996) and the use of primed versus naive T cell subsets (reviewed by Hall, 
1991) but also to the incorrect assumption that HTL express CD4 molecules whereas CTL 
express CD8 molecules. With respect to the latter point, rejection of grafts that only differ 
at a MHC class II locus with the recipient (Simpson, 1993) and transplant rejection by CD8-
depleted animals or by CD4 +T cell transfused nude/SCID animals have generally been 
regarded as evidence against an important role of CTL in transplant rejection: However, 
CD4+T cells themselves can be cytolytic (chapter 3; Dallman and Mason, 1983; Miceli et 
ai, 1988; Erb et ai, 1990), although the extent of their activity seems to be somewhat lower 
than that of CD8+T cells (chapter 6). Moreover, In most studies, animals were depleted for 
CD8+T cells by treatment with specific mAb. Such treatment may not completely have 
eliminated CD8+T celts (reviewed by Steinmulter, 1985 and Hall, 1991). As has recently 
been shown, a unique subpopulation of CD8+T cells remained in hosts treated with CD8-
depleting mAb and these cells rejected MHC class I disparate skin grafts (Rosenberg et 
aI,1991). Consequently, conclusions drawn from such studies must be reconsidered in the 
light of the discovery that cell surface markers did not then and do not now define functional 
distinct T cel! populations and that the immunoincompetent hosts in these studies may have 
harboured CTL. Therefore, in the transplant models discussed below, the function of T cells 
has been taken into account to analyze the requirement for CTL. 
The contention that CTL are proximal mediators of graft rejection is generally based on the 
exquisite antigen-specificity of the rejection response (Sutton et ai, 1989; Martz, 1993; 
Rosenberg, 1993). For example, in a mixed population of target cells in which some cells 
express MHC molecules allogeneic to the CTL and others express MHC molecules syngeneic 
to the CTL, only those expressing allogeneic MHC are destroyed. Additionally, CTL clones 
obtained from rejecting grafts specifically lysed donor target cells in vitro and mediated graft 
destruction in vivo when injected into appropriate hosts (Snider et ai, 1986). More substantial 
evidence comes from studies in which the number of graft infiltrating CTL was estimated and 
compared with the rejection status of the allograft and from studies in which the expression 
of genes restricted principally to CTL were assessed. In this regard, graft destruction 
coincided with an accumulation of donor specific CTL in the allograft (Suitters et ai, 1990; 
Bishop et ai, 1992; Chapter 2). Likewise, mRNA for perforin and granzymes, molecules that 
may be critical to the "lethal hit" delivered by CTL, appeared to correlate with rejection of 
allogeneic grafts (Griffiths et ai, 1991; Chen et ai, 1993; Lipman et ai, 1992,1994). Also the 
observation that CTL are the preponderant lymphocytes in rejecting allografts supports the 
involvement of this subset in transplant rejection. For example, Moreau et aI. (1985) reported 
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that 13 of 16 T cell clones established from rejected human kidney allografts were cytotoxic 
to donor cells and Mayer et al. (1985) reported similar findings. 
In contrast with the previous data, Bishop and co· workers showed that CTL are not essential 
for cardiac transplant rejection (Bishop et ai, 1992; Bishop, 1993). According to their results 
the rejection response is characterized by 3 events; I. expansion of donor specific CTL 
precursors (PCTL) in the spleen and mesenteric lymph nodes; II. vascular alterations in the 
cardiac allograft; III. sequential infiltration of the graft by primed donor specific HTL 
(cHTL) followed by large numbers of primed donor specific CTL (cCTL). This large influx 
of cCTL was associated with loss of graft function. Treatment of cardiac transplant recipients 
with CD4 depleting mAb abrogated all 3 events and resulted in graft acceptance in the 
majority of mice. This observation supports a pivotal role of CD4 +T cells in the initiation 
of transplant rejection and in the expansion and maturation of donor specific CTL. Unlike 
treatment with CD4 depleting mAb, depletion of cardiac transplant recipients for CD8+T 
cells had no effect on graft survival although it totally abolished CTL reactivity. In such 
modified mice, eosinophils seemed responsible for allograft rejection (Chan et ai, 1995). 
Also the finding that 82M-knockout mice which lack CD8+T cells and can not generate CTL, 
are competent to lyse allogeneic skin grafts supports the concept that graft rejection does not 
fully depend on CTL. 
More insight into the relevance of CTL was obtained using rodents that lack T cells. 
Unmodified SCID mice that are genetically deficient of both T- and B-Iymphocytes accept 
allogeneic skin grafts indefinitely but reject the allograft after transfer of either CD4 + or 
CD8+naive T cells. This observation suggests that skin transplants can be rejected by both 
CD4+ and CD8+T lymphocytes. Subsequent limiting dilution analysis (LDA), however, 
revealed that only recipients of CD8+T lymphocytes had detectable numbers of donor specific 
CTL (Shelton et ai, 1992). In the light of the previous study, these data suggest that allograft 
destruction after CD4 +T lymphocyte transfer may involve the activation of alternative 
effector cells with cytolytic potential. Additionally, as the transfused T lymphocytes were 
naive T cells, the data show that CD8+T cells can differentiate into functional CTL without 
the requirement for any helper/inducer activity from CD4 +T cells. Such CTL which produce 
IL-2 themselves, have also been reported by others (Sprent and Schaefer, 1986; Cai and 
Sprent, 1993; Heath et al, 1993). A comparable model was described by vanBuskirk et aI. 
(1996). CD4 +T cells can be modulated by removal or addition of extracellular 1L-4 to 
differentiate into cells with direct cytolytic capacity (CD4 +CTL) or non-cytolytic IL-4 
producing cells, respectively. Using this approach, the authors showed that adoptive transfer 
of either of these CD4 +T cell subsets into SCID mice led to cardiac transplant rejection. 
The occurrence of transplant rejection in animals depleted for CTL is often regarded as 
evidence against the involvement ofCTL in transplant rejection. Above studies demonstrated 
that other cells besides CTL can function as terminal effector cells. However, as the immune 
response can readily be rerouted when pathways for important biological functions are 
blocked, such alternative effector cells may only become involved when the immune system 
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is aberrant. In line with this assumption, eosinophil infiltration appeared not to be a 
prominent feature in the unmodified murine cardiac transplant model reported by Bishop 
(1993). The existence of alternative routes for the effector and induction phase of transplant 
rejection is supported by studies on knockout mice. CD4' and CD8'knockout mice (Simpson, 
1993) as well as CD4'CD8'doubie knockout mice (Schilham, 1993) are all able to reject 
allogeneic skin grafts. In the latter mice, rejection was ascribed to CD4'CD8l'CRa6 + T 
cells, a T cell population that is not found in significant numbers in conventional mice. 
Another example is the rejection of solely MHC class I disparate grafts by CD8·depleted 
rodents. Such rejection is ascribed to B cells whose production of class I specific 
alloantibodies seems to be induced by CD4 +HTL that recognized allo-MHC class I presented 
by self-APC (Gracie et ai, 1990; Clements et ai, 1996). 
Another argument that is often held against the involvement of CTL in transplant rejection, 
is the fact that donor specific CTL can be recovered from well functioning allografts. In 
experiments where rat renal allografts are protected by donor specific blood transfusions it 
has proved possible to recover donor specific CD8+CTL from the allograft (Dallman et al, 
1987; Armstrong et ai, 1987; Ruiz et al, 1988). Likewise, studies on heart transplant patients 
demonstrated that donor specific CTL can be recovered from rejecting grafts but also from 
stable grafts (Ouwehand et al, 1993; Vaessen et al, 1994, Chapter 2,3). Presuming that CTL 
are involved in transplant rejection, the question now arises why the presence of donor 
specific CTL not automatically results in graft rejection. One explanation might be that CTL 
present within stable allografts are prevented from mediating their cytotoxic function by 
cytokines or suppressor cells. Alternatively, donor specific CTL present within the allograft 
during rejection and during stable engraftment may be quantitatively or qualitatively distinct. 
Taken together, several pathways can lead to transplant rejection. The specificity of the 
rejection response as observed in unmodified animals, however, implies the involvement of 
CTL. These CTL may depend on HTL for their activation (as is the case in the cardiac 
transplant model) or may induce their own activation (as is the case in the skin transplant 
model). 
1.2.2. Recognition of target cells. 
The major histocompatibility complex. T cells recognize foreign peptides only when these 
peptides are presented to them by molecules of the major histocompatibility complex (MHC) 
of which the human equivalent is HLA (human leucocyte antigens). The requirement for such 
co-recognition is called MHC restricted antigen recognition. MHC molecules can be divided 
in MHC class I and MHC class II molecules. MHC class I molecules (figure 1) are generally 
expressed on the surface of all nucleated cells and are composed of a heavy peptide chain of 
44 kD which is non-covalently associated with a smaller 12 kD peptide called 62-microglobin 
(82m). The class I heavy chain contains an extracellular, transmembrane, and cytoplasmic 
region. The extracellular region is divided into 3 domains named aI, a2, and a3. The a3 
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and 32m domains are conserved while the al and a2 domains are highly variable and consist 
each of four parallel 3-strands and an a-helix. When the a I and a2 domains interact, a single 
eight-stranded 3-sheet is formed which is covered by the two a-helices. The cleft between 
these two a-helices forms the peptide binding side for antigen. Almost all polymorphic 
residues of the MHC class I molecules are positioned along the cleft and are thought to 
determine the peptide binding specificity. Other functional residues are located outside the 
cleft or point away from the peptide binding side and are thought to be involved in the 
interaction of the MHC molecule with the TCR. Peptides bound in the cleft of MHC class 
I molecules are 8-9 amino acids long. 
Figure 1. Three-dimensional model for the interaction between TCR and MHC/peplide (adapted from Garcia et al, 
1996). The CDRl and CDRl regions of the TCR interact with the a·helices of the MHC molecule while its CDR3 
regions interact with the peptide (pI - P8) in the groove of the MHC molecule. 
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MHC class II molecules have a more restricted expression than MHC class I molecules. 
These molecules are expressed on B cells, cells of the macrophage-monocyte lineage, 
endothelial cells, and activated T cells. MHC class II consist of an a and a fl polypeptide 
chain of 33 and 28 kD, respectively. Each polypeptide chain has two extracellular domains 
(cd and a2; 61 and 62), as also a transmembrane and a cytoplasmic region. The most 
polymorphic domains are the al and 61 domains whereas the a2 and 62 domains are more 
conserved. Recently the crystal structure of MHC class II has been solved and it shows an 
almost identical core structure as MHC class I, the major difference being the longer length 
of the bound peptide (13-26 amino acids). In case of MHC class II, the sides of the peptide 
binding groove are formed by two a-helical structures, one of the a I-chain and one of the 
1l1-chain, while the floor is formed by eight anti-parallel 11 strands. 
After synthesis in the cell, MHC class I and class II molecules follow different intracellular 
routes and bind peptide at different moments during their route to the cell membrane. This 
results in a dichotomy of peptide presentation to T cells. MHC class I molecules present 
peptides predominantly of intracellular origin (endogenous pep tides) while MHC class II 
molecules present peptide predominantly from extracellular origin (exogenous peptides). 
There is also a dichotomy in the T cells that react with antigen presented by MHC class I 
or class II molecules. As CD8 molecules bind to a3 domains whereas CD4 molecules bind 
to 112 domains, CD8+T cells recognize (endogenous) Antigen presented by MHC class I 
molecules while CD4 +T cells recognize (exogenous) antigen presented by MHC class II 
molecules. 
The Tcell receptor. Co-recognition ofMHC plus antigen by T lymphocytes is accomplished 
by their T cell receptor (TCR). This TCR is composed of a polymorphic part involved in 
antigen recognition, and a non-polymorphic part (CD3) involved in signal transduction. The 
CD3 molecule consists of two non-covalently associated heterodimers of the ,- and a-chains 
or the ,- and 'Y-chains and a single disulphide-linked dimer containing either two I-chains or 
one I-chain and one ~-chain. About 90% of the CD3 molecules examined to date incorporate 
the l'l'-homodimer. Upon TCR ligation, specific motifs, named ITAMs (immunoreceptor 
tyrosine-based activation motifs), that are expressed in the cytoplasmic domains of the 
various CD3-chains become phosphorylated. When phosphorylated, these motifs serve as 
binding templates for several kinases involved in signalling pathways (see section on 
signalling). 
The polymorphic part of the TCR consists of two disulphide-linked chains, either an a- and 
a B·chain or a 'Y- and a a-chain which are expressed in a mutually exclusive way on 95% and 
2-5% of the T lymphocytes, respectively. The following description will focus on the 
TCRaB. The a6-chains are clonally variable and are encoded by families of variable (V), 
diversity (D), joining (J), and constant (C) gene segments which assemble by gene 
rearrangements to form an antigen specific TCR chain (Davis and Bjorkman, 1988). The 
formation of a functional a-chain requires the rearrangement of a V-region gene segment to 
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a I-region gene segment, whereas a functional B-chain is formed by rearrangements of V, 
D, and I-region gene segments. The rearranged V-I and V-D-I regions are then attached to 
their respective C regions to assemble the mature a and fi-chains. Gene rearrangement allows 
many combinations of V(D)I with C. This results in the generation of TCR diversity. The 
number of possible combinations is further enhanced by random addition of nucleotides (also 
called N-region addition) at the V-(D)-I junctions. 
The recently determined crystal structure of the TCR (Garcia et ai, 1996; Bentley, 1996) 
supports the view that the secondary and tertiary structure of the TCR resembles that of Fab 
fragments (Chothia et ai, 1988). Four regions of hypervariable amino acid sequence are 
found on both the a- and the fi-chain, three of which are analogous to the antibody 
complementarity-determining regions (CDR) which serve as the primary contact points 
between antibody and ligand. Two CDR regions on both the a- and the fi-chain (CDRla and 
CDR2a, CDRlfi and CDR2fi) are encoded by the V genes and interact with the a-helices of 
the MHC molecule. The third CDR region is encoded by the V-I junction in the a-chain 
(CDR3a) and the V-D-I junction in the fi-chain (CDR3fi) and interacts with the peptide in 
the groove of the MHC molecule. The impact of these CDR regions in TCR-MHC/peptide 
interactions has been supported by a number of studies involving mutagenesis of the TCR 
(Engel and Hedrick, 1988; Nalefski et ai, 1992). A three-dimensional model for the 
interaction between TCR and MHC/peptide is shown in figure I. This model provides a 
solution to the puzzle of how the TCR simultaneously recognizes both peptide and MHC 
determinants. 
Direct and indirect al/orecognition. MHC molecules are highly polymOl]lh and are expressed 
on all nucleated cells throughout the body. In transplant rejection, the immune response is 
mainly directed against the MHC molecules on a transplant as these generally differ from the 
MHC molecules expressed on cells of the recipient. Normally, T cells are .educated in the 
thymus to recognise nominal antigens as processed peptides presented by self-MHC 
molecules. The question now arises how T cells taught to recognise foreign peptides in a self-
MHC restricted way, can recognise allo-MHC expressed on the transplant. 
According to the available data, Iwo pathways of allorecognition exist. In the so-called 
"indirect pathway", allo-MHC or other antigens shed from the allograft are taken up by 
recipient APC, processed, and presented as allo-peptides to T cells in the context of self-
MHC molecules (reviewed by Bradley et ai, 1992; Shoskes and Wood, 1994; Sayegh et ai, 
1994; Bradley, 1996). This pathway resembles the physiological induction of an immune 
response to nominal antigen. 
In the "direct pathway", T cells recognize intact allo-MHC molecules on the surface of donor 
cells (reviewed by Lechler et ai, 1990; Sayegh et ai, 1994). CD8+T cell recognize allo-MHC 
class I while CD4 +T cells recognize allo-MHC class II. The frequency of T cells engaged 
in this form of allorecognition is about lOO-fold higher than that of T cells participating in 
indirect recognition. Depending on the similarities and differences between responder and 
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donor MHC types, two models have been put forward for the direct recognition pathway of 
alloantigen. In case the TCR binding region (Le. the upper face of the ,,-helices) of allo-
MHC molecules resembles the TCR binding region of self-MHC molecules, allo-MHC 
molecules are regarded as self-MHC molecules by the TCR on T cells. The alloresponse in 
such cases would depend on the peptide carried by the allo-MHC molecule. These peptides 
may be foreign (donor) peptides which have not previously been encountered by the 
responder T cells or, alternatively, may be non-immunogenic self-peptides. In both cases, 
binding of these peptides to allo-MHC may induce structural changes in the MHC molecule. 
Due to such conformational changes, allo-MHC molecules may mimic self-MHC molecules 
that have been altered due to their interaction with alloantigen. In support of this hypothesis 
are experimental data showing that many antigen-specific T cell clones also display 
alloreactivity. 
When the TCR binding region of allo-MHC molecules differs from that of self-MHC 
molecules, the actual ligand for the alloreactive T cells may be the MHC molecule itself. In 
such cases the peptide bound to allo-MHC may not be relevant. In support of this concept, 
alloreactive CTL that recognize empty MHC molecules have been reported. To what extent 
the TCR recognizes the endogenous peptide bound in the groove of allo-MHC and to what 
extent it recognizes epitopes of the allogeneic MHC molecule adjacent to the peptide binding 
groove is still unclear. 
Although the existence of indirect and direct pathways of antigen recognition has been 
demonstrated in various experiments, their relative contribution to transplant rejection is less 
well defined. The general consensus is that CD4 +HTL orchestrate and amplify allograft 
induced immune responses. Early after transplantation, CD4 +HTL become activated by the 
direct recognition of donor dendritic cells (DC) present within the graft. In time after 
transplantation, DC migrate out of the graft and are replaced by APC of recipient origin. In 
such circumstances, activation of CD4 +HTL would involve indirect recognition of 
alloantigen. As rejection is most frequently experienced early after transplantation, graft 
rejection is usually considered as the result of direct recognition of allogeneic MHC 
molecules by effector T cells. Recent data, however, showed that this view may be an 
oversimplification and Ihat the indirect pathway of allorecognition plays a more central role 
than expected. CD4 +HTL responding to indirectly presented allogeneic class I molecules 
were found to initiate graft rejection independent of CD8+T cells by eliciting an alloantibody 
response (Gracie et ai, 1990; Clements et ai, 1996). Sherwood and colleques (1986) reported 
that injection of APC obtained from the spleens of mice immunized with allogeneic cells 
sensitized secondary recipients to reject skin grafts in an accelerated and alloantigen-specific 
fashion. This observation suggests that indirect allorecognition may enhance the rejection 
response. Alternatively, the indirect pathway might be relevant for the induction of transplant 
unresponsiveness as preoperative blood transfusions in which the blood donor and recipient 
shared at least one MHC class IT locus were found to improve clinical renal graft survival 
(Lagaaij et ai, 1989). 
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Figure 2. Direct and indirect allorecognition. The 
TCR on a T lymphocyte either recognizes an 
a1lopeplide (A) or a self peptide (8) in the context of 
an aJlo-MHC molecule on a donor cell or an 'empty' 
allo·MHC molecule (C). Alternatively, the TCR 
recognizes a1lopeplide processed and presented by 
MHC molecules of recipient APe (0). 
1.2.3. Assessory molecules involved in CTL activation. 
When effector CTL recognize peptide antigen bound to MHC molecules on the surface of 
an allogeneic target cell, they bind tightly to form a cell-cell conjugate, their cytolytic 
machinery becomes activated, and the target cell is killed. In addition to the antigen specific 
TCR, numerous other receptors on the CTL and ligands on the target cell have been 
implicated in CTL adhesion and activation. Such receptor/ligand pairs include CD8/MHC 
class lor CD4/MHC class II, LFA-liICAM-(l, 2,3), VLA-5/fibronectin, and CD2/LFA-3. 
To study the relative contribution of each of these receptors, the reductionist method has been 
employed. For this approach, the antigen-bearing cell is replaced by an artificial cell 
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membrane onto which the ligand(s) of interest is (are) incorporated at a particular density. 
The ability of this construct to stimulate CTL adhesion and activation is then measured. 
Using this approach, Kane et ai, (1988, 1989) demonstrated that incorporation of purified 
antigen-MHC class I complexes at a density seen for intact cells resulted in degranulation of 
allogeneic CTL lines. As the release of perforin and granzymes by degranulation is an 
important mechanism by which CD8+CTL kill their target cells (Isaaz et ai, 1995; Griffiths, 
1995), this observation suggests that antigen complexed to allogeneic MHC class I molecules 
is sufficient to trigger the effector function of CTL. The MHC class I molecule is a ligand 
not only for TCR but also for CD8. Accordingly, both these molecules might be relevant for 
CTL adhesion and activation. 
To unravel the contribution of TCR and CD8 separately, an extensive study was started by 
the same group (reviewed by Mescher, 1995). To analyse the contribution of CD8 alone, the 
response of CD8 +CTL lines towards immobilized non-antigen MHC class I molecules (Le. 
molecules for which the TCR on these CTL lines is not specific) was analyzed. To examine 
the contribution of TCR alone, CTL were incubated with fluid-phase anti-TCR mAb. Both 
conditions did not result in CTL degranulation. Incubation of CTL with non-antigen MHC 
class I immobilized onto artificial cell membranes did not even result in CTL adhesion. 
However, when CTL were treated with anti-TCR mAb and subsequently incubated with 
immobilized MHC class I, both CTL adhesion and degranulation occurred. To explain these 
data it was proposed that TCR occupation, in itself, is insufficient to trigger CTL 
degranulation but provides a signal which activates adhesion of CD8 to MHC class I. Further 
data revealed that, in case of sufficient CD8/MHC class I interactions, CD8 then generates 
a co-stimulatory signal resulting in degranulation (Kane and Mescher, 1993). The relevance 
of CD8 in this testsystem was supported by the observation that antibodies against CD8 
blocked CTL degranulation. 
Although above data suggest a critical role of CD8 in CTL activation, we should bear in 
mind that these data were obtained using artificial structures as target. It has repeatedly been' 
demonstrated that some CTL can lyse whole target cells in the presence of CD8-b1ocking 
mAb suggesting that these CTL do not require CD8 to display their function. When such 
CD8-independent CTL were tested for their response against immobilized MHC class I 
(where only TCR and CD8 can contribute) they became very sensitive to CD8 blocking. This 
observation indicates that, under physiological circumstances, other receptor/ligand pairs can 
compensate for CD8/MHC class I interactions (Kane et ai, 1989). Accordingly, CD8 might 
not be the only assessory molecule that cooperates with the TCR to initiate functional CTL 
responses. 
Incubation of cloned CTL with fluid-phase anti-TCR mAb and purified fibronectin 
immobilized onto artificial cell membranes resulted in CTL adhesion and degranulation 
provided a second antibody to further cross-link the TCR was added (O'Rourke et ai, 1990). 
This observation implies that also the VLA-5/fibronectin interaction might deliver a signal 
that is co-stimulatory for degranulation. However, as stimulation by fluid-phase anti-TCR 
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mAb plus second antibody alone also resulted in a low but significant degranulation of CTL, 
the contribution of the VLA-5/fibronectin interaction might be restricted to situations in 
which the TCR alone has already partly activ~ted the signalling cascade. 
Another assessory molecule that has been considered to play an important role in T 
lymphocyte activation is CD28 (Linsley and Ledbetter, 1993; June et ai, 1994; Bluestone, 
1995). Upon binding of B7-1 or B7-2 molecules on APC, CD28 molecules are thought to 
transduce an unique signal into the T cell which stimulates its production of growth-
promoting cytokines such as IL-2. To test the involvement of CD28 on CTL activation, 
RMA-S T lymphoma cells that lack B7-1 and B7-2 were pulsed with antigen and analyzed 
for their ability to act as APC for CD8+2C T cells (Cai and Sprent, 1996). The response was 
strongly immunogenic and led to extensive specific killing of antigen-pulsed RMA-S. This 
experiment indicated that the cytolytic response of 2C cells to antigen-pulsed RMA-S cells 
does not require CD28-B7 interactions. Additional experiments, demonstrated that the 
proliferative response ofCD8+2C cells heavily dependent upon CD28-B7 interactions but that 
the requirement for these interactions could be overcome by increasing the antigen density 
on target cells. Likewise, Gervois et al. (1996) demonstrated that melanoma cells that lack 
B7 could efficiently be lysed by CTL clones but that an increase in the antigen density on 
BTmelanoma cells was required to activate cytokine production and proliferation by these 
CTL clones. In another study, Bachman et al. (1996) investigated the requirement for CD28 
co-stimulation using TCR transgenic (TCR-Tg) cells from CD28 deficient mice. This study 
demonstrated that the strength ofTCR-MHC/peptide interactions determined the requirements 
for CD28-mediated co-stimulatory signals both in vitro and in vivo. T cells required CD28 
to proliferate and to produce IL-2 upon weak TCR-MHC/peptide interactions but not upon 
strong TCR-MHC/peptide interactions. In contrast, the cytotoxic capacity of these T cells did 
not dependent on CD28 (Mak, 1994; Bachman et aI, 1996). According to these experiments, 
the CD28-B7 interaction functions to increase the strength with which a CTL interacts with 
its target cell. Such increase is not required to induce the cytotoxic machinery of CTL but 
seems to be essential for the induction of proliferation and cytokine release by CTL. 
1.2.4. Signalling events involved in CTL activation. 
Proliferation, cytokine production, and degranulation are all induced in a TCR specific 
manner. This has led to the assumption that similar signalling events may initiate the 
occurrence of these effector responses. Although a total understanding of the signalling 
events leading to T cell activation and the precise temporal order in which they occur are still 
far from complete, it is generally accepted that TCR engagement is successively coupled to 
protein tyrosine kinase (PTK) and phospholipase C (PLC) activation. According to one model 
(reviewed by Weiss, 1993; Ravichandran et al, Thome et al, 1996), an encounter of the TCR 
with MHC/antigen activates PTK, most likely Lck, which then mediates tyrosine 
phosphorylation of !TAMs expressed in the cytoplasmic domain of the CD3-chains. This, on 
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its tum, causes the recruitment of ZAP-70 and Syk tyrosine kinase to this side as their SH2 
domains bind to the phosphorylated ITAMs of CD31' Subsequent phosphorylation of ZAP-70 
allows its association with the SH2 domain of Lck that is noncovalently associated with the 
cytoplasmic domain of CD4 and CDS (Veillette et aI, 19S5). Interaction of ZAP-70 with 
CDS/CD4 associated Lck then results in the recruitment of CDS or CD4 to the TCR (rhome 
et al, 1995, 1996) allowing both the TCR and its co-receptor to interact with the same 
antigen-MHC complex to enhance the stability of the interaction. Lck, ZAP-70, Syk, or 
additional PTK that have become activated due to their interaction with remaining 
phosphorylated IT AMs then activate PLC which on its tum initiates phosphatidylinositol-4,5-
biphosphate (PIP,) hydrolysis and ca2+mobilisation, a pathway leading to degranulation and 
protein kinase C (PKC) activation. Aside from degranulation, PLC and PKC are thought to 
participate in other signalling pathways leading to cytokine gene transcription and the 
activation of raf-I, MAP-2 kinase, and Ras (June, 1991). 
According to another model suggested for CDS+T cells, TCR occupation activates binding 
of CDS to MHC class I most likely by induction of a conformational change in CDS that 
increases its affinity for MHC class I (Casabo et aI, 1994). Interaction of CDS with MHC 
class I then successively results in sequestration of CDS towards the TCR-CD3 complex, 
phosphorylation (Le. activation) of CDS-associated Lck, phosphorylation of the CD3l'-chain 
by CDS-associated Lck, and recruitment of several kinases such as ZAP-70 to this side. 
When activated, these kinases initiate degranulation by activating PLC (O'Rourke and 
Mescher, 1993; Mescher, 1995). 
As stated in both models, Lck is generally considered to be one of the earliest tyrosine kinase 
involved in T cell signalling. This assumption is based on the observation that tyrosine 
phosphorylation of intracellular substrates does not occur in cells lacking Lck kinase activity 
(Karnitz et al, 1992). The impact of Lck for T cell activation is further supported by the 
observation that introduction of Lck into cells that have lost expression of endogenous Lck 
restores their ability to respond to signalling through the TCR and exhibit cytolytic activity 
(Karnitz et al, 1992; Abraham, 1991; Straus and Weiss, 1992). According to the data of Xu 
and Littman on CD4+T lymphocytes (l993), however, expression of a chimeric receptor 
containing CD4 extracellular and transmembrane domains fused to a kinase-deleted Lck 
resulted in similar IL-2 production as when a kinase functional form of Lck was fused to 
CD4. Similar data were reported by Collins and Burakoff, (l993). In contrast, mutations in 
the SH2 domain of CD4-associated Lck considerably affected the production of Il-2 by these 
cells (Xu and Littman, 1993). This observation suggests that the SH2 domain rather than the 
kinase domain of CD4-associated Lck is essential for T cell activation. Although these data 
suggest that CD4 (and perhaps CDS)-associated Lck kinase activity is dispensable they do 
not exclude the possibility that the T cell response observed was initiated by endogenous free-
Lck present within the cells. As so, the former model in which free-Lck could have initiated 
T cell signalling seems more plausible than the second model in which CDS/CD4-associated 
Lck kinase activity initiates the signalling cascade by phosphorylating ITAMs. 
21 
Nevertheless, Feito et al. (1996) showed that tyrosine phosphorylation of CD3-chains in 
CD4 +T cells was restricted to those physically associated with CD4. This observation implies 
that CD4-associated Lck initiates CD3-chain phosphorylation. 
The above models portray how TCR occupation leads to different T cell responses. In these 
models, we focused on degranulation as the secretion of vesicles containing perforin and 
granzymes is an important mechanism by which CD8+CTL deliver the "kiss of death" to 
apposing cells (Immunological Reviews, no 146, 1995). Aside from degranulation, however, 
T cell-mediated cytotoxicity can be accounted for by a second mechanism. This second 
mechanism, which is the main lytic mechanism of CD4 +CTL but can also be executed by 
CD8+CTL depending on the target cell (Lancki et al, 1995), requires the expression of Fas 
on the target cell and of Fas ligand (FasL) on the CTL. Engagement of FasL with Fas causes 
the activation of death genes in the target cell which results in apoptosis (Immunological 
Reviews, no 146, 1995). 
The signalling pathways resulting in degranulation are speculative. Less is even known about 
the events leading to FasL expression on CTL. According to the available data, the ability 
of CTL to kill via the FasL pathway is tightly controlled by the TCR. Herbimycin A, an 
PTK inhibitor specific for src-like PTK (i.e. Fyn and Lck) has been reported to abrogate 
tyrosine phosphorylation, ca2+mobilisation and inositol phosphate turnover induced by TCR 
occupation. Analysis of its effect on FasL induced cell kill, demonstrated that it totally 
abrogated FasL expression induced through TCR engagement but not through activation of 
PMA plus ionomycin (Anel et al, 1994). PMA triggers the activation of PKC while 
ionomycin triggers caHmobilization. These findings suggest that src-like PTK and 
caHmobilization are implicated in the induction of FasL expression and that the activation 
of src-like PTK precedes PKC activation. Oyaizu et al. (1995) recently addressed the 
question whether Lck was involved in TCR mediated FasL induction. The induction of FasL 
mRNA by TCR triggering was analyzed both in wild type (Jurkat) and Lck-deficient (JCaM) 
cells. Jurkat cells were able to upregulate FasL mRNA after TCR stimulation while JCaM 
cells failed to do so. However, both cell types were able to express FasL mRNA following 
treatment with PMA plus ionomycin. Collectively these data suggest that FasL expression 
is initiated by similar events as degranulation. 
1.3. Impact of the avidity of TCR-MHC/peptide interactions on the T cell 
\'esponse 
As suggested above, the CD8 (or CD4) molecules on T cells play an important role in the 
T cell response to target cells. Both CD8 and CD4 bind to the same ligand as the TCR. CD8 
binds to the ,,3 domain of MHC class I (Salter et al, 1989; Connolly et al, 1990; Shepherd 
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et ai, 1992) while CD4 binds to the 62 domain of MHC class II (Cammarota et al, 1992; 
Nag et al, 1993). Therefore, it is generally believed that these molecules serve to strengthen 
the interaction between the TCR and MHC/peptide. Direct prove for this concept was only 
recently provided by Garcia et al. (1996B). Additionally, both CDS and CD4 are believed 
to playa role in TCR signalling by focusing Lck in the vicinity of the TCR-CD3 complex. 
Several studies, however, have demonstrated that some T cells can exhibit their function in 
the presence of anti-CD4 or anti-CDS mAb. In this section, the significance of such T 
lymphocytes that obviously do not require their co-receptors to display their function is 
discussed. 
1.3.1. The requirement for CD8/CD4 varies according to the avidity of TCR-
MHC/peptlde interactions. 
Over the past years, numerous groups have reported a correlation between the MHC/peptide 
density on target cells and the susceptibility of CDS+CTL to blocking by anti-CDS mAb. In 
19S3, Gromkowski et a!. demonstrated that a reduction in H-2 density by papain treatment 
of target cells was accompanied by an increase in the susceptibility of CTL to CDS-blocking 
mAb. In 19S5, Shimonkevitz et al. compared the ability of CTL clones to lyse target cells 
with a low MHC class I surface expression with their ability to lyse the same target cells 
after IFN-'Y treatment had increased their MHC class I surface expression. Lysis of IFN..,. 
treated cells appeared to be less susceptible to CDS blocking. Using class I bearing artificial 
membranes, Goldstein and Mescher (19S7) showed a reciprocal relationship between the 
number of immobilized class I molecules and the susceptibility of T cells to blocking with 
anti-CDS mAb. Consistent with these findings, Dembic and colleagues (19S6, 19S7) showed 
that anti-CDS mAb blocked the lytic activity of a CDS+T cell clone against target cells with 
a low antigen expression but not against target cells with a high antigen expression. 
Alexander et al. (1991) and AI-Ramadi et al. (1995) reported that CDS-independent CTL 
clones became CDS-dependent when the antigen density on target cells was reduced. A 
similar correlation between the ligand density on antigen-bearing cells and the requirement 
for CD4 in the activation of CD4+T cells has been described (Marrack et al, 19S3; Biddison 
et ai, 19S4; Greenstein et al, 1985; Gougeon et al, 1985; Feito et al, 1996). 
Also the density of the TCR might influence the cell's requirement for CD4 or CDS co-
receptors. In this prospect, Greenstein et al. (19S5) reported that a CD4+murine hybridoma 
which had a 3-fold higher expression of TCR than the parental cell line could be activated 
independently of CD4-MHC class II interactions. Combining this fruding with the previous 
data it can be stated that the requirement for CDS or CD4 co-receptors corresponds 
inversibly with the number of TCR and MHC/peptide complexes that can associate. 
Additional studies in this field indicated that this variable was not the only factor. Under 
conditions where the antigen complexed to MHC was the only variable, it was shown that 
CDS-independent T cells became heavily dependent on CD8 when a mutated variant of this 
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antigen was bound to MHC (Maryanski et aI, 1988). Likewise, Cai and Sprent (1994) 
demonstrated that CD8-independent CTL became CD8-dependent when TCR contact with 
antigen was impaired by anti-TCR mAb. In that same year, Auphan et al. (1994) proved that 
the T cell's dependency on CD8 could be transferred by the TCR. In this study, mice 
transgenic for the TCR isolated from two CD8+CTL clones that were, respectively, highly 
dependent and independent of CD8 for their stimulation by cells expressing the H-2K' 
alloantigen, were generated. Analysis of CD8+T cells derived from these mice demonstrated 
that these cells had the same characteristics of sensitivity to inhibition by anti-CD8 mAb as 
the original CTL clone. 
Recently, soluble TCRs became available which allowed a direct estimation of TCR affinity. 
AI-Ramadi and co-workers (1995) analyzed the ability of soluble 2C TCRs to bind p2Ca 
complexed to soluble H-2L' and compared it with their ability to bind p2Ca-analogs 
complexed to soluble H-2L'. Some p2Ca-analog/H-2L' complexes were as efficiently bound 
as p2CalH-2L' while others were less firmly bound or were not detectably bound by soluble 
2C TCRs. Despite the apparent differences in TCR affinity, 2C CTL could generally lyse 
H-2' target cells expressing various peptide-analogs with comparable efficiency. This 
disparity could not be ascribed to differences in peptide affinity for H-2L'. Additional data, 
however, showed a clear link between the susceptibility of 2C CTL mediated lysis to 
inhibition by anti-CD8 mAb and the affinity of the 2C TCR. Whereas anti-CD8 mAb 
abrogated lysis of H-2' target cells pulsed with p2Ca-analogs for which the 2C TCR had a 
low affinity, it could not inhibit lysis of H-2' target cells for which the 2C TCR had a high 
affinity. 
The above data conclusively demonstrate that variations in either the affinity of the TCR-
ligand interaction or the number of TCR and MHC/peptide that can interact inversibly 
corresponds with the T cell's requirement for CD8/CD4. Along with the observation that 
CD8 and CD4 molecules bind to the same ligand as the TCR, U,e concept arose that 
simultaneous adhesion ofCD8/CD4 co-receptors enhances the avidity (Le. strength) ofTCR-
MHC/peptide interactions. According to this concept, T cells require CD8 or CD4 molecules 
when the avidity of TCR-MHC/ligand interactions is suboptimal and can function without 
these molecules in case the avidity of TCR-MHC/peptide interactions is sufficiently high. 
1.3.2. Signalling events in absence of the CD8/CD4 co-receptor: a model. 
As the cytoplasmic tail of the CD8 and CD4 co-receptor is non-covalently associated with 
Lck, it is generally believed that the co-receptor is involved in the intracellular signalling. 
Addition of anti-CD8 and anti-CD4 mAb prevents the sequestration of Lck to its ligand, the 
TCRlCD3 complex. Despite this, some T cells are perfectly able to display their function in 
the presence of anti-CD8 or anti-CD4 mAb. The question now arises how signalling occurs 
in these CD8/CD4-independent T cells. At present, we can only speculate on this subject. 
As a constitutive active form of Lck was found to substitute for the CD4 co-receptor in 
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enhancing the T cell response (Abraham et ai, 1991), we suspect that differences in the 
relative level of Lck activation might account for the differences in CD8/CD4 dependency. 
One possibility might be that the avidity of TCR-Iigand interactions determines the number 
of Lck that becomes activated. In the absence of CD8/CD4 enhanced binding, a low avidity 
interaction between the TCR and MHC/peptide complex will result in accelerated dissociation 
of TCR-Iigand complexes, which implies shorter TCR ligation times (Luescher et aI,1995). 
The resulting low Lck activation level may now only give rise to monophosphorylation of 
CD31"-chains which is insufficient to bind and activate ZAP-70 (Madrenas et ai, 1995). On 
top of this, anti-CD8/CD4 mAb would prevent the co-receptor from focusing Lck in the 
vicinity of the TCR-CD3 complex to initiate further phosphorylation of CD31"-chains. In case 
of high avidity TCR-MHC/peptide interactions, the TCR ligation times will be sufficiently 
long to allow the phosphorylation of both I-chains even without the CD8/CD4 enhancement. 
high avidity interaction low avidity interaction 
\ / \ I 
'J 'J T T 
full activation no/pal1ial activation 
Figure 3. Intracellular signalling in case of a high Qeft panel) or a low (right panel) avidity TCR-MHC/peptide 
interaction (adapted from Sloan-Lancaster and Allen. 1997). Whereas a high avidity (co-receptor independent) 
interaction leads to saturated phosphorylation of all CD) IT AMs (filled circles) and full T cell activation, a low 
avidity (co-receptor dependent) interaction causes incomplete phosphorylation ofCD31T AMs which results in partial 
T cell activation or no T cell activation at all. 
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This model might also explain why impaired thymic development of CD4+ or CD8+ single-
positive T cells due to altered co-receptors that are unable to associate with Lck can be 
restored by overexpression of these inutant co-receptors (Killeen and Littman, 1993; Chan 
et al, 1993) and why transfection of Lck in cells lacking CD4 is sufficient to recover their 
response to similar levels found for the CD4 +parentalline (Straus and Weiss, 1992). 
In addition to the above model, the resulting shorter TCR ligation time may also affect the 
phosphorylation of additional CD3-chains. A recent study on the involvement of individual 
CD3-subunits revealed that CD3!, alone could induce the tyrosine phosphorylation of various 
cellular substrates including ZAP-70, Fyn, and PLC but was incapable of generating inositol 
triphosphate (IP3) and to mobilize intracellular free Ca" (Jensen et al, 1997). The CD3,-
chain, on the contrary, could drive IP3 production and Ca" mobilization. Along with the 
observation that CD8-independent CTL can lyse their target cells without inducing PIP, 
hydrolysis whereas CD8-dependent CTL can not (Knall et al, 1995), these data might 
indicate that CD8-independent signalling can occur via CD3!, alone whereas additional CD3-
chains such as CD3, are required for the activation of low avidity CTL. In support of this 
hypothesis, altered peptide ligands which are discussed in the subsequent section did not 
stimulate tyrosine phosphorylation of CD3, (Madrenas et al, 1995). 
1.3.3. The avidity of the TCR-MHC/peptide interaction detennlnes the fate of the T ceU. 
TCR triggering is generally believed to occur when the total avidity of individual TCR-
peptide-MHC interactions exceeds a particular threshold. The extent of this interaction 
depends on 1. the number of MHC/peptide comple,xes on the target cell, II. the number of 
TCR and CD8/CD4 molecules on the T cell, and III. the affinity of the TCR for the 
MHC/peptide complex. For a normal T cell repertoire where the TCR and CD8/CD4 
densities show little variation, avidity is controlled by the affinity of the TCR for 
MHC/peptide complexes and the number of these complexes available. The delicate balance 
between these latter two parameters is best reflected when we examine the consequence of 
varying one parameter. In such cases, the effect of altering one parameter can be 
compensated for by making a reciprocal quantitative change in the other component (Sykulev 
et al, 1994B; Kim et al, 1996). The present section will discuss the impact of the avidity of 
TCR-MHC/peptide interactions in the light of CD8/CD4-requirement, ligand density, and 
TCR affinity. 
Although numerous studies have demonstrated the existence of T cells whose function could 
not be blocked by addition of anti-CD8 or anti-CD4 mAb, hardly any attention has been paid 
to the immunological significance of these cells. Our own data in this field refer to donor 
specific CTL propagated from graft biopsies obtained from heart transplant patients at 
different time-intervals after transplantation (chapter 2,3). As reported by others, T cell 
cultures grown from rejecting or stable transplants were both able to specifically lyse donor 
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B-LCL in vitro indicating that donor specific CTL are present within the graft irrespective 
of its rejection status (Dallman et aI, 19S7; Armstrong et ai, 19S7; Ruiz et ai, 19S5). 
Subsequent data, however, demonstrated that donor specific CTL propagated from graft 
samples obtained immediately preceding or during clinical rejection were generally not 
susceptible to inhibition by anti-CDS or anti-CD4 mAb whereas those propagated from "non-
rejecting" graft samples were highly sensitive to CDS or CD4 blocking. Comparable data 
were found with respect to peripheral donor specific CDS+CTL of cardiac transplant (chapter 
4) and corneal transplant (Roelen et ai, 1996) patients. In both studies, CDS-independent 
CTL were far more prominent within blood samples taken during a rejection episode than 
in blood samples taken during "non-rejection". Despite the fact that both CDS/CD4-
dependent and -independent CTL could lyse donor target cells in vitro, the selective presence 
of CDS/CD4-independent CTL during a rejection episode prompted us to believe that only 
this subset is functional in vivo. Several data have shown that CDS/CD4-independent CTL 
can lyse target cells expressing low levels of antigen whereas an increase in surface antigen 
density is required for the activation of CDS/CD4-dependent CTL (Shimonkevitz et ai, 19S5; 
Mentzer et ai, 1990). As target cells used for in vitro assays are generally considered to 
express substantial higher antigen levels than target cells encountered in vivo, the latter target 
cells may only effectively be killed by CDS/CD4-independent CTL. In support of this 
concept are the data of Alexander-Miller and co-workers (1996). They compared the in vitro 
and in vivo efficiency of virus specific CTL lines that differed in their antigen density 
requirements for optimal target cell lysis. Although all CTL lines effectively killed vi rally 
infected cells in vitro, only those that required low antigen determinant density for their 
activation could clear virally infected cells in vivo. These cells were also the less susceptible 
to CDS blocking. Likewise, Auphan et aI. (1994) showed that CDS+T cells of mice 
transgenic for a CDS-dependent TCR were unable to lyse target cells expressing antigen 
levels found in vivo. 
Also supporting the impact of CDS/CD4-independent CfL in transplant rejection was the 
observation that these CTL produced cytokines that promote graft rejection. CDS/CD4-
independent CTL secreted IFN-'Y when they encountered donor cells whereas CDS/CD4-
dependent CTL did not. However, both subsets could produce IFN-'Yafter stimulation by 
immobilized anti-CD3 mAb, a stimulus which bypasses the requirement for TCR-
MHC/peptide association (chapter 5). Likewise, CDS-independent CTL were able to produce 
IL-2 while CDS-dependent CTL could not (Cai and Sprent, 1993; Heath et ai, 1993). These 
latter findings add to the growing body of literature showing that the avidity of TCR-
MHC/peptide interactions not only determines whether or not a T cell will respond but also 
determines the quality of the response. Most studies performed in this field refer to the 
influence of ligand density and TCR affinity on the differentiation of naive HTL into Thl or 
Th2 effector cells (reviewed by Romagnani, 1996; Constant and Bottomly, 1997) or refer to 
the use of altered peptide ligands (APL) that bind with different affinity to either the TCR 
or the MHC molecule (reviewed by Sloan-Lancaster and Allen, 1996). Although these studies 
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generally do not consider the cytotoxic capacity of T cells, they do shed light on the impact 
of avidity in immune responses and are therefore discussed briefly in this thesis. 
Several studies showed that varying the dose of antigen used during CD4 +T cell priming 
could shift the response to a Thl- or a Th2-type response. Priming of naive CD4+T cells 
from a cytochrome c-specific TCR-transgenic mice with a low peptide dose led to their 
differentiation into Th2-like cells producing abundant IL-4, whereas a high dose of the same 
peptide led to their differentiation into Thl-like cells producing abundant IFN-y (Constant 
et al, 1995). In another model of TCR-trangenic mice, priming naive T cells with extremely 
low doses of ovalbumin peptide generated a Th2 response (IL-4 > IFN-y) whereas priming 
with intermediate antigen doses generated a Thl response (IFN-y> IL-4). However a further 
increase in the dose of antigen resulted in the disappearance of IFN-y and the development 
of IL-4 producing cells (O'Garra and Murphy, 1995). An explanation for the induction of 
a Th2-type response after a further increase in antigen dosage may be sought in the 
differential susceptibility of Thl and Th2 cells to apoptosis at high doses of antigen. With 
Thl cells being more sensitive to dose-induced apoptosis than Th2 cells, the IL-4 response 
may be due to the selective outgrowth ofTh2 effector cells (Constant and Bottomly, 1997). 
The previous experiments established that naive CD4 +T cells with a homogeneous TCR 
responded to different doses of peptide antigen by differentiating into distinct effector cell 
types. In light of these findings the prediction follows that the dose of antigen given had 
influenced the antigen density on APC and hence the extent of TCR ligation. By using a set 
of ligands with various class binding affinities but unchanged T cell specificity, it has indeed 
been shown that stimulation with the highest affinity ligand resulted in IFN-y production, 
whereas ligands with relative lower MHC class II binding induced only IL-4 secretion. 
Pfeiffer et al. (1995) analyzed the response of I-A" restricted naive CD4 +T cells primed in 
vivo with their natural ligand 012 or the 0I2-analogs, 0I2G1u and 0I2Ala, which bound less well 
to MHC than 012. CD4 +T cells primed with the 0I2-analogs expressed IL·4 but not IFN·y 
mRNA while CD4+T cells primed with 012 expressed IFN-y but not IL-4 mRNA. Similar 
data were reported by Chaturvedi et al. (1996) using a comparable experimental setting. Also 
the cytoklne pattern of already differentiated T cells can alter by varying the ligand density. 
Kumar et al. (1995) reported that an analog of myelin basic protein (MBP) that bound more 
efficiently to I-A" than MBP induced the production of IFN-y by a Th2 clone. Windhagen 
et al. (1995) analyzed the response of human autoreactive ThO clones specific for MBP 
epitope 85-99 and compared it with the response to MBP analogs that bound MHC class II 
less well. While stimulation with native peptide induced proliferation and the production of 
IL-2, IL·4, IL-lO, and IFN-y, the peptide analogs solely induced TGF-JlI production. 
Further confirmation that weak/strong interactions between TCRs and MHC/peptide ligands 
can influence the quality of the response was obtained by the use of analogs of immunogenic 
peptides in which the TCR contact sites had been manipulated (APL; reviewed by Sioan-
Lancaster and Allen, 1996). These peptide analogs were then tested for their capacity to 
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stimulate a variety of T cell responses in T cells specific for the wild-type ligand. Pfeiffer 
et aI. (1995) compared the cytokine response of I_A' restricted naive CD4+T cells primed 
in vivo with their natural ligand 012 or with a similar dose of the 0I2-analog 0I2Ala, which 
bound equally well to I-A' than 012 but had an 80-fold increased ability to activate IL-2 
production. Priming with 012 led to IL-4 but not IFN-/, gene expression while priming the 
same T cells with 0I2Ala induced IFN-/, but not IL-4 gene expression. Comparing the 
response of cytochrome c specific TCR transgenic naive CD4 +T cells primed with the analog 
K99R with that induced by priming with wild-type peptide, revealed that K99R was less 
potent to stimulate proliferation. Moreover, priming with K99R led to the generation of 
effector cells producing IFN-/, and IL-4 while priming with the wild-type ligand led to the 
generation of effector cells producing IFN/, but no IL-4 (reviewed by Constant and Bottomly, 
1997). Bvavold and Allen (1991) found that a peptide differing from the wild-type peptide 
(murine haemoglobin peptide Hb(64-76» in a single residue lost the capacity to induce 
proliferative responses by a Th2 clone while remaining able to evoke IL-4 production. With 
respect to Thl cells specific for Hb(64-76), peptide analogs stimulated cytolytic activity but 
failed to induce proliferation and cytokine production (Bvavold et ai, 1993). 
The preceding data lend credence to the notion that the total avidity of individual TCR-Iigand 
interactions determines the biological behaviour of T cells. A low avidity interaction results 
in only partial activation of T cells and induces the differentiation of naive HTL into Th2 
effector cells. A high avidity interaction results in complete T cell activation and induces the 
differentiation of naive HTL into Th I. How TCR triggering can generate such distinct 
profiles is unknown. A simple view of the mechanism accounting for the generation of 
distinct effector functions is that the extent of TCR occupation determines the extent of CD3-
chain phosphorylation. In case of a low avidity interaction, the incomplete phosphorylation 
of CD3 IT AMs would result in a lack of binding templates for some SH2-domain containing 
proteins. Thus, some signalling pathways would remain inactive while others may be 
stimulated weakly or completely, depending on the tyrosine phosphorylation state of the 
ITAMs. Such a model has already been proposed above for CD8/CD4-dependent and -
independent signalling. 
Aside from a lower threshold that should be reached to induce a T cell response there may 
also be an upper limit for TCR-Iigand avidity. In support of this concept, high doses of 
peptide antigen presented by APC induced apoptotic death in a high avidity CD8+CTL line 
and this effect could be restored by addition of anti-CD8 mAb (Alexander-Miller et ai, 
1996B). The underlying mechanism for the induction of apoptosis is not known but may 
include the production of TNF-OI as addition of anti-TNF-OI restored proliferation of high 
avidity CD8+CTL in this study. According to Cai et aI. (1997) the T cell may protect itself 
from reaching this upper limit via TCR internalization. Internalization of TCR after contact 
with antigen on a target cell has been viewed as a device to enable a large number of TCR 
molecules to make contact with a limited number of antigenic epitopes on the target cell. 
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This theory would explain the finding that T cell stimulation requires engagement of a 
considerable number of TCR but only few MHC/peptide complexes on the opposing cell 
(Valitutti et ai, 1995; Viola and Lanzavecchia, 1996). According to the data of Cai et aI. 
(1997), however, TCR internalization is not essential for T cell activation but rather is a 
byproduct of strong TCR ligation. This finding is supported by a study in which mice 
trangenic for the TCR isolated from two CDS+CTL clones that were, respectively, highly 
dependent and independent of CDS for their stimulation by cells expressing the H-2K' 
alloantigen were matched with H-2' mice (Auphan et ai, 1994). Both types ofH-2"" mice had 
markedly reduced T cell numbers in their peripheral blood and the remaining T cells were 
aberrant. T cells present within the CDS-dependent TCRtg mice lacked CDS surface 
expression whereas T cells present within CDS-independent TCRtg mice lacked both TCR 
and CDS surface expression. 
According to the above studies, the total avidity of TCR-ligand interactions determines the 
fate of the cell. Not all groups, however, support the impact of TCR affinity in T cell 
activation. In most studies, the affinity of a TCR-peptide interaction is assayed by the ability 
of this peptide to displace a TCR binding mAb or a reference peptide from the TCR. Using 
this approach Sykulev and colleques (1994) and Cai and Sprent (1996) confirmed a strict 
correlation between TCR affinity and the efficiency of specific T cell killing. Others, 
however, reported that the affinity of the TCR for its ligand was not crucial in determining 
T cell activation (Matsui et ai, 1994; Yoon et aI, 1994; Kessler et ai, 1997). An explanation 
for this contradiction was provided by the data of Matsui et aI. (1994). In their study, the 
reactivity of the 2B4 T cell hybridoma specific for PCC bound to the MHC class II molecule 
I-E' was compared with its response to variants of the PCC peptide. Although all peptides 
bound I-E' equivalently, the concentration of peptide required to achieve maximal IL-2 
production varied enormously between PCC and its analogs. Consistent with the above 
concept, these differences in dose-response were ascribed to differences in TCR affinity. To 
investigate this, I-E' molecules loaded with PCC or with a PCC-analog were tested for their 
ability to displace a TCR binding mAb from the TCR. As both complexes were equally 
capable, it was assumed that the TCR had comparable binding affinities for PCC and its 
analog despite the fact that PCC was far more effective in inducing JL-2 production. The 
affinity of a TCR-MHC/peptide interaction is the result of the continuous association (Kon) 
and dissociation (Kort) of the interaction (Kd = Koff/Kon). Comparison of the Kon and Kof 
rates separately, however, revealed that I-E'/PCC associated relatively slow with the TCR 
and dissociated relatively slow from it. The I-E'/PCC-analog, on the contrary, associated 
somewhat faster with the TCR but dissociated almost immediately from it. 
Along with data showing that TCR antagonists have a higher dissociation rate than TCR 
agonists (Lyons et ai, 1996), a model for T cell activation was proposed in which the 
duration of TCR ligation is crucial. An increase in the dissociation rate could then result in 
an inability of the T cell to maintain an adequate local pool of engaged complexes, and TCR-
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peptide-MHC association might not persist for the time needed for the full development of 
cytosolic multiprotein assemblies involved in signal transduction. The role of the CD8/CD4 
co-receptor in this model is simply to stabilize the TCR-MHC/peptide interaction to prolong 
its duration. Likewise, an increase in the number of TCR-ligand interactions will add to the 
stability of TCR ligation. In support of this model it was shown that the immunogenicity of 
antigens was determined by their dissociation rate rather than by their affinity for MHC. In 
comparison to non-immunogenic peptides, immunogenic peptides have a low dissociation 
rate. This low dissociation rate would allow them to form stable MHC-peptide complexes 
which would persist for a time sufficient to activate T ceUs (van der Burg et al, 1996). 
Another point worth discussing is the slow rate with which PCC/I-E' associates with the 2B4 
TCR. This slow association rate indicates that the binding of the TCR to its ligand is in some 
way intrinsically limited. One explanation is that a peptide must induce a conformational 
change in the TCR to elicit a T cell response. This theory was first launched by Janeway and 
co-workers (Janeway, 1995). In support of this theory, it was shown that not the affinity of 
an anti-TCR mAb determined whether a T ceU clone became activated but rather the TCR 
epitope recognized by the antibody (Rojo and Janeway, 1988; Janeway et al, 1989). 
1.3.4. Immuno-therapeutical strategies based on the CTL's avidity. 
Several laboratories are currently investigating adoptive transfer of in vitro expanded 
autologous CTL for the treatment of a number of diseases including cytomegalovirus 
(Riddell, 1992A,B), human immunodeficiency virus type I (Lieberman, 1994), and cancer 
(Topalian and Rosenberg, 1991; Rubin and Lotze, 1993). The conventional approach to elicit 
an optimal CTL response in vivo is by transferring large numbers of in vitro activated 
antigen-specific CTL precursors. However, according to Alexander-Miller et al (1996A), the 
in vivo functionality of such reinfused CTL depends on the avidity with which their TCRs 
interact with MHC/peptide complexes. High avidity CTL lines efficiently cleared antigen-
bearing ceUs in vivo whereas low avidity CTL lines, though effective in vitro, were 
incompetent. This observation is pivotal as it implies that adoptive transfer of high avidity 
CTL rather than of every potential CTL would benefit the efficacy of adoptive 
immunotherapy. 
Numerous groups have demonstrated that high avidity CTL react to ceUs expressing low 
levels of antigen whereas an increase in surface antigen is required to induce the proliferation 
and activation of low avidity CTL (Marcack et al, 1983; Shimonkevitz et al, 1985; Gougeon 
et al, 1985; Mentzer et aI, 1990). Accordingly, to generate high avidity CTL for adoptive 
immunotherapy, one should culture the immune ceUs of a patient with low doses of the 
specific antigen as under such conditions only high avidity CTL would expand. 
In the case of allograft transplantation, we rather would like to undo the immune system of 
its high avidity donor specific CTL. A recent study showed that high avidity CTL were 
selectively eliminated from in vitro cultures after challenge with high doses of antigen. When 
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exposed to supraoptimal antigen doses, high avidity CTL became apoptotic while low avidity 
CTL proliferation was not affected (Alexander-Miller et aI. 1996B). Administration of high 
antigen dosages has been shown to 'result in the selective deletion of antigen reactive T 
lymphocytes in different experimental systems. Virus specific T cells were selectively 
eliminated after challenge with high doses of virus (Moskophidis et ai, 1993). Likewise, 
transfused MBP specific CD4 +T cells were depleted in recipient mice treated with high doses 
of MBP peptide (Critchfield et ai, 1994). Accordingly, administration of high dosages of 
donor antigen might be of utmost importance for the prevention of transplant rejection as 
such treatment would cause the deletion of high avidity, donor specific CTL leaving only low 
avidity CTL inadequate to mediate donor tissue destruction. 
For more than two decades, donor cell transfusions have been associated with prolonged 
survival of donor but not third-party allografts in both experimental and clinical studies 
(Foster et ai, 1988; Westra et ai, 1991; Brennan et ai, 1995). Comparable results were 
obtained when membrane bound donor MHC molecules (Foster et ai, 1992) or recipient cells 
transfected with donor MHC genes (Saitovitch et ai, 1996) were administered demonstrating 
that donor antigens are responsible for inducing suppression of allograft rejection. Despite 
intense investigation, however, considerable controversy remains as to the underlying 
mechanism(s). Answers have been sought in various factors including the establishment of 
donor-recipient microchimerism (Starzl et ai, 1992), anergy (Eynon and Parker, 1992; 
Freeman et ai, 1993), altered cytokine profiles (Salam et ai, 1993), and a reduction in 
antigen specific CTL precursors (Irschick et ai, 1990). As the beneficial effect of donor 
specific transfusions appeared to depend on the number of cells injected (Foster et ai, 1988; 
Heeg and Wagner, 1990), the destruction of high avidity donor specific CTL might be (part 
of) the underlying mechanism. 
Although the body of literature that examines the induction of tolerance is rapidly growing, 
the impact of high avidity CTL in this process has generally been ignored. Only one group 
has analyzed the effect of donor specific transfusion on high avidity CTL (Heeg and Wagner, 
1990). According to their results, donor specific high avidity CTL, while present within the 
peripheral blood of control mice, were undetectable in mice made tolerant to allogeneic skin 
grafts by donor specific transfusion. Additionally, high avidity donor specific CTL have been 
found to disappear from the peripheral blood of heart transplant patients long after 
transplantation when rejection episodes are seldomly experienced (Chapter 4). Though both 
studies demonstrate that high avidity CTL are absent in case of stable engraftment or 
transplant tolerance, a causal relationship has yet to be proven. For this, the effect of 
reconstitution of high avidity donor specific CTL into tolerant animals should be examined. 
In case such a treatment abrogates the tolerant state, transfusion of accurate amounts of donor 
antigen might extend the benefits of current transfusion protocols towards indefinite 
transplant survival even in the clinical setting. 
Finally we would like to mention a newly discovered membrane molecule, p38 (Valiante and 
Trinchieri, 1993). As shown in chapter 6 of this thesis, high avidity CD4+CTL can be 
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delineated from naive- and non-cytotoxic CD4-expressing lymphocytes as well as from low 
avidity CD4+CTL by their surface expression of p38. Within the CD8+T cell population, 
however, p38 is not selectively expressed by high avidity CTL. This observation indicates 
that p38 depleting mAb can not be used to selectively eliminate the high avidity CTL pool. 
However, the p38 molecule might serve as a prognostic marker for acute cardiac rejection. 
Kinetic studies of donor specific, high avidity CTL demonstrated that these cells are absent 
within stable cardiac allografts, but start accumulating approximately 2 weeks prior to the 
diagnosis of acute rejection (chapter 2). Accordingly, increases in the number of high avidity 
CTL present within the cardiac allograft might predict the occurrence of acute rejection. As 
p38 distinguishes high avidity CD4 +CTL from additional CD4-bearing lymphocytes and as 
CD4 +CTL are found in a significant proportion of cardiac biopsies (chapter 3), 
immunohistochemical analysis of CD4 +p38+lymphocytes would inform us about the number 
of high avidity, donor specific CD4+CTL and hence about the rejection status of the cardiac 
allograft. 
1.4. Aim of the study. 
As discussed above, not all CTL but only those with a high avidity may have immunological 
potency. In this thesis, we analyzed the importance of high avidity CTL in clinical cardiac 
rejection. In chapter 2, the kinetics of graft infiltrating CTL with a high avidity for donor 
HLA class I antigens were studied and compared with the rejection status of the cardiac 
allograft. In chapter 3, the frequency and avidity of donor HLA class II specific CTL were 
examined and compared with the rejection status of the cardiac allograft. Both studies 
revealed that high avidity CTL migrate to the allograft during rejection. Accordingly, the 
kinetics of high avidity CTL within the peripheral blood might inform us about the 
immunological status of the transplanted heart and by that provide a method for non-invasive 
monitoring (Le. without the requirement for heart biopsies) of rejection. The results of this 
study are shown in chapter 4. 
To further characterize high avidity CTL and to understand their relevance in transplant 
rejection, the cytokine secretion profile and phenotype of these cells was studied. The results 
are shown in chapter 5 and chapter 6, respectively. 
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Chapter 2 
Progressive accumulation of CTL with high avidity for 
donor antigens during the development of acute cardiac 
rejection 
To study the importance of cytotoxic T lymphocytes (CTL) with high avidity for donor 
antigens (Ag) in the development of acute cardiac allograft rejection, their appearance within 
the graft in relation to rejection was analyzed. For this study, donor directed CTL propagated 
from sequentially taken endomyocardial biopsies (EMB) were enumerated by limiting dilution 
analysis (LDA). Subsequentially, the fraction of these CTL having high avidity for donor Ag 
was determined by addition of a CD8 monoclonal antibody (mAb) to the cytotoxic phase of 
the LDA. Analysis of 37 EMB cultures obtained from II heart transplant (HTx) patients 
before, during, or after they experienced rejection, revealed the kinetics of donor specific 
CTL in relation to rejection for HTx patients in general. For 5 individual recipients, a more 
detailed analysis was performed. 
The kinetics found for individual patients confirmed the pattern found for the total group of 
HTx recipients tested. Frequencies of donor specific precursor CTL (pCTL) as well as of In 
vivo primed donor reactive CTL (committed CTL or cCTL) increased towards rejection and 
decreased after successful rejection therapy. More than 2 weeks before rejection was 
diagnosed, only a small fraction of the graft infiltrating donor specific pCTL and cCTL had 
high avidity for donor Ag (median = 35 % and 11 %, respectively). Within 2 weeks preceding 
rejection, this fraction increased gradually (median= 52% and 55%, respectively) and 
became dominant during rejection (median= 87% and 78%, respectively). After successful 
rejection therapy, a decrease to basal levels (median= 18% and 24%, respectively) was 
observed. 
Conclusively, intragraft accumulation of high avidity, donor specific pCTL and cCTL may 
cause transplant rejection. 
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2.1. Introduction 
During the last several years, immunological events associated with lymphocytic inmtration 
of rejecting allografts have been studied. Data of murine (Orosz et al, 1989; Bishop et al, 
1990,1992) and human cardiac allografts (Suitters et al, 1990) as well as of a rat kidney 
allograft model (Mason and Morris, 1984; Bradley et al, 1985), conclusively demonstrated 
that the presence of donor specific CTL within the transplant coincided with extensive tissue 
destruction. Intragraft granzyme B and perforin gene expression, indicative for the presence 
of activated CTL, was highly restricted to acutely rejecting renal allografts (Lipman et aI, 
1994). These results suggest a key role for CTL in rejection. An intriguing finding, however, 
was the observation that allo-antigen (alloAg) specific CTL were also present within 
transplants in which no histological evidence of rejection was found (Dallman et ai, 1987; 
Weber et ai, 1989; Ouwehand et al, 1993). Little is known about these latter CTL which 
apparently do not interfere with graft destruction. 
Previously, graft infiltrating lymphocytes (GIL) of patients who experienced several acute 
cardiac rejection episodes were compared to those obtained from patients who never clinically 
rejected their cardiac allograft. Significant higher donor specific CTL frequencies were found 
within the rejector group compared to the non-rejector group. More importantly, donor 
specific CTL from both groups proved to have different characteristics. The majority of CTL 
of the rejector group had high avidity for donor Ag whereas CTL of the non-rejector group 
mainly had low avidity for donor Ag (Vaessen et al, 1994). In line with this observation, 
high avidity CTL were found in the peripheral blood of patients with ongoing rejection of , 
their corneal allograft, but were hardly detectable in the blood of patients with good graft 
function (Roelen et al, 1995). 
To elucidate the importance of CTL with high avidity for donor Ag in the development of 
acute cardiac allograft rejection, the kinetics of these CTL in relation to rejection was 
analyzed. For this study, graft infiltrating donor directed CTL propagated from EMB taken 
before, during, or after histologically proven aC,ute rejection, were enumerated and their 
avidity for donor Ag was determined. Analysis of 37 EMB cultures obtained from 11 HTx 
patients, portrays the kinetics of donor specific CTL in general. From 5 patients, EMB taken 
before and during rejection as well as after rejection therapy were successfully cultured. 
These serial EMB cultures were used to analyze the kinetics of donor specific CTL in 
relation to rejection within individual patients. 
To enumerate naive donor specific pCTL as well as CTL that have been activated in vivo by 
contact with donor Ag (cCTL), LDA as described by Orosz et al.(1989) was performed. 
Subsequently, the fraction of pCTL and cCTL with high avidity for donor Ag was 
determined by addition of CD8 mAb to the cytotoxic phase of the LDA. The CD8 molecule 
stabilizes the interaction between a T cell receptor (TCR) and a HLA-peptide complex. CTL 
which benefit most from such interactions and therefore are most dependent on CD8, express 
low affinity TCR for Ag. Likewise, CDS independent CTL express high affinity TCR for 
Ag (MacDonald et al, 1982; Cai and Sprent, 1994; Auphan etal, 1994). Hence, the effect 
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of CD8 blocking on the cytotoxic capacity of CTL reveals their avidity for donor Ag. 
Here we report that donor specific pCTL and cCTL are present within the graft irrespective 
of acute cardiac rejection. During and immediately preceding acute rejection, graft infiltrating 
donor specific pCTL and cCTL mainly have high avidity for donor Ag. In contrast, during 
periods of "non-rejection" , intragraft donor specific pCTL and cCTL mainly have low avidity 
for donor Ag. That high avidity CTL are able to induce myocyte destruction, whereas low 
avidity CTL are not, is discussed. 
2.2. Materials and Methods 
PatielIIs. Endomyocardial biopsies obtained from HTx recipients prior to, during, and after 
histologically proven rejection, were used to study the kinetics of graft inftltrating donor 
specific pCTL and cCTL in the pathogenesis of human cardiac transplant rejection. Patients 
received a preoperative blood transfusion while cyclosporin A and low dose steroids were 
used as maintenance immunosuppression. 
Endomyocardial biopsies were routinely taken at a weekly interval during the first 6 weeks 
post-transplantation and once in two weeks in the following 4 weeks. Later EMB were taken 
less frequently, declining to once every 4 months at 1 year. For the present study, EMB 
taken during the fust 4 months following cardiac transplantation were cultured in IL2 
conditioned medium to obtain GIL. This period was chosen because acute rejections occur 
most frequently during this timespan. Acute cardiac rejection was diagnosed by 
histopathology of EMB according to ISHLT criteria (Billingham et al, 1990). Anti-rejection 
treatment was instituted when mononuclear cell inftltrates coexisted with myocyte damage 
or myocyte necrosis and consisted of bolus steroids or a 2-weeks course of a polyclonal 
rabbit anti-thymocyte globulin preparation in case of ongoing rejection. 
Lymphocyte clI/llIres. Lymphocyte cultures were established from EMB as described 
previously (Ouwehand et al, 1991). Briefly, each biopsy was cultured in a 96-well round 
bottom tissue culture plate (Costar, Cambridge, MA) with 200 1'1 culture medium per well, 
in the presence of 10' irradiated (30 Gy) autologous peripheral blood mononuclear cells 
(PBMC) as feeder cells. Due to the absence of donor Ag in this system, no de novo 
stimulation of donor specific lymphocytes can take place in vitro. Culture medium consisted 
ofRPMI-I640, Dutch Modification (Gibco, Paisley, Scotland), supplemented with 4mM L-
glutamine, 100 JU/ml Penicillin, 100 I'g/ml streptomycin and 10% pooled human serum. 
Additionally, 10% v/v lectin free lymphocult-T (Biotest GmbH, Dreieich, Germany) was 
added as exogenous source of IL2. It is postulated that under these circumstances only those 
lymphocytes which have acquired IL2 receptors due to a previous encounter with Ag can be 
cultured (Mayer et al, 1985; Zeevi et ai, 1986). The plates were incubated in a humidified 
atmosphere at 37°C in 5 % CO,. 
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PBMC were isolated from heparinized venous blood of the transplant recipient by Ficoll-
Hypaque density gradient centrifugation. Cells were washed twice in HBSS (Gibco) and once 
in RPMI-I640. PBMC were irradiated (30 Gy) and used as feeder cells. 
GIL cultures were analyzed for WT3I, CD8 (Becton Dickinson), and CD4 (Immunotech, 
Marseille, France) expression by three-color flow cytometry on a FACScan after staining 
with mAb directly conjugated to fluorescein, PERPC, and phycoerythrin, respectively. After 
phenotyping, a standard 4-hour "Cr release assay was performed to assess the ability of GIL 
cultures to specifically lyse target cells expressing lILA class I and II Ag for which the donor 
and recipient were mismatched (fissue Antigens 1980; 16: 335). Tested GIL cultures were 
stored at -140·C in IL2-free culture medium supplemented with 10% v/v DMSO (Sigma). 
Allogeneic target cells. Phytohaemagglutinin (PHA) stimulated T cell blasts of donor origin 
were obtained by culturing donor spleen cells for 4-7 days in culture medium supplemented 
with 10% v/v lymphocult-T and 1% PHA (Difco, Detroit, MI). 
Limiting Dilution Analysis. GIL cultures considered for LDA had to exhibit donor HLA class 
I directed cytotoxicity in "Cr-release assays and were obtained from individual patients at 
various timepoints after transplantation. LDA was conducted simultaneously on all GIL 
samples of each patient to minimize experimental variation. Limiting dilution cultures were 
set up in 96-well round bottom microculture plates (Costar). Responder cells (GIL) were 
titrated in 8 double dilution steps starting from 5000 cells per well to 39 cells per well. All 
dilutions were performed in 24 replicates and 50,000 irradiated (30 Gy) stimulator cells were 
added to each well in a total volume of 0.2 ml culture medium supplemented with 20 U/ml 
rIL2 (Biotest). As stimulator cells we used either donor spleen cells (or, when not available, 
allogeneic mononuclear cells that shared HLA Ag with the donor) or autologous PBMC. 
When autologous PBMC are used, in vivo activated cCTL are cultured that maintain their 
cytolytic responsiveness to alloAg encountered in vivo (Orosz et ai, 1989). Stimulation by 
donor spleen cells leads to expansion of the total pool of donor specific CTL (tCTL) 
consisting of both donor directed cCTL and their naive precursors (PCTL). Hence, the 
combination of these LDA allows a quantitative comparison between cCTL and pCTL (tCTL-
cCTL) with similar Ag specificity. 
After 7 days of culture, all 96-well plates were split into two and CD8 mAb was added to 
half of the split wells as described below. Subsequently, each well was individually tested 
for its capacity to lyse 2500 "Cr-Iabelled PHA blasts of donor origin. LDA cultures were 
incubated for 4 hrs at 37·C in 5 % Co,. Supernatants were harvested using a Skatron 
harvesting system (Skatron-AS, Lierse, Norway) and the release of "Cr was assayed in a 
Packard gamma-counter (packard Instruments, Downers Grove, USA). Spontaneous and 
maximum release were defined by incubation of target cells with culture medium in the 
absence or presence of Triton X-loo detergent (5% v/v solution in 0.01 TRIS buffer), 
respectively. Microcultures were considered cytolytic when the experimenlallysis percentages 
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exceeded 10%. As a control for specificity, the reactivity of cultures with the highest 
responder cell concentration was tested against PHA blasts of third party cells and against 
the K562 cell line. 
CD8 inhibition study. A 1:500 dilution of ascitic fluid was used for FKI8, a mouse anti-
human antibody of the IgG3 subclass, which recognizes the gp32 chain of the CD8 molecule 
(Koning et ai, 1986; a kind gift of Dr F Koning, Dept of Immunohematology and Bloodbank, 
University Hospital Leiden, the Netherlands). This concentration totally inhibited the 
cytotoxic capacity of CD8-dependent CTL clones but did not affect target cell lysis by CD8-
independent CTL clones. Before addition of "Cr-labelled target cells to the LOA, half of the 
split wells was preincubated with FKI8 during 30 minutes at 37"C in a humidified 
atmosphere containing 5 % CO,. 
Cell mediated lympho/ysis (CML) assay. To control whether the difference in avidity reflected 
by FKI8 sensitivity is indeed caused by blocking the interaction between a CD8 molecule 
and the ",-domain of a HLA class I molecule, CD8-(in)dependent CTL clones were tested 
for donor directed cytotoxicity in a standard 4-h "Cr release assay in the absence and 
presence of FKI8 or TP25.99, a mAb directed against the ",-domain of HLA class I 
molecules (Pouletty et ai, 1993; a kind gift of Dr S Ferrone, Dept of Microbiology, New 
York Medical College Valhalla, NY). Briefly, CTL clones were incubated with 2500 "Cr-
labelled PHA blasts of donor origin at different effector:target (E:T) ratios in 0.2 mI culture 
medium. Alternatively, CML were performed either with CTL clones preincubated with 
FKI8 (a 1:500 dilution of ascitic fluid) or with "Cr-Iabelled target cells preincubated with 
TP25.99 (50 "g/ml). After 4 hours of effector-target cell incubation, supernatants were 
harvested and the release of "Cr was measured as described in the LOA section above. To 
control for specificity, the cytotoxicity of the clones against "Cr-labelled third party PHA 
blasts and the K562 cell line was tested. 
Frequency calculation. Minimal estimates of CTL frequencies were calculated by analysis 
of the Poisson distribution relationship between the percentage of cultures that failed to 
develop cytotoxicity and the number of responder cells per well. Both pCTL and cCTL 
frequencies, expressed as number of cytotoxic cells per 10' ceUs, were calculated with the 
maximum likelihood estimation, adapted with a jackknife method as described by Strijbosch 
et aI (1987). Standard deviation and 95% confidence intervals (95% CI) were calculated as 
well. The calculated frequencies were accepted when the goodness-of-fit did not' exceed 12. 
Subsequently, the fraction of donor specific CTL having high avidity for donor Ag could be 
calculated using the following formula: 
{reg of donor sPec. CTL with CDS mAb 
fraction (%) = lOOx freqofdonorspec, CTLwithoutCD8 mAb 
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Statistics. To determine the importance of allograft specific CTL in the process of transplant 
rejection, the frequency and avidity of donor directed CTL present during rejection were 
compared to values found before and after this period. Differences between these categories 
were analyzed using the Mann-Whitney-U-test. 
2.3. Results 
Endomyocardial biopsies, routinely taken from HTx patients for the diagnosis of acute 
cardiac transplant rejection, were cultured to obtain GIL. Only EMB obtained within 4 
months after transplantation were considered for the present study. Thirty-three percent of 
EMB without histological evidence of acute rejection grew sufficient GIL to allow for 
functional analysis. A significant higher percentage (50%; p=O.OI) was found for rejecting 
EMB. Cytotoxicity towards donor HLA class I Ag was found in 83% and 61 % of the GIL 
cultures established from EMB with and without histological signs of rejection, respectively. 
For the present study, GIL cultures established from 37 EMB of 11 patients were examined. 
No differences were found for the GIL cultures obtained from EMB with (n =7) or without 
(n=30) histological signs of rejection, regarding culture time (median = 25 days: range= 18-
36 days, and 29 days: range= 14-47 days, respectively) nor percentage of CD8+lymphocytes 
present (median= 58%: range= 8-84%, and 46%: range= 1-100%, respectively). 
Phenotypic analysis demonstrated that all GIL cultures examined consisted of T cells only. 
In addition to CD8+lymphocytes, CD4+T cells were present whereas TCR'Y~ cells and NK 
cells were absent. 
Control experiments. Both frequency and avidity of donor specific CTL present within GIL 
cultures were determined using LDA. To control for donor specific target cell lysis in the 
cytotoxic phase of the LDA, the reactivity of GIL cultures against PHA blasts of third party 
cells and against the K562 cell line was tested. No lysis of third party nor K562 cells could 
be detected. 
Five CD8+CTL clones obtained from GIL cultures of HTx patient FO were tested for donor 
directed cytotoxicity in a CML assay. Representative results are shown for 2 clones; F0810 
and F084. Addition of CD8 mAb (FKI8) totally inhibited donor target cell lysis by F0810 
cells but did not affect the cytotoxic capacity of F084 cells (figure 1). Consequently, F0810 
cells have low avidity for donor Ag whereas F084 cells have high avidity for donor Ag. In 
addition, F0810 cells could not lyse donor target cells pretreated with TP25.99 whereas 
F084 cells could. This observation demonstrates that differences in avidity reflected by FKI8 
sensitivity are indeed caused by blocking the interaction between a CD8 molecule on CTL 
and their counterpart (the ",-domain of HLA class I molecules) on target cells. 
GIL cultures regularly exhibited cytotoxicity towards donor HLA class II determinants. 
Analysis of donor HLA class II specific, CD4+CTL clones (n=8) demonstrated that these 
cells efficiently lyse donor B-LCL but fail to lyse PHA blasts of donor origin. Since, donor 
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PHA blasts were used as target cells in the present study, all frequencies of donor specific 
CTL estimated by LDA concern donor HLA class I specific CTL and not donor HLA class 
II specific CTL. 
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Figure 1: Lysis ofjlCr-labelled PHA-blasts of donor origin ( ..... ) by CD8+CTL clone F08IO (upper panel) and F084 
(lower panel) at different effector:target cell (E:1) ratios. Addition of either FK18 (B; a CDS mAb) or TP25.99 ( ..... ; 
a mAb directed against the aJ-domain ofm..A class I molecules) inhibited target cell lysis by F0810 cells but did 
not affect the cytotoxic capacity of F084 cells. To cootrol for donor specificity, the cytotoxicity of the clones 
towards an unrelated third party PHA-blast ( .. ) and towards the K562 cell line (x) was tested. 
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11,e frequency of graft itifiltrating donor specific en increases during the development of 
cardiac transplant rejection. 
Total group of patients: 37 GIL cultures of II HTx patients were classified into 4 groups: 
those propagated from EMB obtained more than 2 weeks preceding rejection (>2 wks), 
within 2 weeks preceding rejection (2-1 wks), at time of rejection (R) and after rejection 
therapy (post R). Subsequently, donor specific pCTL and cCTL present within these GlL 
cultures were enumerated by LOA. Results are shown in figure 2. When several GlL cultures 
of a single patient were assigned to one group, the average pCTL and cCTL fr"'luency was 
used. 
Precursor CTL fr"'luencies found during rejection (median= 3688/10') did not significantly 
exceed values found more than 2 weeks preceding rejection (median= 697/10', p=0.181), 
within 2 weeks preceding rejection (median = 497110', p=0.180), nor after rejection therapy 
(median = 1799/10', p =0.456). A distinct pattern was found for donor directed cCTL (figure 
2). More than 2 weeks before histological diagnosis of rejection, a median fr"'luency of 26 
cCTLlIO' was found. Within 2 weeks preceding rejection this fr"'luency increased 9-fold, 
reaching maximal levels during rejection (median= 1376/10'). This increase was significant 
(p=0.OO8) as was the decrease in cCTL fr"'luency after therapy (median= 459/10'; 
p=0.018). 
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Figure 2: Appearance of donor specific CTL in relation to acute cardiac rejection: kinetics within the total group 
of lITx recipients. Frequencies of graft infiltrating donor specific pCTL (left) and cCTL (right) found more than 2 
weeks preceding rejection (>2wks), within 2 weeks preceding rejection (2-1 wlcs), during rejection (R) and after 
rejection therapy (post R) are shown. No significant difference in pCTL frequency was found. In contrast, cCTL 
frequencies increased significantly (p=O.OO8) towards rejection and recovered to basal levels after trealment 
(p~O.Ot8). 
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Individual patients; Of 5 HTx patients, GIL cultures were obtained from EMB taken before, 
during, as well as after cardiac transplant rejection. Using these serial GIL cultures, the 
kinetics of graft infiltrating donor specific CTL in the pathogenesis of rejection could be 
studied for individual patients. Table 1 shows donor specific tCTL, cCTL, and pCTL (tCTL-
cCTL) frequencies found during rejection (R) as well as n days before (-n) or after (+n) 
rejection. Donor directed pCTL and cCTL frequencies found during clinical rejection were 
compared to values found before and after this period. In figure 3, mean pre- and post-
rejection frequencies are depicted for each patient and combined with the CTL frequency 
found at the time of rejection. 
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Figure 3: Appearance of donor specific CTL in relation to acute cardiac rejection: kinetics within patient ER (A),KO 
(+; Rl), KO (0; R2). MO (y), VE (+) and FO (II). ])(lOOf specific pCTL (left) and cCTL (right) frequencies 
found within the graft during rejection (R) exceeded values found before· as well as after rejection. 
With exception of patient VE, the frequency of donor directed pCTL and cCTL increased 
during rejection. The median donor directed pCTL frequency found before rejection, 
265/10', increased to 3688/10' during rejection. The median donor specific cCTL frequency 
increased from 107/10' to 1376/10'. After successful rejection therapy, the median pCTL 
(74/10') and cCTL (35/10') frequency dropped below values found before rejection. Patient 
KO, who experienced 3 rejection periods, is depicted by dotted lines. Three weeks before 
rejection was diagnosed, donor specific CTL were hardly detectable. During rejection, the 
frequency of donor directed pCTL and cCTL increased enormously to 5649/10' and 
2459/10', respectively. After rejection therapy, the number of pCTL (209/10') and cCTL 
(346/10') decreased but still exceeded pre-rejection levels. A second rejection was diagnosed 
I week later. At the time of this second rejection, the frequency of donor directed pCTL and 
cCTL increased again to 1728/10' and 1767/10', respectively. After rejection therapy, the 
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frequency remained rather high (2327110' pCTL; 1299110' cCTL) and a third rejection was 
diagnosed 2 weeks later. 
CIL with high avidity for donor Ag gradually accumulate in the pathogenesis of acute 
cardiac rejection. 
Total group of patients: Significant more CTL with high avidity for donor Ag could be 
propagated from EMB obtained within 2 weeks preceding rejection than from EMB with 
comparable rejection grades taken before this period (p=O.OO7) or after rejection therapy 
(p<O.OOOI). Thus, despite histological resemblance, graft infiltrating donor directed CTL 
present at various timepoints around rejection have different characteristics. To investigate 
the involvement of high avidity CTL in the development of cardiac rejection, the fraction of 
graft infiltrating donor specific CTL having high avidity for donor Ag was determined 
throughout the rejection process. Figure 4 shows the kinetics for the total group of HTx 
patients tested. When donor specific CTL were absent, their avidity could not be determined. 
100 I 
pcn 
100 
cCTL 
• • 
,., 
• • 
.<;:: ~ 
'0 80 /\ 80 • ,. 
.;; 
• · ,
, , 
'" 
, , , , , , , , • 
.c
, , , 
, 
, , 
.!2' 60 .,' 
, 60 , , , 
..!: , 
.c ,L- , .. • 
, 
, 
, 
, , 
.c , I 
, 
• , 
, 
- · ' 
, , 
• , 
, 
'j; 40 j:' • , 40 r , , , , ' . 
..J • 
, , • 
, 
, , .. 
I- , , • () 20 " 20 I: • .-• .t- , • ~ • ~ • 0 • • I a • • • I a 
, 
.L 
>2wks 2·1wks R post R >2wks 2·1wks R post R 
Figure 4: Appearance of high avidity CTL in relation to acute cardiac rejection: kinetics within the total group of 
Hfx recipients. Fractions nfgrat\ infiltrating donor specific pCTL (left) and cCTL (right) with high avidity for donor 
Ag are depicted for the periods of more than 2 weeks before rejection (>2 wks), within 2 weeks preceding rejection 
(2-1 wks), during rejection (R) and after rejection therapy (post R). The fraction of donor directed cCTL with high 
avidity for donor Ag increases significantly during rejection (p=O.OO4) and decreases after treatment (p=O.OO5). 
More than 2 weeks before rejection, a small fraction of graft infiltrating donor specific pCTL 
appeared to have high avidity for donor Ag (median= 35%). Within 2 weeks preceding 
rejection, this fraction increased significantly, (median= 52%; p=O.OO4) and became 
dominant during rejection (median= 87%). After successful rejection therapy, the fraction 
of high avidity pCTL dropped to levels found for patients who never experienced rejection 
(median= 18%). Similar results were obtained for graft infiltrating donor specific ceTL. 
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More than two weeks preceding rejection, only 11 % (median) of donor specific cCTL had 
high avidity for donor Ag. Within 2 weeks preceding rejection, this fraction increased 
significantly (median= 55%; p=O.04) and became dominant during rejection (median= 
78.5%; p=O.OO4). After successful rejection therapy, the fraction of donor directed cCTL 
with high avidity for donor Ag decreased significantly (median= 24% p=O.OO5). 
Individual patients: The kinetics found for 5 single patients confirmed the pattern found for 
HTx patients in general (figure 5). During rejection, the fraction of graft infiltrating pCTL 
with high avidity for donor Ag (median 87.5%) exceeded the fractions found before rejection 
(median= 43%) as well as after rejection therapy (median= 6%) in 4 out of 5 patients. A 
comparable course was found for donor directed cCTL. For all patients, the fraction of cCTL 
with high avidity for donor Ag increased during rejection (median = 78.5 %) and decreased 
after rejection therapy (median= 22%) to pre-rejection levels (median= 21 %). 
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Figure 5: Appearance ofbigh avidity CTL in relation 10 acute cardiac rejection: kinetics within patient ER (A), KO 
(+ i Rl), KO (OJ R2), MO (',,), VE (.) and FO (D). During rejection (R), an increased fraction of donor specific 
pCTL (left) and cCTL (right) present bad high avidily for donor Ag. 
2.4. Discussion 
To investigate the importance of donor specific CTL in the pathogenesis of acute cardiac 
rejection, the frequency of graft infiltrating donor directed pCTL and cCTL present during 
clinical rejection was compared to values found before and after this period within the same 
patient. From this study, it appeared that donor specific pCTL and cCTL are present in the 
graft during rejection as well as during periods in which no histological signs of myocyte 
damage are observed. Studies using rat allograft models, showed the presence of donor 
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specific CTL within the graft to correlate with tissue destruction and that these cells were 
absent in grafts that survived indefinitely (Mason and Morris, 1984; Bradley et ai, 1985). 
Other studies described the presence of graft specific CTL within non-rejected rat kidneys 
(Dallman et ai, 1987) and within cardiac allografts of patients who never clinically rejected 
their graft (Ouwehand et ai, 1993). On first sight, these contradicting results question the 
importance of donor specific CTL in transplant rejection. The present report, however, 
demonstrates that the number of donor specific pCTL and cCTL present within the graft 
increases during rejection. Moreover, accumulation of donor reactive cCTL is initiated before 
rejection is diagnosed suggesting that the number of donor directed cCTL present within the 
graft is important for the induction of transplant rejection. 
The presence of donor specific pCTL within GIL cultures was not expected since only 
activated IL2-receptor expressing T-Iymphocytes were postulated to expand from EMB under 
the culture conditions used (Mayer et ai, 1985; Zeevi et ai, 1986). Possibly, the 
concentration of IL2 used resulted in expansion of all lymphocytes present within the biopsy. 
Alternatively, the donor directed pCTL measured were not totally naive pCTL nor fully 
mature cCTL but possibly resembled CTL between these two differentiation stages; the 
poised CTL as proposed by Gromo et a!. (1987). These CTL express IL2 receptors but 
require donor Ag to differentiate into cCTL. The heterogeneity of the pCTL pool would also 
explain why the rejection process is more unambiguous reflected by changes in the cCTL 
frequency than by changes in the pCTL frequency. 
According to the frequencies shown, GIL cultures do not totally consist of donor HLA class 
I specific CTL. Previous studies by LDA revealed that donor specific T-helper lymphocytes 
(unpublished results) and CTL specific for third party HLA determinants are present within 
EMB derived GIL cultures as well (Suitters et ai, 1990; Ouwehand et ai, 1993). Additionally, 
GIL cultures may contain donor HLA class II specific CTL (Ouwehand et ai, 1991), T-helper 
lymphocytes specific for third party HLA Ag, or T-Iymphocytes that recognize heat shock 
proteins (Moliterno et ai, 1995). 
The fraction of graft infiltrating donor specific CTL with high avidity for donor Ag could 
be estimated after addition of CD8 mAb to the cytotoxic phase of the LDA. The fraction of 
donor specific pCTL and cCTL with high avidity for donor Ag increased towards rejection 
and became dominant during rejection. After rejection therapy, this fraction recovered to low 
levels. The avidity of graft infiltrating CTL for donor Ag, therefore, seems to be a 
discriminating factor between rejection and "non-rejection". 
Only 2 other groups have studied the presence of high avidity CTL in clinical allograft 
models. Both groups examined PBL instead of GIL. Prior to clinical signs of transplant 
rejection, donor specific, CD8 mAb resistant, tCTL were found in the peripheral blood of 
kidney transplant recipients. In contrast, circulating donor specific tCTL, whose lytic 
capacity was almost completely blocked by CD8 mAb, were found in patients with a well 
functioning graft two years post-transplantation (De Hoop et ai, 1994). Similarly, circulating 
donor specific tCTL of patients with an ongoing rejection of their corneal allograft were 
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significantly less inhibited by CD8 mAb than circulating tCTL of patients with good graft 
functioning (Roelen et ai, 1995). Comparable results were obtained by our group using PBL 
of HTx patients (Vaessen et ai, 1995). 
Since donor specific cCTL are seldomly, if ever, detected in the circulation (Orosz and 
Bishop, 1990; Vaessen et al, 1992) we postulate that, prior to clinical rejection, donor 
specific pCTL with high avidity migrate to the transplant. At the graft side, these pCTL 
accumulate or are selectively expanded and differentiate into donor reactive cCTL with high 
avidity. Sufficient numbers of high avidity cCTL will then cause graft damage as observed 
histologically. After successful rejection treatment, the frequency of donor specific CTL as 
well as the fraction with high avidity decreases to basal levels. These alloAg specific CTL 
possibly died due to the rejection therapy given. 
Several observations support our assumption that donor specific CTL with high avidity for 
donor Ag are responsible for cardiac transplant rejection. First of all, this study shows that 
high avidity CTL are hardly detectable in periods of "non-rejection". Likewise, graft 
infiltrating CTL found after successful rejection therapy (Baan et ai, 1995), in non-rejectors 
(Ouwehand et ai, 1993; Vaessen et ai, 1994) or in neonatally made tolerant mice (Wood and 
Steilein, 1987) mainly have low avidity for donor Ag. Secondly, donor myocyte damage 
coincides with an enormous intragraft accumulation of donor directed CTL with high avidity. 
It has been described that high avidity CTL are reactive to cells expressing even low levels 
of HLA molecules whereas an increase in HLA surface density on target cells is required to 
induce lysis by low avidity CTL (Shimonkevitz et ai, 1985; Mentzer et ai, 1990). This 
illuminates our observation that the presence of donor specific CTL within the transplant not 
necessarily leads to graft damage. During periods of non-rejection, the HLA class I and II 
expression on myocytes is low (Milton and Fabre, 1985). As a result, binding and subsequent 
lysis of donor target cells by the low avidity CTL present is unlikely to occur. However, 
despite their low surface expression of HLA alloAg, myocytes serve as targets when high 
avidity donor specific CTL enter the graft and a rejection period is encountered. Direct 
evidence for the innocent bystander activity of low avidity CTL in vivo was only recently 
provided. Anti-K' Des-TCR transgenic mice able to reject K' skin grafts failed to do so after 
exclusive deletion of high avidity K' specific T ceUs (Hoffmann et ai, 1995). 
Some reports provided evidence that the avidity of CTL can be influenced by the HLA-
aUoAg expression on target cells. An increase in the number of interactions possible between 
CTL and target cells was found to reduce the CTLs susceptibility to CD8 blocking (Mentzer 
et ai, 1990; Hill et ai, 1992). Likewise, a decrease in alloAg density on target ceUs reduced 
the avidity of the CTL (Maryanski et al, 1988). In our test system, however, LDA was 
conducted simultaneously on all GIL samples of each individual patient. In this way, the 
enhanced CTL avidity found shortly before and during rejection can not be ascribed to the 
target cells used. 
Conclusively, data presented in this article imply that sufficient numbers of donor specific 
CTL with high avidity induce transplant rejection. 
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Table 1. Donor specific tCTL, cCTL and pCTL frequencies in absence or presence of CDS mAb. 
RE' R' FREQ (95% CQ FREQ (95% eI) FREQ (95% CQ FREQ (95% en FREQ FREQ 
-1+ n days ten. tCTLFK' ,en. ,CTLFI( pCTL pCTLFK 
ER 
-4' 566 (434-<'7) 11 (0-27) 30 (6-55) 20 (0-3,) 546 0 
ER R 2988' (19304-40475) 32542 ('20968-44117) 986 (752.1220) 877 (673-1080) 28903 31665 
ER +2' 162 (85-240) 2' (0-63) 50 (6-94) 11 «().33) 112 IS 
KO -22 0 II>'J) 0 (0-<» 0 (0-0) 0 (0-0) 0 0 
KO Rl' 8101 (6066-10137) 1458 (1115.1801) 2459 (1907·3012) 800 (618.982) 564' 658 
KO +6/-7 SS5 (420-689) 161 (103-219) 346 (254-437) 72 (33-110) 209 89 
KO R2 3495 ('2469-4520) 154' (1179-1918) 1767 (1305-2228) 1937 (1488-2387) 1728 0 
KO +211-14 3626 ('2769-4484) 1671 ' (1296-2046) 1299 (955-1643) 742 (581-902) 2327 929 
KO R3 NO NO NO NO NO NO 
MO -14 27' (193-365) 132 (79-186) m (150-295) 132 (79-186) 57 0 
MO -7 587 (440-734) 464 (331.597) 145 (71-219) OS ('20-110) 442 399 
MO R 1790 (1429.2151) 1538 (1186-1890) ill (7oz..U48) 502 (361-643) 865 1036 
MO +21 0 II>'J) 0 (0-0) 0 II>'J) 0 (0-0) 0 0 
MO +24 graft failure 
VB -21 1328 (1035-1621) 376 ('276-475) 480 (363-598) 226 (!s7-2'5) 848 !SO 
VB -14 '83 (757-1209) 723 (526-920 448 (346-SS0) 50s (380-630) 535 218 
VB -7 510 (350-66,) 3S1 (246-516) 59 (25-94) 36 (7-65) 451 345 
VB R 178 (119-238) 218 (142-294) 126 (75-178) 97 (48-147) 52 121 
VB +35 2388 (1369-2907) 214 (141.288) S37 (384-691) 160 (103-217) 1851 54 
FO ·27 3799 (2594-5004) 1437 (1017-1858) 23 (15-3!) 11 (0-33) 3776 '426 
FO R 4430S (25423-63187) 33165 ('21339-44991) '784 (1410-2157) 1433 (1141-1724) 42521 31732 
FO +7 36 (7-65) 6 (0-17) 0 (0-<» 0 II>'J) 36 6 
FO +76 43 (11-74) 11 (0-27) 4. (12-70) .7 (0-37) 2 0 
Donor specific tCTL. cCTL and pCTL (tCTL-cCTL) present within cardiae allografts of S heart transplant recipienti at the time of rejection (R) as well as n days before 
(-n) or after rejection (+nf were enumerated by lOA. Subsequently, the frequency of donor specific CTL with high avidity for donor Ag was determined by addition of CDS 
mAb (FK18») to the LDA. The frequency of donor specific CTL as well as the fraction of these CTL having high avidity for donor Ag increases during rejection and decreases 
after rejection therapy. Primary rejections arc stated as Rl<4_ Likewise, secondary and third rejections are stated as R2 and RJ, respectively. One patient (MO) suffered from 
total graft. disfunctioning, as a result graft infiltrating CTL frequencies were below detection limits at that time. 
Chapter 3 
The avidity, not the mere presence, of primed CTL for 
donor HLA class II antigens determines their clinical 
relevance after heart transplantation 
To analyze the relevance of CD4-positive cytotoxic T lymphocytes (CTL) in clinical cardiac 
rejection, we studied the frequency and avidity of donor HLA class II specific CTL present 
within the graft during a rejection episode and during a period without rejection_ For this 
analysis, endomyocardial biopsies (EMB) of heart transplant recipients were cultured to 
obtain graft infiltrating lymphocytes (GIL). GIL cultures exhibiting donor class II directed 
cytotoxicity were considered for the present study. Using limiting dilution analysis (LDA), 
the frequency of donor class II specific CTL that had been primed by donor antigens (Ag) 
in vivo (designated cCTL) was determined in GIL cultures established from EMB taken 
during a rejection episode (n = 10) or during a period without rejection (n = 11). Addition of 
anti-CD4 to the LDA, revealed the fraction of donor class II specific cCTL having a high 
avidity for donor Ag. During a rejection episode, 196 (median) donor class II specific 
cCTLl106 GIL were present. In a period without rejection, the frequency of donor class II 
specific cCTL was not significantly different (median =330/10';p =0. I). Addition of anti-
CD4, however, revealed that donor class II specific cCTL with a high avidity for donor Ag 
are predominant during a rejection episode (median = 100%) but are in minority during a 
period without rejection (median=35%; p<O.OOOI). These results suggest that graft 
infiltrating CD4 +CTL can mediate cardiac rejection provided they have a high avidity for 
donor Ag. 
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3.1. Introduction 
Acute rejection is most commonly seen within the first 3 months after cardiac transplantation 
(Balk et al, 1991) and is characterized by the presence of mononuclear cell infiltrates and 
myocyte damage or myocyte necrosis in the graft. In general, CTL are postulated to function 
as terminal effeclor cells, directly mediating tissue damage. Indeed, enumeration of donor 
HLA class I specific CTL propagated from sequential EMB of heart transplant (HTx) patients 
revealed that increased numbers of donor class I reactive CTL were present within the graft 
at the time of acute rejection. More importantly, during and immediately preceding acute 
rejection, these cells mainly had a high avidity for donor Ag; i.e. these CTL did not require 
CD8 molecules to stabilize their binding with donor target cells. In contrast, in the absence 
of rejection, graft infiltrating donor class I specific CTL mainly had a low avidity for donor 
Ag (Van Emmerik et al, 1996). This relationship between the CTLs avidity for donor class 
I Ag and the occurrence of graft rejection is supported by data of other groups (roelen et ai, 
1995; Hoffmann et al, 1995). 
Unlike CTL specific for allogeneic HLA class I determinants, HLA class II allospecific CTL 
are rarely reported in correlation with clinical transplant rejection. In only 2 studies data have 
been obtained by testing GIL cultures for cytotoxicity towards donor class II determinants 
(Micelli et al, 1988; Duwehand et ai, 1991). Using GIL cultures established from biopsies 
performed at different time points after cardiac transplantation, we reported a significant 
decrease in the incidence of donor class II directed cytotoxicity more than 3 months after 
transplantation (Duwehand et ai, 1991). This decrease run parallel with a decline in the 
occurrence of acute rejection. Although this observation suggested an involvement of class 
II specific CTL during the most reactive phase after transplantation it did not prove a direct 
causal relation between class II alloreactivity and transplant rejection. 
In the present report, we analyzed whether donor HLA class II specific CTL propagated 
from EMB taken during rejection episodes or during periods without rejection were distinct 
with respect to their frequency and avidity for donor Ag. LDA was employed to selectively 
quantitate CTL that had been primed by donor class II Ag in vivo (designated cCTL; Orosz 
et al, 1989). The fraction of these cCTL having a high avidity for donor class II Ag was 
determined by addition of CD4 mAb to the cytotoxic phase of the LDA. The CD4 molecule 
stabilizes the interaction between a T cell receptor (TCR) and a HLA class II-peptide 
complex. CTL which benefit most from such interactions and therefore are most dependent 
on CD4, express TCR with low affinity for their Ag. Likewise, CD4 independent CTL 
express TCR with high affinity for their Ag (Biddison et al, 1982; Marrack et al, 1983; 
Greenstein et al, 1985; Gougeon et al, 1985; Sleckman et al, 1987). Hence the effect of CD4 
blocking on the cytotoxic capacity of CTL reveals their overall avidity for HLA class II 
determinants. Alternatively, it has been suggested that CD4 blocking directly delivers 
negative signals to the CD4+CTL (Fleischer et al, 1986). Thus, inhibition of CD4+CTL 
reactivity by CD4 mAb would reflect a negative signal transmitted by this antibody rather 
than their low avidity. However, as reviewed by De Vries et al. (1989) the "negative signal" 
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hypothesis is only valid in case of non-antigen specific T cell activation by CD3 mAb and 
therefore does not apply to the present report. 
The results obtained demonstrate that cCTL with a high avidity for donor class II Ag are 
predominant within the graft during an acute rejection episode whereas cCTL with a low 
avidity for donor class II Ag are predominant within the graft during periods without 
rejection. 
3.2. Materiais and Methods 
Patiellls. We studied 1409 EMB (135 with and 1274 without histological signs of acute 
rejection) obtained from 94 heart transplant patients during the first year after transplantation. 
These patients had mismatches for both HLA class I (HLA-A and B) and class II (HLA-DR) 
with their donor. An patients received a preoperative blood transfusion while cyclosporin A 
and low dose steroids only were used as maintenance immunosuppression. EMB were 
routinely taken at a weekly interval during the first 6 weeks after transplantation and once 
in two weeks in the following 4 weeks. Later EMB were taken less frequently, declining to 
once every 4 months at 1 year. Acute cardiac rejection was diagnosed by histopathology of 
EMB according to ISHLT criteria (Billingham et ai, 1990). Anti-rejection treatment was 
instituted when mononuclear cen infiltrates coexisted with myocyte damage or myocyte 
necrosis (grade 3A or more) and consisted of bolus steroids or a 2-weeks course of a 
polyclonal rabbit anti-thymocyte globulin preparation in case of ongoing rejection. 
Lymphocyte cultures. Graft infiltrating lymphocyte (GIL) cultures were established as 
described previously (Ouwehand et ai, 1991). Briefly, each biopsy was cultured in a 96-well 
round bottom culture plate (Costar, Cambridge, MA) with 200 "I culture medium per wen, 
in the presence of 10' irradiated (30 Gy) autologous peripheral blood mononuclear cells 
(PBMC) as feeder cells. Due to the absence of donor Ag in this system, no de novo 
stimulation can take place in vitro. As a result only those CTL that have already been primed 
by donor Ag in vivo (cCTL) will be functional against donor Ag. Naive precursor CTL 
(PCTL) will not differentiate into eCTL. Culture medium consisted of RPMI-I640 Dutch 
Modification (Gibco, Paisley, Scotland), supplemented with 4mM L-glutamine, 100 IU/mI 
penicillin, 100 "g/ml streptomycin and 10% pooled human serum. Additionally, 10% vlv 
lectin free Iymphocult-T-LF (Biotest GmbH, Dreieich, Germany) was added as source of 
IL2. The plates were incubated in a humidified atmosphere at 37°C in 5% CO,. Established 
GIL cultures were phenotyped and tested for cytotoxicity against HLA-A, B and DR 
determinants for which the cardiac donor and the recipient were mismatched. 
Donor specific T cen clones were generated from GIL cultures by limiting dilution at 0.3 
cellslwell in culture medium supplemented with lymphocult-T-LF and 0.5-1 % 
phytohaemagglutinin (PHA; Difeo, Detroit, MI). Irradiated (30 Gy) donor B-LCL (5x10' 
e/ml) and PBMC of hcalthy blood donors (5x10' e/ml) were added as feeder cells. After 2 
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weeks, wells with visible cell growth were restimulated with irradiated donor B-LCL and 
PBMC of healthy blood donors. 7-14 days later, clones were phenotype<! as described below 
and assayed for donor specific cytotoxicity. Clones used in the present study totally consisted 
of CD4+WT31 +cells and exhibited cytotoxicity towards I HLA-DR determinant for which 
the recipient and donor were mismatched. 
PBMC were isolated from heparinized venous blood of the transplant recipient by Ficoll-
Hypaque density gradient centrifugation. Cells were washed twice in HBSS (Gibco) and once 
in RPMI-I640. 
T-cell blasts were obtained by culturing PBMC or spleen cells for 4-7 days in culture 
medium supplemented with 10% v/v Iymphocult-T (Biotesl) and 1% PHA. 
B-lymphoblastoid cell lines (B-LCL) originated from infection of fresh PBMC or spleen cells 
with Epstein Barr Virus obtained from the marmoset cell line B95-8 as described by Moreau 
et al. (1986). These cell lines were maintained in RPMI-I640 supplemented with 10% heat-
inactivated bovine calf serum (Hyclone, Logan, Utah). 
Phenotypic analysis. GIL cultures and T cell clones established from GIL cultures were 
analyzed for WT31, CD8 (Becton Dickinson), and CD4 (immunotech, Marseille, France) 
expression by three-color flow cytometry on a FACScan after staining with mAb directly 
conjugated for fluorescein, PERPC, and phycoerythrin, respectively. 
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Figure 1: Lysis by CD4+CTL clones of T cell blasts (+) and B-LCL (U) expressing similar lILA class II 
determinants. Lysis ofunrelaled B·LCL <,,> was used as a control for spedficity. 
Cell mediated /ympholysis (CML). The cytotoxic capacity of GIL cultures (or T cell clones 
established from GIL cultures) was tested against donor cells and a panel of target cells 
sharing either HLA class I or class II determinants with the donor. Briefly, effector cells 
were incubated with 2500 "Cr-Iabelled target cells at different effector:target (E:T) ratios in 
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0.2 ml culture mooium. After 4 hours of incubation, supernatants were harvestoo and the 
release of "Cr was measuroo as describoo in the LDA section. 
B-LCL servoo as target ceHs to measure donor class I (lILA-A and B) directoo cytotoxicity 
as weH as donor class II (lILA-DR) directoo cytotoxicity. T cell blasts servoo as target cells 
to measure donor class I directoo cytotoxicity exclusively. The incapability of T ceH blasts 
to serve as target ceHs for class II alloreactive CTL is base<! on CML assays using donor 
class II specific CD4+CTL clones establishoo from GIL cultures. These CTL clones (n=8) 
effiCiently Iysoo donor B-LCL but failoo to lyse donor T cell blasts even when use<! at high 
E:T (20: I) ratios (figure I). 
As a control for specificity, GIL cultures were testoo against unrelatoo target cells and the 
K562 cell line. A CML assay was consideroo positive when the percentage of specific lysis 
of target cells exceOOoo 10% and the slope of the graph was positive. 
Limiting Dillltion Analysis. Limiting dilution cultures were set up in 96-weH round bottom 
microculture plates (Costar). Responder cells (GIL) were titratoo in 8 double dilution steps 
starting from 5000 ceHs per well to 39 ceHs per well. AH dilutions were performoo in 24 
replicates and 50,000 irradiatoo (30 Gy) autologous PBMC were addoo to each well in a total 
volume of 0.2 ml culture medium supplementoo with 20 U/ml rIL2 (Biotest). When 
autologous PBMC are used as stimulators, only in vivo activated CTL (cCTL) and not their 
naive precursors (PCTL) proliferate and develop LDA-detectable cytolytic activity (Orosz et 
ai, 1989). After 7 days of culture, all 96-weH plates were split into two and CD4 mAb was 
added to half of the split wells as described below. Subsequently, each weH was individually 
tested for its capacity to lyse 2500 "Cr-Iabelled target cells. 
As described in the CML section, B-LCL can serve as target cells for HLA class II specific 
CTL. However, by using donor B-LCL as target ceHs in LDA, the total sum of donor class 
I and II specific cCTL would be quantitated. To selectively quantitate donor class II specific 
CTL, B-LCL that lack HLA class I similarities but share HLA class II similarities with the 
donor are requiroo. In the present report, we usoo B-LCL sharing HLA-DR Ag with the 
donor. LDA cultures were incubated for 4 hrs at 37'C in 5% Co,. Supernatants were 
harvesled using a Skatron harvesting system (Skatron-AS, Lierse, Norway) and release of 
"Cr was assayoo in a Packard gamma-counter (packard Downers Grove, USA). Spontaneous 
and maximum release were defined by incubation of target cells with culture mooium in the 
absence or presence of triton X-loo detergent (5% v/v solution in 0.01 TRIS buffer), 
respectively. Microcultures were considered cytolytic when the experimental lysis percentages 
exceOOed 10%. As a control for specificity, the reactivity of cultures with the highest 
responder concentration was tested against third party B-LCL and against the K562 ceHline. 
CD4 inhibition slIIdy. Before addition of "Cr-Iabelled target cells to the LDA, half of the 
split wells were preincubated with ll'g/ml RIV6, a mouse anti-human antibody of the IgG2A 
subclass directoo against the CD4 molecule (a kind gift of Dr. M.F. Leeriing, RIVM, 
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Bilthoven, The Netherlands) during 30 minutes at 37°C in a humidified atmosphere 
containing 5 % CO,. This concentration of CD4 mAb totally inhibited the cytotoxic capacity 
of CD4-dependent CTL clones but did not affect target cell lysis by CD4-independent CTL 
clones (figure 4). As a control antibody, FKl8 (a mouse anti-human antibody of the IgG3 
subclass directed against the gp32 chain of the CD8 molecule) was used at a 1 :500 dilution 
of ascitic fluid (2). Irrespective of their susceptibility to inhibition by RIV6, CD4+CTL 
clones were not affected by FKI8. Likewise, addition of FKI8 to LDA cultures with the 
highest responder cell concentration did not influence their cytolytic response towards donor 
class II Ag. 
Frequency calculation. Minimal estimates of graft infiltrating cCTL frequencies were 
calculated by analysis of the Poisson distribution relationship between the number of 
responder cells added to the wells and the percentage of replicate cultures that failed to 
develop cytotoxicity (Strijbosch et aI, 1987). In our test system, microcultures were only 
considered cytolytic when the experimental lysis percentages exceeded 10%. The frequency 
of donor reactive cCTL, expressed as the number of cCTL per 10' GIL, was calculated with 
the maximum likelihood estimation adapted with a jackknife method. The calculated 
frequencies were accepted when the goodness-of-fit did not exceed 12. 
Subsequently, the fraction of class II allospecific cCTL having high avidity for donor HLA 
class II Ag could be calculated using the following formula: 
freg of donor spec. CTL willt CD4 mAb 
fraction (%) = loox freq of donor spec. CTL without CD4 mAb 
Statistics. The frequency and avidity of donor directed cCTL present during a rejection 
episode or during a period without rejection were compared using the Mann-Whitney-U-Test. 
3.3. Results 
CIL specific for donor class 11 Ag can be propagated from EMB of cardiac transplant 
recipients. To analyze the participation of both CD8+CTL and CD4 +CTL in acute cardiac 
rejection, we tested the cytotoxic function of 525 lymphocyte cultures established from 1409 
EMB obtained from 94 heart transplant recipients during the first year following 
transplantation. To distinguish between the activity of donor specific CD8+CTL and 
CD4+CTL, target cells were used sharing either HLA class I or class II determinants with 
the donor. Results of the CML assays are shown in figure 2. The presence of donor specific 
CTL appeared not to be restricted to grafts showing histological evidence of acute rejection 
(Le. myocyte damage). Donor directed cytotoxicity was observed in 87% and 76% of the 
lymphocyte cultures e.,tablished from EMB with and without myocyte damage, respectively. 
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Of these donor reactive cultures, no less than 60% exhibited cytotoxicity towards donor HLA 
class II Ag (either alone or in combination with reactivity towards donor class lAg). 
" •
" .'l 0 
~ 
" ~ 
" 0 
'0 
"' 
80 
60 
o 
no rejection 
n"'454 
Bcute rejection 
n=71 
reactivity against: 
Odonor class t only 
IIdonot class t and 11 
III donor class 11 only 
Ftgure 2: The cytotoxic capacity of lymphocyte cultures established from EMB of cardiac trallsplant recipients was 
tested against a panel of target cells sharing either HLA class I or class IT Ag with the donor. Reactivity towards 
donor HLA class I and/or class IT determinants was observed both in cultures obtained from EMB with and without 
histological signs of rejection. 
Acute cardiac rejection does not coincide with an increosed frequency of donor closs II 
specijic cCTL. Donor class II specific cCfL were enumerated within 21 GIL cultures 
showing donor class II specific cytotoxicity in CML assays. Ten GIL cultures were 
established from EMB taken during a rejection episode (8 EMB were obtained at the time 
of acute rejection, 2 EMB were obtained 1 week preceding acute rejection). Eleven GIL 
cultures were obtained from EMB taken during a period without rejection. EMB depicting 
a rejection episode were taken early aner transplantation [median =40 days post-transplant 
(range=21-125 days)] whereas EMB representing a period without rejection were obtained 
at later timepoints [median=213 days post-transplant (range = 122-280 days)]. No differences 
were found in the percentage of CD4+lymphocytes present [median=37% (range=2-99%) 
and 45% (range = 1-98%), respectively], the culture time [median =29.5 days (range=20-45 
days) and 34 days (range=25-79 days) respectively] nor the number ofHLA-DR disparities 
between donor and acceptor [mean = 1.50 and 1.64, respectively]. 
In figure 3A, frequencies of cCTL reactive to target cells expressing donor HLA class II Ag 
are depicted. During a rejection episode, 196 (median; range=48-404) donor class II reactive 
cCTLlI0' GIL were found. In a period without rejection, the frequency of donor class II 
reactive cCTL was not significantly different (median=330/l0' GIL; range=95-2799; 
p=O.lO). No reactivity towards the K562 cell-line nor towards third party B-LCL was 
observed. 
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Figure 3: Donor lILA class II specific cCTL propagated from EMB taken during a rejection episode or during a 
period without rejection were enumerated by LOA. The frequency (figure 3A; median) of donor class II specific 
cCTL fouod within both periods is comparable (p=O.I: Mann-Wbitney-U-test). The fraction of these cCTL baving 
a high avidity for donor Ag was determined by addition of RIV6 to the cytotoxic phase of the LOA (figure 38). A 
significant higher fraction (median) of the donor class II specific cCTL bad a high avidity for donor Ag during a 
rejection episode than during a period without rejection (p <0.0001: Mann-Whitney-U·test). 
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Figure 4: The susceptibility of class n directed CD4 tCTL clones for RIV6 is depicted. RIV6 did not affect the 
cytolytic capacity of clone 39 (+j E:T= 2.5:1) but effectively inhibited target cell lysis by clone 18 (.j E:T= 20:1). 
Dased on the dose·response curves, 1 flg/ml RIV6 was added to the cytotoxic pbase of LOA to discriminate between 
CTL with a high (RIV6 resistant) and those with a low avidity for class n Ag (RIV6 sensitive). Addition of the 
control antibody. FKl8 (a murine anti·buman CD8 mAb) did not affect the cytotoxic activity of the clones. 
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ACllte cardiac rejection Is associated with the quality of the donor class J/ specific cCIL 
poplllation presellf. The ability of CD4+CTL clones to exhibit class IT directed cytotoxicity 
in the presence of different doses of RIV6 (a CD4 mAb) was tested in a CML assay. 
Representative results are shown in figure 4. Concentrations of RIV6 as high as 5 I'giml did 
not affect the cytolytic capacity of clone 39. In contrast, target cell lysis by clone 18, even 
when used at an E:T ratio of20:1, was strongly inhibited by RIV6. Hence, clone 39 cells 
have a high avidity for Ag whereas clone 18 cells have a low avidity for Ag. As a control 
antibody, FKI8 (a CD8 mAb) was used (2). This antibody did not affect target cell lysis by 
CD4 + CTL clone 18 nor by CD4 + CTL clone 39. 
We added RIV6 at a concentration of 1 I'giml to the cytotoxic phase of the LDA. As 
depicted by figure 4, this concentration of RIV6 is very effective to discriminate between 
class II specific CTL with either a high or a low avidity for Ag. The fraction of donor class 
II specific cCTL having a high avidity for donor Ag is shown in figure 3B. A prominent 
fraction of the donor class II specific cCTL propagated from EMB taken during a rejection 
episode had a high avidity for donor Ag (median=IOO%; range= 57-100%). In contrast, a 
significant smaller fraction of the donor class II specific cCTL propagated from EMB 
obtained during a period without rejection had a high avidity for donor Ag (median=35%; 
range= 0-66%; p <0.0001). These data show that cCTL with a high avidity for donor class 
II Ag are selectively present within the cardiac allograft immediately preceding and during 
acute rejection. 
3.4. Discussion 
Although it is well accepted that T cells mediate acute allograft rejection, there is still 
controversy over which T-cell subset is responsible for the tissue destruction. Since 
accumulation of donor specific CTL in allografts coincides with graft destruction (Suitters 
et al, 1990; Bishop et al, 1992; Van Emmerik et ai, 1996), it is tempting to believe that CTL 
act as terminal effector cells. Support for the involvement of CTL is provided by experiments 
showing the exquisite antigen specificity of the alloresponse (Mintz et al, 1967; Sutton et al, 
1989) and the ability of CTL clones grown from rejecting allografts to destroy allogeneic 
tissue when injected into appropriate hosts (Snider et al, 1986). In contrast, experiments 
showing the occurrence of graft rejection in the absence of CD8+T cells have been 
interpreted as evidence against a critical role for CTL in transplant rejection (Simpson, 
1993). This interpretation, however, is dependent on the assumption that all cytotoxic T cells 
are contained in the CD8+subset thereby neglecting the existence of CD4+CTL. 
In the present report, the contribution of CD4 +CTL to clinical cardiac rejection is analyzed 
and compared to data on CD8+CTL obtained by previous studies. First, we studied whether 
the presence of donor specific CD8+CTL and CD4 +CTL within the graft is associated with 
acute cardiac rejection. For this analysis, graft infiltrating lymphocytes propagated from 
routinely taken EMB were tested for cytotoxicity towards HLA class I and II determinants 
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for which the acceptor and donor were mismatched. In general, class I directed cytotoxicity 
is more frequently observed than class II directed cytotoxicity (figure 2). This might be due 
to the distribution of potential target cells in the transplanted human heart. Whereas HLA 
class I expression is observed on both myocytes and interstitial structures, HLA class II is 
only expressed on interstitial structures. 
Lymphocyte cultures established from EMB with histological signs of acute rejection 
frequently displayed cytotoxicity towards donor HLA class I and/or class II determinants. 
Yet, EMB without histological signs of rejection also regularly grew lymphocytes exhibiting 
donor class I and/or class II directed cytotoxicity in vitro. If CTL are implicated in allograft 
rejection, the question arises why these latter CTL do not mediate destruction of the graft 
from which they were recovered. 
Enumeration of donor HLA class I specific cCTL propagated from sequential EMB of heart 
transplant recipients recently revealed that increased numbers of donor class I reactive cCTL 
were present within the graft at the time these patients experienced acute rejection. More 
importantly, it appeared that class I specific cCTL present within the cardiac allograft during 
a rejection episode or during a period without rejection had different characteristics. During 
and immediately preceding acute rejection, graft infiltrating donor class I specific cCTL 
mainly had a high avidity for donor Ag. During a period without rejection, intragraft donor 
class I specific cCTL mainly had a low avidity for donor Ag (Van Emmerik et ai, 1996). 
Accordingly, the frequency and avidity of donor specific cCTL seem to be discriminating 
factors between rejection and no-rejection. 
Subsequently, we analyzed whether donor class II specific cCTL propagated from EMB taken 
during a rejection episode or during a period without rejection were distinct with respect to 
their frequency and avidity for donor Ag. No differences were found for the number of donor 
class II specific cCTL present. During a rejection episode, however, the majority of the graft 
infiltrating donor class II specific cCTL had a high avidity for donor Ag. In contrast, during 
a period without rejection, intragraft donor class II specific cCTL were generally found to 
have a low avidity for donor Ag. These data imply that a predominance of high avidity cCTL 
among the graft infiltrating donor specific cCTL population is relevant for acute cardiac 
rejection. 
Only a few other studies have been reported on the avidity of donor specific CTL in relation 
to transplant rejection. All of these studies considered CDS+CTL directed towards donor 
class I Ag. Donor specific CTL present within the peripheral blood of corneal transplant 
patients experiencing rejection mainly had a high avidity for donor Ag whereas circulating 
donor specific CTL of corneal transplant patients with a good graft function mainly had a low 
avidity for donor Ag (Roelen et ai, 1995). Kinetic analysis within individual heart transplant 
recipients demonstrated that a progressive accumulation of high avidity, donor specific cCTL 
within the allograft coincided with acute rejection (Van Emmerik et aI 1996). In addition, 
early after cardiac transplantation when acute rejection is most frequently experienced, graft 
infiltrating CTL of patients that never rejected their allograft generally had a low avidity for 
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donor Ag (Vaessen et al, 1994). Likewise, CTL in heart transplants of neonatally made 
tolerant mice (Wood and Streilein, 1987) had a low avidity. According to these observations 
and the data presented in this report, high avidity donor specific CTL might be crucial·for 
the occurrence of transplant rejection whereas low avidity donor specific CTL might be 
insignificant in vivo. 
To explain this concept we suggest the following model. High avidity CTL have been 
described to lyse cells expressing even low levels of HLA molecules whereas a strong HLA 
surface expression on target cells is required for target cell lysis by low avidity CTL 
(Marrack et al, 1983; Gougeon et al, 1985; Shimonkevitz et al, 1995; Mentzer et al, 1990). 
In absence of acute rejection, the HLA class I and II expression on donor heart tissue is weak 
(Milton et al, 1985; Suitters et al, 1987). As a consequence, binding and subsequently lysis 
of donor target cells by the low avidity donor specific cCTL present is unlikely to occur. 
Nevertheless, donor cells with a low surface expression of HLA class I and II determinants 
might serve as targets when high avidity donor specific cCTL enter the cardiac allograft. 
Direct evidence for the inability of low avidity CTL to mediate tissue destruction in vivo was 
only recently provided. Anti-Kb TCR transgenic mice able to reject K" skin grafts failed to 
do so after exclusive deletion of high avidity Kb specific T cells (Hoffmann et al, 1995). 
Our opinion that cCTL exhibiting donor class II directed cytotoxicity might contribute to 
cardiac tissue destruction, is challenged by others. Rejection of cardiac allografts in mice 
depleted for CD8-bearing cells was reported to occur in the absence of detectable numbers 
of graft infiltrating CD4+cCTL (Bishop et ai, 1993). However, donor T cell blasts were used 
as target cells to enumerate these CD4+cCTL. Since we have repeatedly failed to detect class 
II directed cytotoxicity in CML assays using T cell blasts (figure I) we question whether 
CD4 +cCTL would still be undetectable in this experimental system when B cell blasts had 
been used as target cells instead. 
To investigate the ability of CTL to mediate cardiac tissue destruction and if so, whether this 
ability depends on their avidity for donor Ag, one should actually use donor myocytes as 
target cells. Unfortunately, up to now one has failed to grow adult type myocytes to solve 
this issue. 
In conclusion, cited literature and the results of the present study suggest that graft 
infiltrating cCTL with a high avidity for donor HLA class I or II Ag may be involved in 
cardiac allograft rejection whereas intragraft cCTL with a low avidity for either donor class 
I or class II Ag may not. 
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Chapter 4 
Kinetics of circulating CTL precursors that have a high 
avidity for donor antigens: Correlation with the rejection status 
of the human cardiac allograft 
Studies on graft infiltrating cells demonstrated that accumulation of cytotoxic T lymphocytes 
(CTL) with a high avidity for donor antigens (Ag) coincided with acute cardiac rejection. In 
the present study, we analyze whether such high avidity CTL are present within the 
peripheral blood of cardiac transplant recipients and whether their kinetics correspond with 
the rejection status of the allograft. Using limiting dilution analysis (LDA), donor specific 
CTL were enumerated in serial blood samples of 7 patients. From each patient, 7-11 samples 
were obtained during the first year after transplantation and 1-3 samples were obtained later. 
Enumerated donor specific CTL were divided into CTL with a high or a low avidity for 
donor Ag depending on their sensitivity to CD8-blocking. In contrast to the situation in the 
graft, donor specific CTL present within the peripheral blood were CTL precursors (PCTL) 
and not fully mature CTL (cCTL). The number of donor specific pCTL among peripheral 
blood cells fluctuated irrespective of the rejection grade of the allograft indicating that the 
frequency of circulating donor specific pCTL does not reflect the immunological status of 
the allograft. During acute cardiac rejection, 66% (median) of the circulating donor specific 
pCTL had a high avidity for donor Ag. This percentage significantly exceeded pre- and post-
rejection values obtained during the first year post-transplantation (median=39% and 37%, 
respectively). The disparity in avidity increased even further more than I year after 
transplantation when stable engraftment was achieved. Among peripheral donor specific 
pCTL those with a high avidity were absent (median=O%). Hence, the avidity of circulating 
donor specific pCTL might inform us about the immune status of the cardiac allograft. 
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4.1. Introduction 
Several attempts have been made to associate the number of donor specific CTL among 
peripheral blood mononuclear cells (PBMC) with the immunological status of the human 
allograft. Stable engraftment achieved long after transplantation was found to correspond with 
a reduction of circulating donor specific CTL in some (Herzog et ai, 1987; Mathew et ai, 
1993; Hu et ai, 1994) but not all cases (Zanker et ai, 1993; Eberspacher et ai, 1994). During 
a period of immunological activity, the relationship between the frequency of circulating 
donor specific CfL and the rejection status of the allograft appeared to be controversial as 
well. Reader et al. (1990), demonstrated that donor specific CTL frequencies found in blood 
samples of heart transplant recipients at the time of acute rejection exceeded those found in 
blood samples obtained in the absence of acute rejection. In contrast, no such distinction 
could be made according to data reported by others (Steinmann et ai, 1990; Roelen et ai, 
1995). Apparently, the frequency of circulating CTL does not adequately reflect the rejection 
grade of the allograft. 
In a previous study on heart transplant recipients, we demonstrated that donor specific CfL 
propagated from endomyocardial biopsies (EMB) obtained during a rejection episode were 
distinct from those obtained during a period without rejection. Whereas the former CTL 
mainly had a high avidity for donor Ag, the latter CTL generally had a low avidity for donor 
Ag (Ouwehand et ai, 1993; Vaessen et ai, 1994; Van Emmerik et ai, 1997). These data 
suggest that the avidity of donor specific CfL might serve as a parameter to distinguish 
between "acute rejection" and "non-rejection". Subsequent kinetic studies within individual 
patients demonstrated that CTL with a high avidity for donor Ag accumulated within the graft 
shortly before and during acute rejection (Van Emmerik et ai, 1996), which made us 
reasoning that these CTL might be present within the peripheral blood ~efore they enter the 
graft. 
In order to assess the relationship between the avidity of circulating donor specific CTL and 
the immunological status of the cardiac allograft, donor specific CTL present within serial 
PBMC samples of heart transplant recipients were enumerated by limiting dilution analysis 
(LDA). Subsequently, these CTL were divided into CTL having a high or a low avidity for 
donor Ag based on their resistance or sensitivity to CD8 mAb, respectively (MacDonald et 
ai, 1982; Cai and Sprent, 1994; De Vries et al, 1989; Auphan et ai, 1994). The fraction of 
donor specific CTL that had a high avidity for donor Ag was then compared with the 
rejection status of the graft in order to determine whether the avidity of circulating donor 
specific CTL is indicative of cardiac rejection. 
4.2. Materials and Methods 
Patients. Seven recipients of cardiac allografts form the basis of this report. These patients 
received a single preoperative blood transfusion. After transplantation, a 7 days course of 
OKT3 was given as induction therapy while only cyclosporin A and low dose steroids were 
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used as maintenance immunosuppression. The number of HLA mismatches between donor 
and recipient for the A, B, and DR antigens are shown in table 1. In the early posttransplant 
period serial biopsies were obtained at weekly intervals. Later EMB were taken less 
frequently, declining to ones every 4 months at I year. The rejection status of the graft was 
determined by applying standard histological criteria (Billingham et al, 1990). Anti-rejection 
treatment was instituted when mononuclear cell infiltrates coexisted with myocyte damage 
or myocyte necrosis (lSHLT criteria: 3A or 3B) and consisted of solumedrol or a 2-weeks 
course of a polyclonal rabbit anti-thymocyte globulin preparation in case of an ongoing 
rejection. After an acute rejection episode the next biopsy was taken I week following anti-
rejection therapy. Along with EMB, peripheral blood samples were collected. PBMC were 
isolated from these blood samples by Ficoll-Hypaque density gradient centrifugation and 
stored at -140·C. Serial PBMC samples of individual patients were then used to analyze the 
kinetics of circulating donor specific CTL. 
Table 1. Number of HLA mismatches between donor and recipient 
mismatches with the donor 
patients HLA-A HLA-B HLA-DR 
BO I 1 
SE 2 2 2 
HE 1 2 2 
VE 2 1 
SC 1 1 2 
DO 2 1 2 
HU 2 1 0 
Allogeneic target cells. Phytohaemagglutinin (PHA) stimulated T cell blasts of donor origin 
were obtained by culturing donor spleen cells for 4-7 days in culture medium supplemented 
with 10% vlv lymphocult-T (Biotest) and 1% PHA (Difco, Detroit, MI). Culture medium 
consisted ofRPMI-I640, Dutch Modification (Gibco), supplemented with 4mM L-glutamine, 
100 IUlml penicillin, 100 "g/ml streptomycin, and 10% pooled human serum (sera were 
tested in a mixed lymphocyte culture assay and excluded from the pool if inhibitory or 
stimulatory effects on proliferation were observed). 
Limiting Dilwion Ana/ys/s. LDA was conducted simultaneously on all early PBMC samples 
of each individual patient to minimize experimental variation. Limiting dilution cultures were 
set up in 96-well round bottom microculture plates (Costar). Responder cells were titrated 
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in 8 double dilution steps starting from 50000 cells per well to 390 cells per well. All 
dilutions were performed in 24 replicates and 50000 irradiated (30 Gy) stimulator cells were 
added to each well in a total volume of 0.2 ml culture medium supplemented with 20 Ulml 
rIL2 (proleukin, Eurocetus, Amsterdam, the Netherlands). As stimulator cells we used donor 
spleen cells. Additionally, wells with the highest responder cell concentration were stimulated 
with autologous PBMC. When autologous PBMC are used as stimulator cells, only in vivo 
activated CTL (cCTL) and not their naive precursors (PCTL) proliferate and develop LDA-
detectable cytolytic activity (Orosz et al, 1989). When donor spleen cells are used, the total 
pool of donor specific CTL consisting of both donor directed cCTL and pCTL will expand. 
At day 7, half of the medium of the limiting dilution cultures was replaced by fresh culture 
medium containing 20 Ulml r1L2. After 10 days of culture, all 96-well plates were split into 
two and CD8 mAb was added to half of the split wells as described below. Subsequently, 
each well was individually tested for its capacity to lyse 2500 "Cr-Iabelled PHA blasts of 
donor origin. LDA cultures were incubated for 4 hrs at 37°C in 5 % CO,. Supernatants were 
harvested using a Skatron harvesting system (Skatron-AS, Lierse, Norway) and the release 
of "Cr was assayed in a Packard gamma-counter (packard Instruments, Downers Grove, 
USA). Spontaneous and maximum release were defined by incubation of target cells with 
culture medium in the absence or presence of Triton X-IOO detergent (5% vlv solution in 
0.01 M TRIS buffer), respectively. Microcultures were considered cytolytic when the 
experimental lysis percentages exceeded 10%. 
CD8 inhibition study. A 1:500 dilution of ascitic fluid (± 1 "g) was used for FKI8, a mouse 
anti-human antibody of the IgG3 subclass which recognizes the gp32 chain of the CD8 
molecule (Koning et al, 1986; The FKI8 hybridoma cell line was kindly provided by Dr F 
Koning, Dept of Immunohaematology and Bloodbank, University Hospital Leiden, the 
Netherlands). This concentration totally inhibited the cytotoxic capacity of CD8-dependent 
CTL clones but did not affect target cell lysis by CD8-independent CTL clones (Van 
Emmerik et al, 1996). Before addition of "Cr-labelled target cells to the LDA, half of the 
split wells was preincubated with FK18 during 30 minutes at 37°C in a humidified 
atmosphere containing 5% CO,. 
LDA cOlllro/s. As a control for specificity, the reactivity of LDA cultures with the highest 
responder cell concentration was tested against PHA blasts of autologous PBMC. LDA 
cultures mediating cytolysis of autologous target cells were excluded from the study. 
It should be noticed that by using donor PHA-blasts as target cells in the cytotoxic phase of 
the LDA, only CTL directed against donor HLA class 1 Ag (and not those directed towards 
donor HLA class II Ag) are enumerated (Van Emmerik et al, 1997). As a result, addition 
of CD8 mAb in the absence of CD4 mAb, is sufficient to analyze the avidity of the CTL 
enumerated in the present report. Controls showing the specificity of the CD8 mAb used 
(FKI8), have been reported previously (Van Emmerik et al, 1996). 
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T3ble 2. Frequency of peripheral dooor specific pCTL in the presence and absence of CDS mAb. 
patient d.y PA' freq:1 95% CI· fre<r 95%CI patient d.y PA (req 95%CI treq 95%CI 
·mAb +mAb ·mAb +mAb 
BO • 0 2 0-4 0 VE 0 '4 8·20 
, 0-2 
23 0 6 2·10 0 • 0 7 3·11 
, 0-2 
37 'A 28 2Q.36 ,. 13·26 22 'A 5 2-' , 0-2 
45 3A 25 17·32 17 11·23 36 'A 20 13,27 '5 9·21 54 0 20 21·37 20 13·26 43 'A S 4·12 6 2·10 
3A 57 3A '5 9·21 '4 9·20 
8. 'A , 0-2 0 65 'A 8 4-12 2 0-4 
'03 'A 2. 20·33 11 "'5 113 'A 23 15·31 '0 "'4 129 lA 3. 27·50 36 25-46 '42 0 24 16·31 13 8·18 
'56 3A 35 25-46 35 24·46 365 0 '4 7·22 4 '-7 
'64 2 '5 9·21 '0 6·15 7'5 'A 9 5·14 2 0-4 732 'A '5 9·21 1 0-2 5E 0 26 19·34 , 0-2 
HE 0 '6 10·n 3 '-5 6 0 29 20·38 4 '-6 
8 0 7 3·10 , 0-2 '3 'A 3' 22·40 4 2-7 
'4 2 '0 "'4 3 '-6 20 0 115 82·147 '8 7·29 17 3A 12 7·17 4 '-6 27 2 
"' 
84·154 36 20·51 
22 'A '8 "·24 2 0-5 34 3A 45 28·63 6 2·11 
28 0 ,. 12·25 0 4' 2 '0' 79·139 10 6·15 36 3A 13 8·18 3 1-6 48 38 77 53·100 4 2-7 
45 3A '5 9·21 2 0-4 66 lA 2' 21·36 5 2-8 80 'A '5 9,21 0 '0' 'A 67 47·87 14 8·19 115 2 4 1-6 0 312 0 '20 94-146 '7 11·23 4.3 2 72 57·87 0 59' 'A 18 11·24 4 '-6 
7'7 0 72 53·92 0 906 0 2 0-4 0 
931 2 69 45·94 0 HU 7 0 40 30·50 15 10·21 
5C • 2 0 0 '4 0 25 17·32 '0 5·14 23 'A 20 13·26 7 3·10 21 'A 38 27·48 13 8·18 
30 lA 7 3·10 3 '-5 35 0 '8 12·25 7 3·11 44 3A 13 8·18 • 5·14 4' 0 39 29·49 20 14·26 63 'A '8 12·24 11 6·15 55 'B 24 17·32 11 6·16 84 'A • 5·11 5 2-8 62 0 11 6·16 4 1-6 9' 3 9 5·13 6 2-9 175 'A 4' 28-53 0 
317 'A • "'4 4 '-6 910 0 '0 5-15 0 545 'A 2 0-6 0 
00 0 42 31·52 28 20-36 
6 'A 4' 31·51 2. 21·37 
'3 'A 37 28·46 '2 7·17 20 3A 54 42·66 32 23·41 
27 'A 7' 55·87 27 19·35 
55 'A 5' 39·63 26 18·33 
433 0 7 3-10 0 
Donor specific pCTL present within serial blood samples of individual heart tUlnsplant patients were enumerated and their avidity wos detefmined. The table depicts the days after 
transplantation at which the blood samples were collected. the rejection {lrede (PAl of the transplant as defined by histological eveluation of EMB taken simultaneously with the blood samples!, 
the frequency of donor specifiC pCTl2• the frequency of donor specifiC pCTl with a high avidity and the corresponding 95% confidence intervals·. The rejection status was defined according 
to ISHlT criteria'''; PA O. no infiltrate; PA 1 AlB. focal/diffuse but sparse infiltrate without necrosis; PA 2. one focus with aOressive infiltration and/or myocyte damage: PA 3A/B. multitocal 
aggressiVe infiltrates and/or myocyte damage. 
FrequellCY estilllatioll. Minimal estimates of perL frequencies were calculated by analysis 
of the Poisson distribution relationship between the percentage of cultures that failed to 
develop cytotoxicity and the number of responder cells per well. The perL frequencies, 
expressed as number of cytotoxic cells per 10' cells, were calculated with the maximum 
likelihood estimation, adapted with a jackknife method as described by Strijbosch et al. 
(1987). Standard deviation and 95% confidence intervals (95% CI) were calculated as well. 
The calculated frequencies were accepted when the goodness-of-fit did not exceed 12. 
Subsequently, the fraction of donor specific erL having high avidity for donor Ag could be 
calculated using the following formula: 
freg of donor spec. CTL with CDS mAb 
fraction (%) = lOOx freq of donor spec. CTL without CDS mAh 
Statistical analysis of the kinetics within individual patients (Figure 1) was performed by 
using the non-parametric Wilcoxon signed rank test. For the statistical analysis of differences 
between groups (Figure 3), the Mann-Whitney U test was performed. Both tests are part of 
the statistical program INSTAT. 
4.3. Results 
Killetics of eirculatillg dOllor specific pCTL in relation to acllle rejection. The frequency of 
donor specific CTL was measured in 60 PBMC samples of 7 heart transplant recipients 
obtained immediately before and at various time points after transplantation. In all but three 
PBMC samples, donor specific CTL were present. In only 5 cultures, in vivo activated donor 
specific CTL (cCTL) could be identified demonstrating that circulating erL are primarily 
CTL precursors (perL). Figure 1 and 2 show the longitudinal changes in donor specific 
perL frequencies for each patient (bars; left Y-axes). Data of patients who experienced acute 
cardiac rejection are shown in figure 1. Data of a patient that never experienced acute cardiac 
rejection are shown in figure 2. The occurrence of acute cardiac rejection as defined by 
histological examination of associated EMB (ISHLT criteria: 3A13B) is depicted by arrows. 
For 95 % CI intervals and the rejection score of individual EMB, we refer to Table 2. 
The number of donor specific pCTL among PBMC fluctuates irrespective of the rejection 
grade of the allograft. Hence, the frequency of circulating donor specific perL not simply 
reflects the immunological status of the allograft. Statistical analysis of the individual profiles 
revealed that pCTL frequencies found during acute rejection (median=15/10'; range=9-
53/10') did not significantly exceed values found before acute rejection (median = 16/10'; 
range=7-73/10', P=0.38) nor those found after successful rejection therapy 
(median = 16.5/10'; range=I-611l0', P=0.81). 
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Figure 1: The frequency (bar; left. Y-axes) and avidity (broken line; right Y-axes) of donor specific pCTL present 
within peripheral blood samples of heart transplant recipients obtained before and at various time-points after 
transplantation were determined by LDA. Values were compared with the rejection grade of the cardiac allograft. 
Within the individual patients, the CTL frequency found during acute cardiac rejection (arrow) did not significantly 
exceed frequencies found before the diagnosis of acute rejection (p=O.38) nor those found after rejection therapy 
(p=O.81). During acute rejection. the percentage of donor specific pCTL with a high avidity for donor Ag had 
increased significantly when compared to values found before (p=O.OO8) or after this period (p=O.03). 
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The avidity for donor Ag of above quantitated donor specific pCfL w~s determined in split 
well analysis by addition of a CDS mAb (FKIS) to the cytotoxic phase of the LDA as low 
avidity CfL are susceptible to CDS blocking whereas high avidity CTL are resistant to CDS 
blocking (MacDonald et ai, 19S2; De Vries et ai, 19S9; Cal and Sprent, 1994; Auphan et 
ai, 1994). Donor specific pCTL frequencies found in the presence of CDS mAb along with 
their 95 % CI intervals are depicted in Table 2. The fraction of donor specific pCTL with a 
high avidity for donor Ag is shown in figure 1 and 2 (broken line; right Y-axes). In case 
donor specific pCfL were hardly detectable, their avidity could not be determined. 
The individual profiles of the rejectors show that one pattern of changes is predominant. The 
fraction of the donor specific pCfL with a high avidity for donor Ag increases towards 
rejection (arrow) and decreases after successful rejection therapy. During acute rejection, 
66% (median; range = 13-100%) of the donor specific pCfL enumerated had a high avidity 
for donor Ag. This fraction significantly exceeded both pre-rejection values (median=39%; 
range=0-65%, P <O.OOS) and post-rejection values (median =37%; range=0-66%, P <0.03) 
of the same patient. Nevertheless, as demonstrated for the non-rejector HU (figure 2), a 
considerable part of the circulating donor specific CfL might also have a high avidity for 
donor Ag in the absence of histological signs of graft damage. However, the profile of this 
patient only showed minor fluctuations during the early posttransplant period. According to 
these results, the kinetics of circulating high avidity pCTL rather than an absolute proportion 
of these cells corresponds with the immunological status of the transplanted heart. 
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Figure 2: Kinetics of donor specific pCTL within the peripheral blood of a cardiac transplant recipient that never 
experienced clinical rejection. The numbers of donor specific pCTL per million PBMC Oeft Y-axes) are shown as 
bars. The fraction of these pCTL that has a high avidity for donor Ag (right Y-axes) is depicted by the broken line. 
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Presence of circulating donor specific pCTL dllring stable engraftment. The previous 
experiments evaluated the kinetics of high avidity pCTL during the peak of the alloresponse. 
We questioned whether these cells do persist long after the immune response has subsided. 
To evaluate this possibility, II PBMC samples obtained from the 7 patients described above 
more than I year after transplantation (range: 1-2.5 year) were analyzed for their frequency 
and avidity of donor specific pCTL. At this time, all patients had achieved a state of stable 
engraftment as they did not experience allograft rejection hereafter. The results (fable 2) 
were compared with values of these patients acquired during the first year after 
transplantation. 
As depicted by figure 3A, donor specific pCTL frequencies found more that I year after 
transplantation (> 12 months; median = 12/10') were comparable to values found during the 
first 3 months (90 days) after transplantation « 3 months; n=47; median = 19/10'; P=0.39) 
and those found during the intermediate period (3-12 months; n=l1; median=29/IO'; 
P=0.24). It should be noted, however, that donor specific pCTL were absent in 2 samples 
obtained more than I year after transplantation and only in 3 samples obtained during the 
early period. As a consequence these samples could not be evaluated for their avidity and 
therefore are not depicted in figure 3B. 
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Figure 3: Peripheral blood samples of cardiac transplant recipients obtained during the first 3 months after 
transplantation «3 months), between the 3td and 121k month after transplantation (3·12 months), and more than one 
year after transplantation (> 12 months) were compared for their frequency of donor specific pCTL (panel a). No 
significant difference was observed between these 3 groups. Subsequently, the avidity of these pCTL for donor Ag 
was determined by analyzing their resistance to COS mAb. The percentages of the donor specific pCTL enumerated 
that had a high avidity for donor Ag are depicted in panel b. A significant smaller fraction of the donor specific 
pCTL had a high avidity for donor Ag more than I year after transplantation when compared to values found during 
the early «3 months; P<O.OOl) and intermediate period of time (3-12 months; P<O.02). 
Addition of CDS mAb revealed what part of the circulating donor specific pCTL pool could 
be scored as high avidity pCTL (figure 3B). During the first year after transplantation, the 
proportion of donor specific pCTL with a high avidity showed a broad range. In several 
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blood samples, the donor specific perL pool mainly consisted of pCTL with a high avidity 
for donor Ag. In other samples, high avidity pCTL were outnumbered by low avidity perL. 
Within 3 months after transplantation, 35 % (median) of the donor specific perL enumerated 
had a high avidity for donor Ag. During the intermediate period a comparable fraction was 
found (median~44%). More than one year after transplantation, however, a significant lower 
percentage of the donor specific pCTL had a high avidity for donor Ag (median~O%) when 
compared to the early (p < 0.001) and intermediate period (p<0.02). 
As shown in· figure 3B, 3 samples obtained more than 1 year after transplantation still contain 
some high avidity pCTL. These samples were obtained from patient VB at day 365 and 715 
post-transplantation and from patient SE at day 591 post-transplantation. For patient SE, 
donor specific pCTL became totally absent at a later timepoint (day 906) and with that high 
avidity pCTL are suspected to be absent as well. For patient VE, the proportion of donor 
specific perL with a high avidity also successively decreased from 50% (mean at < 3 
months) and 49% (mean at 3-12 months) to 29% (at day 365) and 20% (at day 715). In 4 
patients, donor specific pCTL with a high avidity became absent more than 1 year after 
transplantation whereas in another patient both high and low avidity donor specific perL 
became absent. Based on these individual profiles, it appears that high avidity perL are 
absent (6 patients) or are reduced (l patient) more than 1 year after transplantation when 
stable engraftment is achieved. 
4.4. Discussion 
During the last several years we have focused our studies on the relevance of donor specific 
CTL in human cardiac allograft rejection. Initially, EMB, routinely taken from heart 
transplant recipients for the diagnosis of acute rejection, were cultured to obtain the graft 
infiltrating lymphocytes. The number of donor specific erL present among these graft 
infiltrating lymphocytes was then estimated using LDA. Obtained data demonstrated that 
donor specific cCTL and their precursors (perL) were both present within the cardiac 
allograft irrespective of its rejection grade (Vaessen et al, 1994). On first sight, this 
observation questions the importance of donor specific erL in acute cardiac rejection. 
However, donor specific erL grown from EMB with and without histological evidence of 
acute rejection appeared to have different characteristics. Whereas the former CTL generally 
had a high avidity for donor Ag, the latter CTL mainly had a low avidity for donor Ag 
(Ouwehand et al, 1993; Vaessen et al, 1994; Van Emmerik et aI, 1997). According to these 
data, we reasoned that high avidity erL might be important in allograft rejection. The 
clinical relevance of high avidity erL in cardiac transplant rejection was strengthened by 
longitudinal studies within individual heart transplant recipients. Analysis of donor specific 
CTL propagated from sequential EMB revealed that intragraft accumulation of perL and 
cCTL with a high avidity for donor Ag coincided with myocyte destruction (Van Emmerik 
et al, 1996). 
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The intragraft accumulation of high avidity CTL during a rejection episode implies the 
migration of these cells towards the allograft before acute rejection becomes evident. In the 
present study we analyzed the kinetics of circulating donor specific CTL within 7 patients 
and compared the results with the rejection status of their cardiac allograft as defined by 
histological evaluation of associated EMB. 
The number of donor specific CTL within PBMC samples obtained immediately before and 
at various time points after cardiac transplantation was estimated by LDA. Donor specific 
cCTL were rarely detected among PBMC indicating that donor specific CTL circulate as 
CTL precursors. This is in line with earlier data of our group using a different approach 
(Vaessen et al, 1992). Since the induction of the (allo) immune response is thought to occur 
within the secondary lymphoid organs (Austyn and Larsen, 1990; Larsen et al, 1990), donor 
specific pCTL present within the peripheral blood not necessarily are totally naive CTL 
precursors. Instead they might be activated CTL that have not yet differentiated into 
functional cCTL; the so-called poised CTL (Gromo et al, 1987). During a rejection episode, 
numerous cCTL are present within the allograft (Vaessen et al, 1994; Van Emmerik et al, 
1996). This observation implies that the final differentiation of pCTL into cCTL occurs at 
the graft side. Similar results have been obtained by others in a murine transplant model 
(Orosz and Bishop, 1990). 
According to the present study, donor specific pCTL (either naive or poised) are detectable 
within the peripheral blood of heart transplant patients throughout the whole follow-up 
period. Their number, however, fluctuated irrespective of the rejection status of the cardiac 
allograft. Hence, alterations in the frequency of circulating donor specific pCTL do not 
correlate with the clinical outcome after heart transplantation. In contrast, Reader et al. 
(1990) reported that the frequency of donor specific CTL within the PBMC population of 
cardiac transplant patients correlated well with the rejection grade of associated EMB. The 
kinetics of 2 representative patients depicted in their report, however, did not confirm this 
hypothesis. 
Addition of CD8 mAb revealed which proportion of the circulating donor specific pCTL pool 
had a high avidity for donor Ag. Acute rejection episodes were found to correspond with 
increased proportions of donor specific pCTL with a high avidity. Although this observation 
implies that the overall avidity of circulating pCTL might reflect immunological processes 
occurring within the allograft, the current method can not be used to monitor for acute 
cardiac rejection. As shown by the present kinetic studies, acute cardiac rejection is 
associated with an increase in the number of high avidity pCTL among the circulating donor 
specific pCTL present. The percentage of donor specific pCTL scored as high avidity pCTL 
during acute cardiac rejection, however, differs from patient to patient. High avidity pCTL 
may become the predominant subset or still be outnumbered by low avidity pCTL. 
Accordingly, changes in the percentage of donor specific pCTL with a high avidity rather 
than the percentage itself inform us about the rejection status of the allograft. Therefore, to 
evaluate a blood sample of a particular patient, the results of this blood sample should be 
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analyzed in the light of the results of preceding samples. The LDA t~hnique described here, 
however, requires a 10 day culture period which can not be reduced without losing its 
sensitivity (data not shown). As a result, analysis of the avidity of donor s~ific pCTL is 
too time consuming to actually monitor for acute cardiac rej~tion. Another argument against 
the application of this t~hnic to monitor for acute cardiac rej~tion is that the increase in the 
percentage of donor s~ific pCTL with a high avidity can be very small and therefore might 
not be regarded as being one. 
Next, we questioned whether these high avidity donor s~ific pCTL persist long after 
transplantation when the immune response has subsided. For this analysis, PBL samples 
obtained more than I year after heart transplantation were analyzed for their frequency and 
avidity of donor s~ific pCTL. The results were compared with values acquired during the 
first 3 months after transplantation and with values obtained between the 3'" and 12~ month 
post-transplantation. No significant reduction in the number of donor s~ific pCTL was 
observed with time after transplantation. More than 1 year after transplantation, however, 
a significant smaller fraction of the donor s~ific pCTL present had a high avidity for donor 
Ag. This observation implies that high avidity pCTL disappear from the circulation with time 
after transplantation. 
Only one other group has analysed the avidity of donor s~ific CTL in PBMC samples 
obtained long after transplantation. This study was performed on corneal transplant patients 
that either had a well functioning graft or experienced ongoing rej~tion more than I year 
posttransplantation (Roelen et ai, 1995). Whereas high avidity CTL were hardly found among 
peripheral donor s~ific CTL of patients with a well functioning graft, they were extensively 
present within patients with a rej~ting graft. Along with our data, this observation implies 
that stable engraftment corresponds with an absence of high avidity CTL within the 
peripheral blood. As such, quantification of high avidity CTL within peripheral blood 
samples might inform us whether stable engraftment has been achieved. 
According to the present data, a rej~tion episode is depicted by an increase in the fraction 
of donor s~ific pCTL with a high avidity whereas stable engraftment is depicted by a 
d~rease in this fraction. Kinetic studies on IL-2 producing T cells showed that a similar 
correlation exists between the number of donor s~ific IL-2 producing T cells and the 
immune status of the cardiac allograft (DeBruyne et ai, 1993). Accordingly, IL-2 producing 
cells and high avidity CTL might represent distinct functional activities of the same 
population of donor reactive T cells. In line with this hypothesis, Cai and Sprent (1994) and 
Heath et al. (1993) reported that CD8+T cells that interacted with a high avidity with Ag-
bearing cells produced IL-2 after stimulation whereas CD8 'T cells that interacted with a low 
avidity with Ag-bearing cells did not. R~ently, we analyzed high (n=8) and low (n=7) 
avidity CTL clones obtained from the peripheral blood and graft of heart transplant patients 
for their IL-2 production profile (chapter 5). Only 2 high avidity CTL clones and 1 low 
avidity CTL clone produced IL-2 when stimulated by donor cells. This observation indicates 
that the IL-2 producing T cells found in correlation with acute cardiac rej~tion do not belong 
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to the same T cell population as high avidity CTL. 
As reported previously, donor specific pCTL and cCTL with a high avidity for donor Ag 
accumulate within the cardiac allograft during and immediately preceding acute rejection. In 
absence of acute rejection, however, these CTL are hardly present within the graft (Vaessen 
et al, 1994; Van Emmerik et al, 1996,1997; Baan et al, 1995). In combination with the 
present data it is tempting to speculate that, prior to acute rejection, circulating donor specific 
pCTL with a high avidity for donor Ag selectively home to the allograft. However, aside 
from their expansion during acute rejection, high avidity pCTL can be found within the 
peripheral blood during the first year after transplantation. To explain their selective homing 
to the allograft in case of a rejection episode, only speculations can be made. An explanation 
might be that, prior to visible sights of graft damage, pCTL with a high avidity for donor 
Ag become activated in the spleen or draining lymphnodes of the cardiac transplant recipient. 
In contrast to naive donor specific pCTL, the resulting poised CTL might have characteristics 
that allow their passage from the peripheral blood into the allograft. At the graft side, these 
poised CTL are triggered to differentiate into fully mature donor specific cCTL with a high 
avidity. Sufficient numbers of these cCTL then cause graft destruction as observed by 
histology. The relevance of high avidity pCTL for the initiation of the acute rejection cascade 
is confirmed by our observation that the disappearance of these cells from the peripheral 
blood correlates with stable engraftment. 
Several mechanisms for "transplant tolerance" have already been suggested. With respect to 
the downregulation of the activity of alloreactive CTL, clonal deletion, anergy, and active 
suppression have been put forward as possible mechanisms (Charpentier et aI, 1982; Herzog 
et al, 1987; Wramner et al, 1987; MGller-Ruchholtz et al, 1992; Mathew et al, 1993; Hu et 
al, 1994; Burlingham et al, 1995). In the present report, we demonstrated that peripheral 
pCTL with a high avidity for donor Ag were largely reduced in number more than I year 
after transplantation when the immune response had subsided. Similarly, Heeg and Wagner 
(1990) reported that peripheral donor specific pCTL with a high avidity became undetectable 
in mice made tolerant to allogeneic skin grafts. Hence, processes that selectively affect high 
avidity CTL might influence the induction of transplant unresponsiveness. According to the 
murine model, a functional deletion of peripheral pCTL with a high avidity for donor Ag 
accounts for the acquired unresponsiveness. Which mechanism causes the reduction of high 
avidity CTL in our study is yet unknown but should be studied as the results might lead to 
the establishment of conditions that would induce a permanent state of transplant 
unresponsiveness. 
The question remains why only high avidity CTL are detrimental for cardiac allograft 
survival since both CTL with a high and low avidity display donor directed cytotoxicity in 
vitro. As suggested previously (Van Emmerik et aI, 1996), low avidity CTL only lyse target 
cells expressing high levels of HLA molecules whereas high avidity CTL are even reactive 
to cells with a low HLA surface density (Shimonkevitz et al, 1985; Mentzer et al, 1990). The 
HLA expression on myocytes of the transplanted heart is low (Milton and Fabre, 1985). As 
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a result, binding and subsequent lysis by low avidity CTL does not occur. Nevertheless, 
donor myocytes serve as targets when high avidity CTL accumulate within the graft and a 
rejection episode is encountered. Target cells used in vitro seem to express sufficient HLA 
molecules for recognition and cytotoxicity by both high and low avidity CTL. 
In conclusion, acute cardiac rejection correlates with an increase in the number of high 
avidity pCTL among donor specific pCTL whereas stable engraftment correlates with a 
(total) reduction in the number of high avidity pCTL among donor specific pCTL. Although 
this observation indicates that the kinetics of high avidity pCTL might inform us about the 
rejection status of the cardiac allograft, the technic in its present form can not be used to 
monitor for acute cardiac rejection. However, the current technic might distinguish patients 
who achieved stable engraftment and therefore might tolerate steroid withdrawal. 
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Chapter 5 
The avidity of allospecific CTL determines their cytokine 
production profile 
Donor specific cytotoxic T lymphocytes (CTL) present within the cardiac allograft during a 
rejection episode are distinct from those that populate the cardiac allograft in the absence of 
rejection. Whereas the former generally have a high avidity for donor cells, the latter mainly 
have a low avidity for donor cells. This observation made us reason that high avidity CTL 
are implicated in transplant rejection whereas low avidity CTL are not. In the present study, 
we analyzed whether both CTL subsets were distinct with respect to their IL·2, IL·4, IL·6, 
and IFN·'Y secretion pattern. CTL clones with either a high or a low avidity for donor 
antigens (Ag) were stimulated with donor cells, third party cells, or immobilized anti-CD3 
monoclonal antibody (mAb) and the amount of cytokine released was measured. High and 
low avidity CTL clones were found to differ with respect to their IFN·'Y production proftle. 
Stimulation with donor cells resulted in IFN·'Y secretion by high avidity CTL clones but not 
by low avidity CTL clones. CD3 stimulation, on the contrary, led to secretion of equivalent 
amounts of IFN·'Y by both CTL subsets. These observations indicate that low avidity CTL 
are fully capable of producing IFN·'Y but, in contrast to high avidity CTL, fail to do so when 
they encounter donor cells. As IFN·'Y favours the occurrence of transplant rejection, this 
observation emphasizes the relevance of high avidity CTL in the rejection process. 
Additionally, the data show that the cytokine production profile of CTL depends on the 
nature of the stimulus. 
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5.1. Introduction 
The relevance of donor specific CTL in acute allograft rejection is still a matter of debate. 
Support for the involvement of CTL as terminal effector cells is provided by experiments 
showing the exquisite Ag specificity of the alloresponse (Sutton et al, 1989; Mintz and 
Silvers, 1967) and the ability of CTL clones grown from rejecting allografts to destroy 
allogeneic tissue when injected into appropriate hosts (Snider et al, 1986). In contrast, 
experiments showing the occurrence of graft rejection in CD8+lymphocyte depleted mice 
have been interpreted as evidence against a critical role for CTL in transplant rejection 
(Bishop et al, 1993). In such modified animals, eosinophils were assumed to be responsible 
for the observed graft damage (Chan et al, 1995). This recruitment of eosinophils into the 
graft was ascribed to a decrease in the Th 1 to Th2 cytokine ratio which in tum was assigned 
to the depletion ofThl-promoting, Th2-suppressing donor reactive CD8+CTL. Although this 
model demonstrates that other cells besides donor specific CTL can function as terminal 
effector cells, these cells may only become relevant when the immune system is aberrant. 
Also the presence of donor specific CTL within stable transplants (Dallman et ai, 1987; 
Weber et al, 1989) argues against a critical role of CTL within the rejection process. 
However, we found that donor specific CTL propagated from rejecting and stable allografts 
were distinct (Ouwehand et al, 1993; Vaessen et ai, 1994; Van Emmerik et al, 1997). As 
assessed by their sensitivity to CD8 or CD4 blocking, the former CTL mainly had a high 
avidity for donor cells whereas the latter CTL generally had a low avidity for donor cells 
(MacDonald et al, 1982; Marrack et al, 1983; Biddison et al, 1984; De Vries et al, 1989). 
The avidity of a T lymphocyte is a term that reflects the relative strength with which this T 
cell binds an Ag-bearing cell. According to current concepts, the avidity of a T cell portrays 
the overall strength of T cell receptor (fCR)-MHC/peptide interactions and hence depends 
on the intrinsic affinity of the TCR for its ligand and the number of TCR-MHC/peptide 
complexes that associate (Maryanski et al, 1988; Auphan et al, 1994; Kim et al, 1996; AI-
Ramadi et al, 1995). 
The selective presence of high avidity, donor specific CTL within rejecting allografts made 
us reason that this particular CTL subset is important in acute rejection. A relationship 
between the avidity of donor specific CTL and the rejection status of the allograft was indeed 
found by subsequent longitudinal studies within individual heart transplant recipients. It 
appeared that high avidity CTL populated the cardiac allograft immediately preceding and 
during acute rejection whereas low avidity CTL populated the cardiac allograft outside a 
rejection episode (Van Emmerik et al, 1996). In the same period, the in vivo efficiency of 
virus specific CTL was reported to depend on their avidity. Despite the fact that both high 
and low avidity CTL effectively killed virus infected cells in vitro, only high avidity CTL 
could do so in vivo (Alexander-Miller et ai, 1996A). Yet, in the transplant model, only CTL 
with a high avidity for donor cells might exhibit their effector function in vivo. 
In the present study, we further characterized the response of high and low avidity CTL 
towards donor cells. Since increasing evidence has indicated that T-lymphocytes producing 
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different cytokine profiles have different cytolytic potentials (Romagnani et al, 1996), we 
assumed that it might be informative to analyze both high and low avidity CTL clones for 
their cytokine secretion pattern. Previous analysis of solid endomyocardial biopsies (EMB) 
obtained from heart transplant recipients showed that EMB with and without histological 
signs of clinical cardiac rejection differed with respect to their cytokine gene expression 
(Baan et al, 1994). The IL-2, IL-4 and IL-6 genes were considerably more often expressed 
in the former EMB than in the latter EMB. However, the source as well as the specificity 
of the observed response remained undefined. In the present study, we evaluated the ability 
of high and low avidity CTL clones to release these cytokines after donor, third party, and 
polyclonal (CD3) stimulation. Additionally, we analyzed their ability to release IFN-')' as the 
gene expression and production of this cytokine within the allograft (Kupiec-Weglinski et al, 
1993; Mottramm et al, 1995; Egawa et al, 1995) and the draining lymph nodes (Fallarino 
et al, 1996) repeatedly have been found associated with rejection. 
S.2. Materials and Methods 
All experiments described in this paper have been performed with donor specific CTL clones 
established from graft infiltrating lymphocyte (GIL) cultures or peripheral blood of 6 heart 
transplant patients (KU, BE, MI, ZA, PO, FO). 
Generation olCTL clones. GIL and PBMC were obtained from endomyocardial biopsies and 
blood samples of heart transplant recipients, respectively as described before (Van Emmerik 
et al, 1996). Donor specific T cell clones were generated from GIL or PBMC by limiting 
dilution at 0.3 cells/well in culture medium expanded with 0.5-1 % phytohaemagglutinin 
(PHA; Difco, Detroit, MI). Culture medium consisted of RPMI-I640 Dutch Modification 
(Gibco, Paisley, Scotland) supplemented with 4 mM L-glutamine, 100 IU/ml penicillin, 100 
J'g/ml streptomycin, 10% pooled human serum, and 10% lectin free Iymphocult-T-LF 
(Biotest GmbH, Dreieich, Germany) as a source of IL2. Irradiated (30 Gy) donor B-
lymphoblastoid cell lines (B-LCL; 5xl0' cells/ml) and PBMC of healthy blood donors (5x10' 
cells/ml) were added as feeder cells. After 2 weeks, wells with visible cell growth were 
restimulated with irradiated donor B-LCL and PBMC of healthy blood donors. 7-14 days 
later, clones were phenotyped as described below and assayed for donor specific cytotoxicity. 
Clones used in the present study totally consisted of either CD4 +WT31 +cells or 
CD8+WT31 +cells and exhibited cytotoxicity towards donor cells but not towards third party 
cells or the NK sensitive cell line, K562. 
Target cells. B-LCL originated from infection of fresh PBMC or spleen cells with Epstein 
Barr Virus obtained from the marmoset cell line B95-8. These cell lines were maintained in 
RPMI-I640 supplemented with 10% heat-inactivated bovine calf serum (Hyclone, Logan, 
Utah). 
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Phenotypic analysis. T cell clones were analyzed for WT31, CD8 (Becton Dickinson, San 
Jose, CAl, and CD4 (Immunotech, Marseille, France) expression by three-color flow 
cytometry on a FACScan after staining with mAb directly conjugated for fluorescein, 
peridinin chlorophyll protein, and phycoerythrin, respectively. 
Cell mediated lympholysis (CML). The cytotoxic capacity of T cell clones was tested against 
donor B-LCL, third party B-LCL (B-LCL that do not share MHC antigens with the donor 
nor with the acceptor), and the K562 cell line. Briefly, effector cells (cloned cells) were 
incubated with 2500 "Cr-Iabelled target cells at different effector:target (E:T) ratios in 0.2 
ml culture medium without Lymphocult-T-LF. After 4 hours of incubation (37'C, 5%CO,), 
supernatants were harvested using a Skatron harvesting system (Skatron-AS, Lierse, Norway) 
and the release of "Cr was assayed in a Packard gamma-counter (packard, Downers Grove, 
USA). Spontaneous and maximum release were defined by incubation of target cells with 
culture medium (without Lymphocult-T-LF) in the absence or presence of Triton X-IOO 
detergent (5% v/v solution in 0.01 TRIS buffer), respectively. Microcultures were considered 
cytolytic when the experimental lysis percentages exceeded 10%. The cytotoxicity of all 
clones was directed towards MHC molecules of the donor. 
C1L avidity. As CD8 and CD4 molecules interact with the same ligand (MHC class I and 
II molecules on Ag bearing cells, respectively) as the TCR, it is believed that both CD8 and 
CD4 molecules serve to enhance the overall strength of TCR-MHC/peptide interactions. 
Accordingly, by blocking the CD8 or CD4 molecules on a T cell, one can define whether 
the avidity of this T cell for an Ag-bearing cell is sufficiently high to overcome the need for 
these molecules. To block CD8 molecules a 1:500 dilution ofFK18 (2I'g/ml), a mouse anti-
human CD8 mAb of the IgG3 subclass, was used (a kind gift of Dr F Koning, Dept of 
Immunohematology and B100dbank, University Hospital Leiden, the Netherlands). To block 
CD4 molecules a 1:250 dilution of RIV6 (2I'g/ml), a mouse anti-human CD4 mAb of the 
IgG2A subclass, was used (a kind gift of Dr. M.F. Leerling, RIVM, Bilthoven, The 
Netherlands). 
To analyze the avidity of a CTL clone, CML experiments were performed in the absence and 
presence of FK18 or RIV6. For this, clones were preincubated with FKI8 or R1V6 for 30 
minutes at 37'C before "Cr-Iabelled target cells were added. As a control for TCR mediated 
lysis, CML experiments were performed in the presence of Il'glml anti-CD3 mAb (RIV9, 
RIVM). 
Cytokine production. Clones to be tested for cytokine release were used at least I week after 
the last restimulation. The day before the cytokine-release assay, the clones were washed and 
seeded (5xl0' cells/well) in V-bottom 96-well plates (Greiner, Alphen aan de Rijn, The 
Netherlands) in culture medium without Iymphocult-T-LF. The next day, cells were 
incubated with irradiated (60 Gy) donor B-LCL or irradiated third party B-LCL (5xlO' 
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cells/well) in a final volume of 0.2 ml culture medium without Iymphocult-T-LF. For 
polyclonal stimulation by immobilized anti-CD3 mAb, cells were transferred to 96-well 
round bottom culture plates (Costar, Cambridge, MA) that had been preincubated with 
5"g/ml RIV9 (90 min, 37·C). Controls were wells containing clones incubated with medium 
alone and wells containing stimulator cells incubated with medium alone. Plates were 
centrifuged for 5 minutes at 400 g and incubated for the indicated time at 37·C. After 
incubation, supernatants were removed and analyzed for the amount of cytokine released. IL-
2, IL-4, and IL-6 release was assessed using commercially available ELISA (IL-2, 
Immunotech; IL-4, IL-6, CLB, Amsterdam, The Netherlands). 
IFN-y release was determined according to the following protocol. IFNy-binding mAb 
350BI0G6 (Medgenix, Fleurus, Belgium) was covalently coupled to microtiterplates with a 
hydrazide surface (carbohydrate binding plates, Costar) as described by Brillhart and Ngo 
(1991). In situ oxidation and coupling was performed by addition of 50 "I of mAb 350BIOG6 
(2 "g/ml) in 50 mM acetate buffer (PH 5.0) to each well. After 30 minutes of incubation at 
room temperature, 50 "I of 5 mM Naja, in acetate buffer was added to each well. The plates 
were incubated again for 30 minutes, washed with washing buffer (Tris buffered saline + 
0.05% Tween 20, pH 7.4), and blocked with 100 mM Tris + 0.05% Tween-20 + 1 % BSA 
(PH 7.5). After 1 hour, plates were decanted and stored at -20·C until use. 
Plates were washed and standards (3000 - 4.1 pg/ml; diluted in cell culture medium without 
Lymphocult-T-LF) prepared from a stock solution of recombinant human IFN-y (R&D 
Systems, Minneapolis, MN, USA) or cell culture supernatants were added to the wells (100 
"lIwell). After 2 hours, wells were washed and incubated for another 2 hours with 100 "I 
(0.25 "g/ml) of biotin conjugated anti-human IFN-y (Medgenix, clone 67F12A8) diluted in 
High Performance ELISA buffer (CLB, Amsterdam, The Netherlands). Plates were washed 
and 100 "I poly HRP-Iabelled streptavidin (1:10000, CLB) was added to each well. After 30 
minutes, wells were washed again and 100 "I substrate solution 
(3,5,3' ,5' ,tetramethylbenzidine, 0.1 mg/ml in 0.11 M acetate buffer, pH 5.5 + 0.003% 
HPJ was added. The reaction was stopped after 15 minutes by addition of 50 "lIwell of2N 
H2SO, and the optical density was measured at 450 nm. 
Statistical analysis. Differences between groups were analyzed using the Mann-Whitney U 
test of the statistical program INSTAT (Graphpad Software, San Diego, CA). 
5.3. Results 
Cytotoxic capacity and avidity ofT cell clones. T cell clones obtained from peripheral blood 
or GIL cultures of heart transplant recipients were tested for their cytotoxic capacity in a 
standard 4-hour "Cr release assay. Clones that specifically lysed B-LCL of donor origin were 
selected and subsequently examined for their avidity for donor Ag. For this analysis, 
CD8+CTL clones were tested for their capacity to lyse donor B-LCL in the absence or 
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presence of anti-CDS mAb (figure lA). Likewise, CD4+CTL were tested for donor directed 
cytotoxicity in the absence or presence of anti-CD4 mAb (figure lB). As depicted by figure 
1, 2l'g/ml of anti-CDS or anti-CD4 mAb is sufficient to distinguish between clones that bind 
donor ceUs with a high (+) or a low (.) avidity. As a control for TCR mediated 
cytotoxicity, blocking experiments were performed with anti-CD3 mAb. All clones used in 
the present report showed a significant reduction of donor target ceUlysis after preincubation 
with anti-CD3 mAb. 
Figure 1: The susceptibility of 
CDS +CTL (top) and CD4 + CTL 
(bottom) clones to inhibition by 
different doses of anti·CDS 
mAb (FKlS) and anli-CD4 
mAb (RlV6), respectively. 
Clones whose cytotoxic 
capacity is not affected by 
FK18 or RIV6 (+) are 
considered to bind their target 
cells with a high avidity. 
Clones that fail to lyse their 
target cells in the presence of 
FKI8 or RIV6 (.; lysis 
< 10%) are considered to bind 
these cells with a low avidity. 
Alternatively, FKl8 was added 
to CD4-bearing cells and RIV6 
to CDS·bearing cells to conlrol 
for the specificity of the 
response (c). Anti·CD3 mAb 
was added as a conlrol for TCR 
mediated lysis. 
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Cylokine profile of high and low avidity CTL clones. Fifteen donor specific CTL clones 
obtained from peripheral blood samples or GIL cultures of heart transplant patients were 
characterized for their IL-2, IL-4, IL-6, and IFN--y release after donor, third party, or CD3 
triggering. The results are shown in Table I. The number, name and source of each clone 
(either PBL or GIL) are depicted by the first column (Clone). The phenotype (either CD4 
or CD8) of the clones is depicted by the second column (Type). The cytotoxic capacity of 
the clones to lyse donor target cells in the absence and presence of anti-CD4 or anti-CD8 
mAb are shown in the third (%Lysis-mAb) and fourth (%Lysis+mAb) column, respectively. 
Addition of anti-CD4 or anti-CD8 mAb to "Cr release assays almost completely reduced 
donor directed cytotoxicity exhibited by clone I to 7 (Lysis < 10%) but hardly effected donor 
target cell lysis by clone 8 to 15. Hence, the former 7 clones bind donor cells with a low 
avidity whereas the latter 8 clones bind donor cells with a high avidity. The remaining 
columns show the cytokine production profile of both high and low avidity CTL clones. For 
this analysis, CTL clones were stimulated for 6 and 20 hours with irradiated B-LCL of donor 
origin (do), with irradiated B-LCL that did not share HLA antigens with the donor or 
acceptor (3P), and with immobilized anti-CD3 mAb afterwhich the amount of cytokine 
released was assessed by ELISA. 
As a control, unstimulated CTL clones and irradiated stimulator cells were tested for their 
cytokine production profile. Unstimulated clones did not secrete IL-2, 11.-4, 11.-6 nor IFN--y 
indicating that these cytokines are not constitutively produced by CTL (data not shown). 
Irradiated stimulator cells, on the contrary, occasionally produced IL-6 but did not produce 
detectable amounts of 11.-2, 11.-4, or IFN--y (data not shown). This observation implies that 
the amount of 11.-6 detected in the supernatant of stimulated CTL clones may also partly be 
the product of the stimulator cells added. 
Some general remarks can be made with respect to the data in Table I. Comparing the 
cytokine profile after donor and third party stimulation reveals that the production of 11.-2, 
11.-4, and IFN--y is donor specific. CTL clones fail to produce these cytokines after 
stimulation by third party B-LCL but may do so when stimulated by donor B-LCL. IL-6, on 
the contrary, can be found in the supernatant after both donor and third party stimulation, 
indicating that the production of this cytokine is aspecific. Alternatively, as stated above, the 
11.-6 detected may be the product of the stimulator cells used. 
Comparing the cytokine profile after stimulation with donor cells and immobilized RIV9 
shows that the release of IL-2, 11.-4, and IFN--y but not of 11.-6 can be induced or 
significantly increased by CD3 stimulation. For example, only 3 clones (20%) produce 
detectable amounts of IL-2 after 20 hours of donor stimulation whereas 9 clones (60%) do 
so after 20 hours of CD3 stimulation. This observation indicates that care should be taken 
with ascribing functions to T cells that are simply grounded on their cytokine profile as such 
a profile can easily be modulated by the stimulus chosen. 
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Comparing the amount of cytokines produced after 6 and 20 hours of stimulation, it can be 
stated that the amount of cytokine secreted and the number of clones producing detectable 
levels of cytokine is increased after 20 hours of stimulation. 
Despite these common characteristics, the data in table I show that CTL clones are rather 
diverse in their cytokine profile. We analyzed whether the various cytokine patterns observed 
could be explained by differences in the source (PBL versus GIL), phenotype (CD4 versus 
CD8), or avidity (high versus low) of the clones. This analysis lead to one striking 
observation. It appeared that low avidity CTL and high avidity CTL were distinct with 
respect to their IFN-oy cytokine profile. Low avidity CTL barely produced IFN-oy after donor 
B-LCL stimulation whereas high avidity CTL produced significant amounts of IFN-oy both 
after 6 and 20 hours of donor B-LCL stimulation (p<O.OOI and P<0.OOO3, respectively). 
No correlation was found between the IFN-oy profile and the phenotype or the source of the 
clones demonstrating that the avidity of CTL clones is the only variable associated with the 
observed IFN-oy production profile. The results are shown in figure 2. 
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F1gure 2: The amount ofIFN·'Y released by low and high F1gure 3: The amount of IFN·'Y released by low avidity 
avidity crL clones after 20 hours of Ag-specific crL after 20 hours of stimulation by donor B-LCL (Ag-
stimulation by donor B-LCL. Det«tion level is 4 pglml. specific; left) and immobilized anti-CD3 mAb (right), 
respectively. 
In contrast to donor stimulation, CD3 stimulation resulted in the production of equivalent 
amounts of IFN-oy by both high and low avidity CTL at 6 and 20 hours of stimulation 
(p<0.1O and P<0.40, respectively). This observation indicates that low avidity CTL are 
fully capable to produce IFN-oy but, in contrast to high avidity CTL, fail to do so when they 
encounter donor cells (figure 3). This observation also emphasizes that the cytokine profile 
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of cells can easily be influenced by the nature of the stimulus used. 
No distinction between high and low avidity CTL could be made with respect to their IL-2, 
IL-4, or IL-6 production pattern. Likewise, no differences in IL-2, IL-4, or IL-6 profile were 
found between CD4- and CD8-expressing CTL clones and between peripheral blood and graft 
derived CTL clones. 
5.4. Discussion 
Although numerous studies have demonstrated the existence of T cells that do not require 
CD8 or CD4 co-receptors to exhibit their function, hardly any attention has been paid to the 
immunological significance of these cells. Our data in this field refer to donor specific CTL 
propagated from graft biopsies or blood samples of heart transplant patients. Kinetic studies 
showed that CDS/CD4-dependent (low avidity) donor specific CTL were prominent within 
the cardiac graft until 2 weeks precening acute rejection. From that point onwards, 
CD8/CD4-independent (high avidity) donor specific CTL rapidly accumulated within the 
graft and became predominant at the time of acute rejection. Successful anti-rejection therapy 
resulted in the destruction of these CTL and the graft was repopulated again by low avidity 
donor specific CTL (Van Emmerik et ai, 1996). As intragraft accumulation of donor specific 
CTL with a high avidity precedes myocyte destruction (I.e. acute rejection) we believe that 
these CTL, as opposed to low avidity donor specific CTL, are involved in graft rejection. 
In a subsequent study, the kinetics of circulating donor specific CTL was analyzed and their 
avidity was compared with the rejection status of the graft. Obtained data showed that donor 
specific CTL with a high avidity were most prominent in blood samples taken during a 
rejection episode (submitted for publication). Analysis of the maturation status of peripheral 
donor specific CTL revealed that these cells were precursor CTL and not fully mature CTL 
such as found within the graft. Together these data suggest that, prior to rejection, peripheral 
donor specific CTL with a high avidity selectively home to the graft and differentiate into 
mature CTL which mediate graft destruction. 
In the present study, donor specific CTL clones obtained from the graft and peripheral blood 
of heart transplant patients were analyzed for their IL-2, IL-4, IL-6, and IFN-'Y production 
profile and the results were compared with their avidity for donor Ag. It appeared that CTL 
clones that differed in the avidity with which they interacted with donor cells were distinct 
with respect to their IFN-'Y production profile. CTI, clones that interacted with donor cells 
with a high avidity produced significant amounts of IFN-'Y after donor stimulation while CTL 
clones that associated with donor cells with a low avidity did not. 
IFN-'Y is considered to playa potential role in allograft rejection as it is believed to recruit 
macrophages into the graft, activate macrophages and lymphocytes, and increase the 
immunogenicity of the allograft by enhancing MHC expression on donor tissue (Halloran et 
al, 1993). In support of this concept, proteins and/or transcripts for intragraft IFN-'Y have 
consistently been shown to correlate with transplant rejection (Kupiec-Weglinski et al, 1993; 
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Mottramm et al, 1995; Egawa et al, 1995). The fact that high avidity CTL produce IFN-y 
when they encounter donor cells whereas low avidity CTL do not, therefore, underscores our 
concept that high avidity CTL are involved in allograft rejection (Ouwehand et al, 1993; 
Vaessen et al, 1994; Van Emmerik et al, 1996, 1997; Roelen et al, 1995). 
Stimulation of high avidity CTL clones with third party B-LCL did not result in IFN-y 
production demonstrating that the release of this cytokine after donor stimulation is specific 
and hence is based on TCR-MHC/peptide interactions. To explain a relationship between the 
avidity of T cells and their ability to produce IFN-y, we should bear in mind that the avidity 
of a T cell as defined by CD4/CD8 inhibition studies actually reflects the overall strength of 
TCR-MHC/peptide interactions (AI-Ramadi et al, 1995; Kim et al, 1996). Most likely, the 
overall strength ofTCR-MHC/peptide interactions determines the intensity ofTCR triggering 
and consequently whether thresholds of intracellular signal pathways leading to IFN-y 
production are reached. In support of this view, low avidity CTL clones were fully capable 
of producing IFN-y after stimulation by immobilized anti-CD3 mAb, a stimulus which 
bypasses the requirement for TCR-Iigand association. 
The above theory suggests that the IFN-y production profile of T cells is governed by the 
avidity with which these cells interact with Ag-bearing cells. Some other studies support this 
view. It has been reported that antigenic peptides that bind well to MHC molecules and/or 
TCR favour the generation of IFN-y producing cells whereas peptides that bind less well do 
not (Ffeiffer et al, 1995, Kumar et al, 1995). Additionally, it has been shown that TCR 
transgenic CD4+ T cells differentiate into IFN-y producing T cells only when high Ag doses 
are used for priming (Constant et al, 1995). In these studies, the extent of TCR-MHC/peptide 
interactions is enhanced and hence the avidity of the T cell-antigenic cell interaction. 
Also the production of IL-2 by CD8+T cells (Heath et al, 1993; Cai and Sprent, 1994) and 
IL-4 by CD4 +T cells (Ffeiffer et al, 1995; Kumar et al, 1995; Constant et al, 1995) has been 
reported to depend on the avidity with which these cells bind Ag-bearing cells. We, however, 
did not find any distinction between high and low avidity CTL with respect to their JL-2 or 
IL-4 production profile. The reported association between the production of JL-4 and the 
avidity of the interaction was found to depend upon the use of naive cells as the starting 
population (Constant et al, 1995). Accordingly, Ihe observed disparity in data mighl be 
explained by the differentiation status of the T cell population examined. While all above 
mentioned sludies were performed on naive T cell populations, we used mature T cells. 
Additionally, above mentioned studies were performed on murine T cell subsets (either CD4 + 
or CD8+T cells) with unknown cytolytic potential whereas we used human CTL clones as 
Ihe starting population. These variables (human versus murine T cells; CTL versus T cells 
which may not be cytolytic; and T cell clones versus T cell subsets) might also have 
contributed to the diversity in data. 
An additional point we would like to emphasize in this manuscript is that the type of stimulus 
used to assess the cytokine production profile of cells has an important impact on their 
response. More clones produced a particular cytokine after CD3 stimulation than after Ag-
85 
specific stimulation. Low avidity donor specific CTL clones, generally unable to produce 
IFN-r after stimulation with donor cells, did produce significant amounts of IFN-r after CD3 
stimulation. Likewise, CD3 stimulation led to IL-2 and IL-4 production by clones that failed 
to produce these cytokines after Ag-specific stimulation. Our data are in line with those of 
Maccalli et aI. (1994) who demonstrated that the cytokine pattern in response to the Ag-
specific stimulus was different from the one induced by CD3 stimulation. Hence, it is clear 
that the cytokine profiles of T-Iymphocytes can be easily modulated by the type of activation 
signals delivered to the T cells. 
In conclusion, our in vitro studies show that the avidity of donor specific CTL determines 
their ability to produce IFN-r when they encounter donor cells. If a similar situation exists 
in vivo, this may be the explanation for the earlier observed association between the avidity 
of graft infiltrating CTL and the rejection status of the transplanted human heart. 
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Chapter 6 
Cl. 7 monoclonal antibody designates high avidity 
CD4+cytotoxic T lymphocytes (CTL) involved in clinical 
heart rejection 
It is assumed that not all donor specific CTL but only those with a high avidity for donor 
antigens (Ag) can function as terminal effector cells in transplant rejection. In the present 
study we searched for markers that would exclusively designate these high avidity CTL. 
FACS analysis of donor specific CTL clones obtained from heart transplant patients revealed 
that high and low avidity CTL varied in their expression of p38, a surface molecule involved 
in signal transduction that is stained by the antibody Cl. 7. High and low avidity CD8+CTL 
and high avidity CD4 +CTL expressed p38 whereas low avidity CD4 +CTL did not. Non-
cytotoxic and naive CD4 +lymphocytes also lacked p38 surface expression. Therefore, we 
conclude that p38 is a marker for CD4 +lymphocytes with the potency to damage the 
transplanted heart. Accordingly, p38 might be used to analyze the contribution of CD4+CTL 
in immune responses such as transplant rejection. 
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During the last years we have focused our research on the significance of donor specific CTL 
in clinical cardiac rejection. Donor specific CTL could be recovered both from rejecting and 
stable cardiac allografts. However, donor specific CTL propagated from rejecting allografts 
could lyse donor target cells in the presence of anti-CD8 or anti-CD4 monoclonal antibodies 
(mAb) whereas those recovered from stable allografts could not (Vaessen et al, 1994; van 
Emmerik et al, 1996;1997). As CD8 and CD4 co-receptors enhance the overall strength of 
T cell receptor (TCR)-MHC/peptide interactions (De Vries et al, 1989; Auphan et al, 1994; 
AI-Ramadi et al, 1995), these data imply that CTL present within rejecting cardiac allografts 
bind donor cells with sufficient high avidity to overcome their need for CD8 or CD4 
molecules while CTL present within stable allografts bind donor cells with a low avidity. 
In the same period, Alexander-Miller and co-workers (l996A) reported that the avidity of 
virus specific CTL is critical for their in vivo efficiency. Although both high and low avidity 
CTL were able to kill viral infected cells in vitro, only high avidity CTL could do so in vivo. 
Combining these observations, we assume that CTL with a high avidity for donor cells are 
responsible for the observed myocyte damage associated with clinical cardiac rejection 
whereas low avidity donor specific CTL are not functional in vivo. 
The avidity of heart infiltrating CTL as assessed by CD8/CD4 blocking assays r""uires the 
time-consuming culturing of these cells from cardiac transplant biopsies. In the present study 
we searched for a surface marker specific for high avidity CTL which could directly inform 
us about the immunological status of the transplanted heart. 
One explanation for the observed differences in susceptibility to inhibition by anti-CD8 or 
anti-CD4 mAb exhibited by CTL could be a heterogeneous expression of CD8 or CD4 
molecules. Alternatively, as the r""uirement for CD8 or CD4 co-receptors is linked to the 
number of TCR and MHC/peptide complexes that can associate (De Vries et al, 1989), high 
and low avidity CTL might vary in their TCR density. In the present study we investigated 
these possibilities. Kane et al. (1989) showed that CTL that did not r""uire CD8 molecules 
to lyse whole target cells (high avidity CTL) became very sensitive to anti-CD8 mAb when 
tested against immobilized MHC class I molecules (where only the TCR and CD8 can 
interact). This observation implies that the CTL's r""uirement for CD8 might depend on the 
extent with which other receptor-ligand pairs compensate for CD8-MHC class I interactions. 
Therefore, we examined whether high and low avidity CTL differed in CDlla (LFA-1) and 
CD2 (LFA-2) surface expression since both molecules are implicated in adhesion and co-
stimulation of T cells (De Vries et al, 1989). Additionally, we analyzed whether high and 
low avidity CTL clones differed in activation status (CD45RO expression) or in p38 
expression. 
The expression of p38 on different leucocyte subsets has extensively been studied by Valiante 
and Trinchieri (1993). As shown by their data, p38 is a signal transduction molecule 
expressed on NK cells and approximately half of CD8+T cells. On CD8+T lymphocytes, p38 
expression correlates with higher cytotoxic activity. As high avidity CTL are reactive to cells 
expressing low levels of Ag whereas an increase in Ag density is r""uired to induce lysis by 
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low avidity CTL (Shimonkevitz et al, 1985; Mentzer et al, 1990), high avidity CTL seem 
more competent to lyse target cells than low avidity CTL. Accordingly, on the basis of p38 
expression, high avidity CTL might be distinguished from low avidity CTL. 
In the present study, donor specific CTL clones generated from peripheral blood and 
endomyocardial biopsies of heart transplant patients were stained for the above mentioned 
molecules and their phenotype was compared with their avidity. Briefly, cloned T cells were 
incubated with 2500 "Cr-Iabelled donor cells, third party cells (cells that did not share MHC 
antigens with the donor and acceptor), and NK-sensitive K562 cells at different 
effector:target (E:T) ratios in 0.2 ml culture medium. After 4 hours of incubation (37°C, 
5%CO,), supernatants were harvested and the release of "Cr was assayed in a Packard 
gamma-counter (packard Instruments, Downers Grove, USA). This study included 26 T cell 
clones that lysed donor target cells specifically. These clones were assessed for their avidity 
by performing also "Cr-release assays in the presence of 2 "g/ml mouse anti-human CD8 
(FKI8; a kind gift of Dr F Koning, University Hospital Leiden, the Netherlands) or CD4 
mAb (RIV6; a kind gift of Dr MF Leerling, RIVM, Bilthoven, the Netherlands). Addition 
of anti-CD8/CD4 mAb totally reduced donor directed lysis by 14 CD8+CTL and CD4+CTL 
clones (low avidity CTL) but did not affect the cytolytic activity of 12 other donor specific 
CD8+CTL and CD4 +CTL clones (high avidity CTL). 
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Figure 1: Donor specific CTL clones that differ in their avidity for donor antigen were examined for their p38 
surface expression by FACS analysis using PE.-conjugated Cl.7 mAb (thick lines). Thin lines indicate staining with 
PE-goat anti·mouse JgG alone. Low avidity CD4 'eTL (A) lack p38 surface expression while high avidity CD4+CTL 
(B), low avidity CDS+CTL (C), and high avidity CDS'eTL (0) express p38 on their cell surface. 
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The cell surface phenotype of both donor specific CTL subsets was successively analyzed by 
flow-cytometry after staining with a panel of mAb directly conjugated with fluorescein 
(FlTC), peridinin chlorophyll protein (pERPC), or phycoerythrin (PE). Aliquotes of lxlG' 
cells were incubated at 4·C for 30 minutes with the relevant fluorescent mAb (mAb specific 
for TCR"O (WT3l), CD8, CD4, and CD45RO were obtained from Becton Dickinson, 
California, USA; mAb specific for CD2, CDlla, and p38 were obtained from Immunotech, 
Marseille, France) in 50!,1 Hanks' balanced salt solution (Gibco, Paisley, Scotland) 
supplemented with 1 % bovine serum albumin and 0.1 % sodiumazide. Subsequently, cells 
were washed and analyzed on a FACScan {Becton Dickinson, Mountain View, CAl. Non-
specific staining of the clones was assessed by incubating the cells with irrelevant isotypically 
matched murine mAb. 
FACS analysis demonstrated that all CTL clones studied expressed comparable levels of 
TCR"n, CD8 (or CD4), CD2, CDlla, and CD45RO despite the fact that they differed in 
avidity (data not shown). Staining with PE-conjugated Ct.7 mAb, however, revealed that 
these CTL clones varied in their p38 surface expression level. Low avidity CD4 +CTL (n =8) 
did not react with CI.7 mAb and thus lack p38 surface expression (fi~ure lA) while high 
avidity CD4+CTL (figure lB; n=6), low avidity CD8+CTL (figure IC; n=6), and high 
avidity CD8+CTL (figure ID; n=6) expressed p38 on their cell surface. The level of p38 
did not alter after restimulation demonstrating that this molecule, when present, is constantly 
expressed. According to these results, the p38 molecule delineates high avidity CD4 +CTL 
from low avidity CD4 +CTL. 
Table 1: p38 expression by naive and stimulated CD4+ and CD8+T cells 
Experiment II 
CD4 CD8 CD4 CD8 
p38+T cells (%): 
- no stimulus 0 36 0 54 
- PHA stimulus 34 57 28 53 
- RIV9 stip'ulus 15 78 24 64 
Peripheral CD4+ and CD8+T lymphocytes of2 healthy blood donors were analyzed for their pJ8 surface expression 
before and S days after stimulation with either PHA or immobilized anti·CDl (RN9). The percentage of p3S-
expressing lymphocytes is shown. 
We then questioned whether p38 is expressed on other CD4 +T cells besides high avidity 
CD4 +CTL. To analyze the p38 expression on naive T lymphocytes, fresh peripheral blood 
lymphocytes (PBL) of 2 healthy volunteers were stained simultaneouly with PE-conjugated 
Ct.7 mAb and PERCP-conjugated anti-CD4 mAb or FlTC-conjugated anti-CD8 mAb. The 
FACScan results are shown in table 1. None of the CD4+T cells expressed the p38 surface 
molecule whereas 36% and 54 % of the CD8+T cells present within both PBL samples stained 
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positive. A considerable proportion of the CD4 +T cells, however, did become p38-positive 
after 5 days of stimulation with either phytohaemagglutinin (PHA; Difco, Detroit, MI, USA) 
or immobilized anti-CD3 (RIV9; RIVM). Hence, naive CD4 +T cells lack p38 but may 
become positive after priming. 
As Valiante and Trinchieri demonstrated that cell mediated cytotoxicity exhibited by CD8+T 
lymphocytes is generally restricted to those bearing p38, we questioned whether the same 
would be true for CD4 +T lymphocytes. For this analysis, five non-cytotoxic CD4 +T cell 
clones of3 heart transplant recipients were examined for their p38 expression. Additionally, 
we analyzed whether the cytotoxic capacity of p38-negativc low avidity CD4 +CTL differed 
from that of p38-positive high avidity CD4+CTL, low avidity CD8+CTL, or high avidity 
CD8+CTL. The results are depicted in figure 2. Non-cytolytic CD4+CTL totally lacked p38 
surface expression. Low avidity CD4 +CTL that are also negative for p38, lysed their specific 
target cells less efficiently than did p38-expressing CTL subsets (p=0.02; Mann Whitney U-
test). The p38-expressing CTL subsets were comparable with respect to their lytic capacity 
(N.S; Mann Whitney U-test). 
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Figure 2: The ability ofT cell clones obtained from beart transplant patients to lyse donor target cells in 'ICr-release 
assays (E:T ratio = 5:1) is compared with their p38 surface expression. Non-cytoloxic T ceUs (CD4-) do not express 
p38. Low avidity CD4+CTL (CD4L). that also lack p38, are less destructive (p<O.02) lowards donor target cells 
than p38-expressing high avidity CD4+CTL (CD4H), low avidity CDS+CTL (CD8L), or high avidity CD8+CTL 
(CDSH). 
Although this observation implies that T cells lacking p38 surface expression are not cytolytic 
or less efficient CTL, the reverse is not always true. As shown in figure 2, p38-expressing 
CTL clones vary enormously in their ability to lyse their specific target cells (range: 16-90% 
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lysis). Four of these CTL clones lysed their target cells in the same range as low avidity 
CD4+CTL. However, in contrast to low avidity CD4 +CTL, these clones did stain with C1.7 
mAb. 
In an attempt to analyze the significance of p38 on CTL, we examined whether blocking of 
this molecule would affect their cytolytic capacity. Concentrations of C1.7 mAb reported to 
modify non-HLA-restricted cytotoxicity of lymphocytes and NK cells (Valiante and 
Trinchieri, 1993) did not influence antigen-specific lysis by p38-expressing CTL clones in 
"Cr release assays demonstrating that CTL do not require this molecule to interact with their 
specific target cells (table 2). 
Table 2: Effect of p38 blocking on the cytolytic capacity of CTL. 
%Iysis 
0 0.01 0.1 10 I'g/ml C1.7 
CD4 low 26 13 21 29 32 
CD4 high 52 51 47 49 53 
CD8 low 67 54 66 60 62 
CD8 high 57 51 40 51 59 
Donor specific CD4 ·CTL (E:T = 5:1) and CD8+CTL (E:T = 2.5: 1) clones with either a high or a low avidity were 
tested for their capacity to lyse donor target cells in the presence of increasing concentrations of soluble Cl.7 mAb. 
Although the existance of CD4+T cells with cytolytic potential has long been accepted, most 
studies on CTL still elaborate on the assumption that all cytotoxic T cells are contained in 
the CD8+subset. Due to this prejudice, the contribution of CD4 +CTL in immune responses 
has largely been overlooked. According to our studies on cardiac transplant patients, 
approximately half of the graft derived cell cultures displayed cytotoxicity towards donor 
HLA class II antigens (Van Emmerik et ai, 1997). As for donor HLA class I specific 
CD8+CTL, the avidity of donor HLA class II specific CD4 +CTL correlated with the 
rejection status of the cardiac transplant. Donor HLA class II specific CD4 +CTL propagated 
from rejecting grafts mainly had a high avidity for donor Ag whereas those established from 
stable grafts mainly had a low avidity. According to the current concept, high avidity CTL 
are able to display their cytotoxic function in vivo whereas low avidity CTL are not. In the 
present study it is shown that high avidity CD4+CTL are the only cells within the 
CD4 +lymphocyte population that express p38 on their cell surface. Accordingly, histological 
staining of high avidity CD4 +CTL by p38 might provide us with a tool to directly examine 
the contribution of in vivo functional CD4+CTL in immune processes such as allograft 
rejection. It might reveal when CD4 +CTL come into play and which cells serve as their 
target. 
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Summary and discussion 
Although it is well established that T-lymphocytes are required for allograft rejection, there 
is still controversy over which cell subset is responsible for the tissue destruction. Support 
for the involvement of CTL as terminal effector cells is provided by experiments showing 
the exquisite antigen specificity of the alloresponse (Sutton et aI, 1989; Mintz and Silver, 
1967) and the ability of CTL clones grown from rejecting allografts to destroy allogeneic 
tissue when injected into appropriate hosts (Snider et aI, 1986). However, donor specific 
CTL were also found within transplants in which no histological evidence of rejection was 
found. If allospecific CTL are implicated in graft rejection, the question arises why their 
presence does not automatically result in graft destruction. To explain these contradicting 
data, two speculations were made. the occurrence of graft damage may depend on the 
number of donor specific CTL present within the allograft. Alternatively, donor specific CTL 
that populate the allograft in the presence or absence of rejection may have different 
characteristics. In the present thesis, both possibilities were studied to analyze the relevance 
of donor specific CTL in the development of acute cardiac rejection in human. 
Our first study (chapter 2) concerned the importance of CTL directed towards donor HLA 
class I antigen. Endomyocardial biopsies routinely taken for the diagnosis of acute cardiac 
rejection, were cultured to obtain graft infiltrating lymphocytes (GIL). The number of donor 
class I specific CTL present among serial GIL cultures was then estimated by a modified 
limiting dilution assay (LDA). The data of this longitudinal follow-up study demonstrated that 
donor class I specific CTL that had been activated in vivo (cCTL) and their precursors 
(PCTL) both accumulate within the graft during acute rejection. After successful rejection 
therapy, donor specific cCTL and pCTL frequencies recovered to levels found before 
rejection. This observation implies that the number of graft infiltrating, donor class I specific 
CTL might be relevant for the OCCurrence of acute cardiac rejection. 
Subsequently, these graft infiltrating CTL were divided into CTL with a high or a low 
avidity for donor class I antigen based on their resistance or sensitivity to anti-CD8 mAb, 
respectively. The results revealed that donor specific cCTL and pCTL propagated from EMB 
taken during or immediately preceding acute cardiac rejection generally had a high avidity 
for donor antigen. In contrast, donor specific cCTL and pCTL grown from EMB obtained 
before or after the rejection period generally had a low avidity for donor antigen. According 
to these data we reasoned that high avidity CTL might be implicated for allograft rejection 
whereas low avidity CTL might not be involved. Support for this hypothesis was only 
recently provided by Alexander Miller et al (l996A). According to their data, the in vivo 
functionality of CTL depends on their avidity for antigen. High avidity CTL efficiently 
cleared antigen-bearing cells in vivo whereas low avidity CTL lines, though effective in 
vitro, were incompetent. 
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The relationship between the occurrence of graft rejection and the presence of high avidity 
CTL was then extended to donor HLA class II specific CTL (chapter 3). Lymphocyte 
cultures established from EMB exhibit cytotoxicity towards donor HLA class II determinants 
in 46% of the cases. We analyzed the frequency of donor HLA class II specific cCTL within 
these cultures and compared the results with the rejection status of the transplant. Frequencies 
of donor class II specific cCTL found during a rejection period were comparable to values 
found in the absence of rejection. Addition of anti-CD4 mAb to the LDA revealed how many 
of the class II specific cCTL enumerated could be scored as high (resistant to anti-CD4 mAb) 
or low avidity cCTL (sensitive to anti-CD4 mAb). During a rejection episode, the majority 
of the class II specific cCTL had a high avidity for donor antigen. In the absence of 
rejection, class II specific cCTL mainly had a low avidity for donor antigen. These data 
support the concept that CTL with a high avidity for donor antigen are implicated in the 
rejection process whereas CTL with a low avidity are not. 
The accumulation of high avidity CTL within the cardiac allograft implies the migration of 
these cells towards the allograft before acute rejection is diagnosed by histology. 
Accordingly, the kinetics of high avidity CTL within the peripheral blood might inform us 
about the immunological status of the transplanted heart and by that provide a method to 
monitor for acute rejection (chapter 4). In order to assess this idea, donor specific CTL 
present within peripheral blood samples of heart transplant recipients obtained immediately 
preceding and at various timepoints after transplantation were enumerated by LDA. 
Subsequently, we analyzed how many of the donor specific CTL present could be scored as 
high avidity CTL. The fraction of donor specific CTL with a high avidity was then compared 
with the rejection status of the cardiac allograft. 
Donor specific cCTL were rarely observed within the peripheral blood indicating that donor 
specific CTL circulate as pCTL. Since cCTL can be detected within the graft, this 
observation demonstrates that the final differentiation of pCTL into cCTL occurs at the graft 
site. The number of donor specific pCTL among the peripheral blood cells was found to 
fluctuate in· time after transplantation and did not associate with the rejection status of the 
graft. During acute rejection, however, a significant higher fraction of these donor specific 
pCTL had a high avidity for donor antigen when compared to values found before the 
diagnosis of rejection or after rejection therapy. More than one year after transplantation, 
when all patients included in the study had achieved stable engraftment, high avidity pCTL 
were even absent. These observations imply that changes in the overall avidity of circulating 
donor specific pCTL reflect immunological processes occurring within the allograft. The 
application of this technic for non-invasive monitoring of acute cardiac rejection, however, 
is currently hindered by the duration of the experiments (10 days). 
Combining the results of the graft and the peripheral blood, we assume that, prior to acute 
cardiac rejection, circulating donor specific pCTL with a high avidity selectively home to the 
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transplanted heart. At the graft site these pCTL differentiate into functional cCTL with a high 
avidity. Sufficient numbers of these cCTL then cause graft damage as observed by histology. 
Subsequent anti-rejection therapy terminates the process again by depleting lymphocytes both 
in the graft and in the circulation. The importance of circulating CTL with a high avidity for 
donor antigen for the initiation of the rejection cascade is supported by the observation that 
high avidity, donor specific pCTL have disappeared from the peripheral blood when stable 
engraftment is achieved. 
The above data suggest that not all donor specific CTL but only those with a high avidity for 
donor antigen are important for the rejection process. Accordingly, the characterisation of 
this particular subset might shed light on pivotal events in allograft rejection and support the 
development of selective immunotherapeutic strategies. As the cytoldne profile of cells often 
corresponds with their function we examined whether high and low avidity CTL were distinct 
with respect to their cytoldne production profile (chapter 5). Obtained data demonstrated that 
both subsets differ with respect to their IFN-'Y production profile. Stimulation with donor 
cells resulted in IFN-'Y secretion by high avidity CTL but not by low avidity CTL. CD3 
stimulation, on the contrary, led to secretion of equivalent amounts of IFN-'Y by both CTL 
subsets. These observations indicate that low avidity CTL are fully capable to produce IFN-'Y 
but, in contrast to high avidity CTL, fail to do so when they encounter donor cells. As IFN-'Y 
favours the occurrence of transplant rejection, the production of this cytoldne by high avidity 
CTL might explain the earlier observed association between the presence of these cells and 
the rejection status of the transplanted human heart. 
Additionally, we analyzed whether high and low avidity CTL differed with respect to their 
surface phenotype. In chapter 6, we describe a surface molecule, p38, which delineates high 
avidity CTL within the CD4+lymphocyte population. We believe that this marker provides 
us with a tool to analyse the contribution of CD4+CTL in cardiac rejection and to define 
their target cells (as human myocytes may not serve as target cells as they lack MHC class 
II). Additionally, staining of routinely taken endomyocardial biopsies for both p38 and CD4 
expression, might predict the occurrence of acute rejection. Kinetic studies of donor specific, 
high avidity CTL demonstrated that these cells are absent within stable cardiac allografts, but 
start accumulating approximately 2 weeks prior to the diagnosis of acute rejection (chapter 
2). As a result, increases in the number of high avidity CTL present within the cardiac 
allograft would predict the occurrence of acute rejection. As CD4 +CTL are found in a 
significant proportion of cardiac biopsies (chapter 3), immunohistochemical analysis of 
CD4+p38+lymphocytes would inform us about the number of high avidity, donor specific 
CTL among graft infiltrating CD4+T cells and hence about the rejection status of the cardiac 
allograft. 
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Samenvatting 
Hoewe! het algemeen geaccepteerd is dat T cellen een essentie!e fa! spe!en bij 
transp!antaatafstoting blijft de bijdrage van de afzonderlijke T ce! subsets en met name die 
van de cytotoxische T cellen (CTL) een punt van discussie. Zoals vermeld in hoofdstuk I van 
dit proefschrift doet de specificiteit waarmee het afstotingsprocces verioopt sterk vermoeden 
dat CTL functioneren als terminale effector cellen wiens specifieke binding aan donorcellen 
!eidt tot de destructie van de laatsten. Echter, donorspecifieke CTL worden ook aangetroffen 
in transplantaten welke geen tekenen van afstoting vertonen. Wanneer CTL daadwerkelijk 
verantwoordelijk zijn voor de weefselschade die een afstoting karakteriseren dan rijst de 
vraag waarom de aanwezigheid van deze cellen in het transplantaat niet altijd gepaard gaat 
met afstoting. Van de mogelijke verklaringen werden er twee onderzocht: I. Het optreden 
van afstoting zou athankelijk kunnen zijn van het aanta! in het transplantaat aanwezig zijnde 
donorspecifieke CTL. II. Het optreden van afstoting zou athankelijk kunnen zijn van het type 
donorspecifieke CTL dat in het transplantaat aanwezig is. 
Het eerste onderzoek waarvan de data beschreven staan in hoofdstuk 2 betreft CTL die 
donor HLA klasse I antigenen herkennen. Endomyocardbiopten, op verschillende tijdstippen 
na transplantatie afgenomen voor de diagnose van afstoting, werden in kweek gebracht om 
zo de transplantaat infiltrerende lymfocyten (TIL) te verkrijgen. Vervolgens werd met behulp 
van limiting dilution analysis (LDA) het aantal donor HLA klasse I specifieke CTL dat zich 
onder deze TIL bevond bepaald. Deze longitudinale studie toonde aan dat in vivo 
geactiveerde donor HLA klasse I specifieke CTL (cCTL) en hun naive precursors (PCTL) 
beide aanwezig waren in het transplantaat ongeacht de afstotingsgraad van de laatste maar 
dat hun aantal drastisch toenam kort voor en tijdens afstoting. Na een succesvolle 
afstotingsbehandeling daalden de donorspecifieke cCTL en pCTL frequenties weer tot 
waarden die voor de aanvang van afstoting gevonden werden. Deze waameming impliceert 
dat het aantal in het transplantaat aanwezig zijnde donor HLA klasse I specifieke CTL van 
belang is voor het optreden van acute afstoting. 
Vervolgens werden deze donor HLA klasse I specifieke CTL onderverdeeld in CTL met een 
hoge of een lage aviditeit voor donor-antigeen al naar gelang hun (on)gevoeligheid voor 
CD8-blokerende antilichamen. De verkregen data onthulden dat donor HLA klasse I 
specifieke pCTL en cCTL gekweekt uit afstotingsbiopten of uit biopten afgenomen kart voor 
(1-2 weken) afstoting een hoge aviditeit voor donor-antigeen hadden terwijl CTL afkomstig 
uit EMB die op andere tijdstippen afgenomen waren juist een lage aviditeit voor donor-
antigeen hadden. Deze resultaten leidden tot de hypothese dat alleen hoog avide 
donorspecifieke CTL betrokken waren bij transplantaatafstoting. Deze hypothesis werd 
onlangs gesteund door data van Alexander-Miller en medewerkers (l996A) welke aantoonden 
dat het in vivo functioneren van virus specifieke CTL athing van hun aviditeit. 
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De gevonden relatie tussen het optreden van transplantaatafstoting en de aanwezigheid van 
hoog avide erL werd nu uitgebreidt naar donor HLA klasse IT spedfieke CTL, een erL 
subset wiens impact in immunologische processen vaak verwaarloosd wordt. Onze studies 
lieten echter zien dat deze subset uit 46% van de endomyocardbiopten gekweekt kon worden, 
een percentage dat niet overeenstemt met een onbeduidende rol (hoofdstuk 3). Het aantal 
donor HLA klasse II specifieke cCTL in deze biopt cultures werd bepaald met behulp van 
LDA en vergeleken met de afstotingsgraad van het transplantaat. In tegenstelling tot de data 
gevonden voor donor HLA klasse I specifieke cerL (hoofdstuk 2) werd er geen correlatie 
gevonden tussen de frequentie aan donor HLA klasse II specifieke cerL en de mate van 
afstoting. 
Toevoeging van anti-CD4 antilichamen aan de LDA onthulde welk percentage van de 
aanwezige HLA klasse II specifieke cerL een hoge aviditeit (i.e. resistent tegen CD4-
blokerende antilichamen) en welk percentage een lage aviditeit (i.e. gevoelig voor CD4-
blokerende antilichamen) voor donor-antigeen had. Deze studie toonde aan dat donor HLA 
klasse II specifieke cCTL die aanwezig zijn in het getransplanteerde hart ten tijde van 
afstoting nagenoeg allen een hoge aviditeit voor donor-antigeen hadden. Dit in tegenstelling 
tot diegene die in het hart aangetroffen werden gedurende een periode zonder afstoting en 
met name een lage aviditeit hadden. 
De accumulatie van hoog avide erL in het getransplanteerde hart suggereert de migratie van 
deze cellen naar het transplantaat voordat acute afstoting gediagnostiseerd wordt. Dit gegeven 
impliceert dat de kinetiek van hoog avide donor specifieke erL in het bloed informatie zou 
kunnen verstrekken over de immunologische status van het getransplanteerde hart zonder dat 
daarvoor biopten afgenomen behoeven te worden. Om deze optie te verifieren werd in 
bloedmonsters die op verschillende tijdstippen na transplantatie afgenomen waren de 
frequentie en aviditeit van donor HLA klasse I specifieke erL bepaald. Vervolgens werden 
deze gegevens vergeleken met de afstotingsgraad van het getransplanteerde hart op het 
moment van bloedafname. De resultaten van deze studie staan beschreven in hoofdstuk 4. 
Donor specifieke cerL werden zelden aangetroffen in de bloedmonsters wat aangeeft dat 
donorspecifieke CTL cireuleren als perL. Voorgaande studies hebben echter aangetoond dat 
eCTL aanwezig zijn in het getransplanteerde hart. Deze waameming demonstreert dat de 
uiteindelijke differentiatie van perL naar eerL plaatsvindt in het transplantaat. Het aantal 
donor specifieke perL in het perifere bloed vertoonde fluctuaties in tijd na transplantatie 
welke niet associeerde met de rejectie status van het transplantaat. Wanneer men echter de 
aviditeit van de aanwezige donor specifieke pCTL in besehouwing nam dan bleek dat, net 
als in de voorgaande studies, het percentage donor specifieke pCTL met een hoge aviditeit 
steeg tijdens acute afstoting; i.e. hoog avide donor specifieke perL waren prominenter 
aanwezig in het bloed van harttransplantatie patienten ten tijde van afstoting. 
Meer dan 1 jaar na transplantatie bleek de "rust" in het transplantaat wedergekeerd daar geen 
van de onderzochte harttransplantatie patienten nog afstoting ondervond. Hoewel het aantal 
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donor specifieke pCTL dat in deze periode in het bloed aanwezig was niet afweek van 
eerdere waardes bleken hoog avide pCTL verdwenen te zijn. Deze down-regulatie van hoog 
avide donor specifieke pCTL (maar niet van laag avide donor specifieke pCTL) ten tijde van 
"immunologische rust" gecombineerd met hun toename ten tijde van afstoting impliceert het 
belang van deze subset bij afstoting. Bovendien suggereert het dat de kinetiek van 
circulerende donor specifieke hoog avide pCTL ons kan informeren over de welsland van het 
transplantaat, een gegeven dat nieuwe deuren opent voor non-invasieve monitoring van acute 
cardiale afstoting. 
Wanneer we de tot nu toe verkregen data bundelen komen we tot het volgende concept. Kort 
voor acute afstoting optreedt migreren pCTL met een hoge aviditeit voor donor-antigeen 
selectief naar het getransplanteerde hart waar zij accumuleren en uitdifferentieren tot 
functionele cCTL. Ben voldoende aantal van deze cCTL leidt nu tot histologisch 
waarneembare myocytschade (i.e. acute afstoting). De hierop volgende anti-rejectie therapie 
beeindigt het process door de depletie van T-lymfocyten in de periferie en het transplantaat. 
Het belang van circulerende CTL met een hoge aviditeit voor donor-antigeen voor het 
initieren van de afstotingscascade wordt ondersteund door het gegeven dat deze subset na I 
jaar, wanneer afstoting nog zelden optreedt, uit het bloed verdwenen is. Dit concept houdt 
in dat niet aile donor specifieke CTL maar slechts diegene met een hoge aviditeit for donor-
antigeen van belang zijn voor het afstotingsproces. De karakterisering van deze subset zou 
dan ook informatie kunnen verstrekken over de immunologische fasen die leiden tot 
transplantaat afstoting. Daarnaast zou de karakterisering van deze subset een potenticle 
waarde kunnen hebben voor de ontwikkeling van selectieve immunotherapeutische 
strategieen. 
Daar het cytokine profiel van cellen vaak informatie verschaft over hun functie werd 
onderzocht of hoog en laag avide CTL verschilden in cytokine productie profiel. De 
resultaten van dit onderzoek staan beschreven in hoofdstuk S. Beiden CTL subsets bleken 
te verschillen in hun IFN-'Y productie profiel. Ben encounter met donor cellen induceerde de 
productie van IFN-'Y door hoog avide CTL maar niet door laag avide CTL. CD3-stimulatie 
daarintegen induceerde de produktie van geIijke hoeveelheden IFN-'Y door beide CTL 
subsets. Deze waarneming impliceert dat laag avide CTL volledig capable zijn om IFN-'Y te 
produceren maar dat zij in tegenstelling tot hoog avide CTL dit niet doen wanneer zij donor 
cellen tegen komen. Het is bekent dat IFN-'Y seeretie het optreden van afstoting begunstigd. 
De produktie van dit cytokine door hoog avide CTL ondersteunt dan ook de eerder gevonden 
relatie tussen de aanwezigheid van hoog avide CTL in het humane getransplanteerde hart en 
het optreden van afstoting. 
Ben volgend onderzoek richlte zich op het fenotype van hoog en laag avide donor specifieke 
CTL. Onderzocht werd of dat beide subsets verschilden in de expressie van oppervlakte 
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moltx!ulen. In hoofdstuk 6 beschrijven we p38, een oppervlakte moltx!uul dat herkend wordt 
door het C1.7 antilichaam en dat aileen op hoog avide CTL binnen de CD4+T cel populatie 
tot expressie komt. Gezien dit resultaat geloven wij dat deze marker gebruikt kan worden om 
de bijdrage van CD4 +CTL in cardiale afstoting te onderzoeken en indirtx!t om de target 
cellen van CD4+CTL te definieren. Op dit moment is het namelijk nog onduidelijk ofdat 
humane myocyten herkent kunnen worden door CD4 +CTL daar zij geen HLA kIasse IT 
moltx!ulen tot expressie brengen. Met enig optimisme lOU het aantal p38+CD4+T cellen dat 
in opeenvolgende endomyocardbiopten aanwezig is ook het optreden van acute afstoting 
kunnen voorspellen. 
Kinetiek studies demonstreerden dat donor HLA kIasse I specifieke hoog avide CTL tot 2 
weken voor afstoting afwezig zijn in het getransplanteerde hart waarna zij in groten getale 
in het transplantaat accumuleren (hoofdstuk 2). Dit geeft aan dat een toename van hoog avide 
CTL binnen het getransplanteerde hart gezien kan worden als een voorbode van acute 
afstoting. Daar CD4 +CTL in een significant percentage van de endomyocardbiopten aanwezig 
zijn (hoofdstuk 3), zou immunohistochemischeanalyse van CD4+p38+1ymfocyten ons kunnen 
informeren over het aantal hoog avide donor specifieke CTL binnen de transplantaat 
infiltrerende CD4 +T cel populatie en daarmee over de rejtx!tie status van he! 
getransplanteerde hart. 
109 
List of pUblications 
Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijksen G, Jackman AL, and Schornagel 
JH. Membrane transport of natural folates and anti-folate compounds in murine L1210 leukemia 
cells: Role of carrier- and receptor-mediated transport systems. Cancer Res 1991; 51:5507-5513. 
Vandebriel RJ, Van Wichen DF, Van Poppel MN, Robertus-Teunissen M, Zimmermann D, 
Korswagen HC, van Emmerik NE, De Weger RA. Specific T-cell factor production and 
lymphocytes in the direct surroundings of a subcutaneous allogeneic tumor. Cell ImmunoI1992; 
144: 269. 
Baan CC, van Emmerik NEM, Balk AHMM, Quint WGY, Mochtar B, Jutte NHPM, Niesters 
HGM, Weimar W. Cytokine mRNA expression in endomyocardial biopsies during acute rejection 
from human heart transplants. Clin Exp Immunol1994; 97: 293-298. 
van Emmerik NEM, Baan CC, Vaessen LMB, JUlie NHPM, Quint WGY, Balk AHMM, Bos E, 
Niesters HGM, Weimar W. Cytokine gene expression profiles in human endomyocardial biopsy 
(EMB) derived lymphocyte cultures and in EMB tissue. Transpllnt 1994; 7: S623-S626. 
Daane CR, van Besouw NR, van Emmerik NEM, Baan CC, Balk AHMM, Jutte NHPM, 
Niesters HGM, Vaessen LMB, Weimar W. Discrepancy between mRNA expression and 
production of IL-2 and IL-4 by cultured graft infiltrating cells propagated from endomyocardial 
biopsies. Transpl 11111994; 7: S627-S628. 
van Emmerik NEM, Vaessen LMB, Balk AHMM, Bos E, Claas FHJ, Weimar W. Progressive 
accumulation of CTL with high avidity for donor antigens during the development of acute 
cardiac rejection. Transplalllation 1996; 62: 529-30. 
van Emmerik NEM, Loonen EHM, Vaessen LMB, Balk AHMM, Mochtar B, Claas FHJ, 
Weimar W. The avidity, not the mere presence, of donor HLA class II specific CTL correlates 
with acute cardiac rejection. J Bean Lllng Transplalll1997; 16: 240-5f'. 
van Emmerik NEM, Vaessen LMB, Knoop CJ, Daane CR, Balk AHMM, Mochtar B, Claas 
FHJ, Weimar W. Kinetics of circulating CTL precursors that have a high avidity for donor 
antigens: Correlation with the rejection status of the human cardiac allograft. SlIbmiffed. 
van Emmerik NEM, Daane CR, Knoop CJ, Hesse C, Vaessen LMB, Balk AHMM, Mochtar B, 
Claas FHl, Weimar W. The avidity of allospecific CTL determines their cytokine production 
profile. Clin Exp 1111111110011997; 110:447-453. 
van Emmerik NEM, Knoop CJ, Vaessen LMB, Balk AHMM, Mochtar B, Claas FHJ, Weimar 
W. C1.7 delineates high avidity CD4+lymphocytes involved in clinical heart rejection. 
Transplantation, In press. 
'nominated for the Caves Award 1996. 
110 
Curriculum Vitae 
De auteur van dit proefschrift werd op 9 september 1968 te Goirle geboren. In 1986 behaalde 
zij het Atheneum B diploma aan de Rijksscholengemeenschap Koning Wmem II te Tilburg. 
In dat zelfde jaar begon zij aan de studie Medische Biologie aan de Rijksuniversiteit Utrecht. 
Als student werkte zij gedurende 8 maanden bij de afdeling Oncologie van het AZU waar 
zij onder leiding van Dr. G. Westerhof en Dr. G. Jansen participeerde in onderzoek naar het 
membraantransport van folaten en folaat-analogen in tumorcellen. Deze bijvakstage werd 
opgevolgd door een hoofvakstage van 15 maanden bij de afdeling Experimentele Pathologie 
van het AZU waar onder leiding van Dr. R. Vandebriel en Dr. R. de Weger de 
betrokkenheid van 'YoIT cellen in de immuunrespons tegen allogene tumoren onderzocht werd. 
Het doctoraal diploma werd in Augustus 1992 afgelegd. Vervolgens werd zij als AID 
aangesteld bij de afdeling Thoraxchirurgie (hoofd: Prof. Dr. E. Bos) en werlde onder 
supervisie van Prof. Dr. W. Weimar op het transplantatielab van de afdeling Interne 
Geneeskunde I van het Academisch Ziekenhuis Rotterdam aan het in dit proefschrift 
beschreven onderzoek. Vanaf 1 juli 1997 is zij als post-doc werkzaam bij de afdeling 
Cellulaire Immunologie van het NIMR instituut te Londen. 
111 
Dankwool'd 
Tijdens mijn AIO periode heb ik er vaak aan getwijfeld of mijn werk tot een proefschrift lOU 
leiden. Het waren 4 (en nog wat) jaren waar ik me door het ene, dan weer het andere 
probleem heen leek te worstelen. Ik ben dan ook dank verschuldigd aan de mensen van de 
Interne I. Graag wil ik mijn promotor Willem bedanken voor de kritische begeleiding van 
het onderzoek, voor het vakkundig nakijken van manuscripten ondanks het hoge gehalte aan 
"immunologisch gewouwel", en voor zijn inzet ( ... en natuurlijk die van Willie) om de sociale 
band tussen zijn mensen te versterken (etenties, labweekenden). Van het lab wil ik een aantal 
mensen met name bedanken voor hun essentiele bijdragen aan dit proefschrift. Len, jij hebt 
me laten zien dat ik in staat ben om zelfstandig onderzoek te doen. Bedankt voor je 
vertrouwen. Chris, Rene, en Lisette, jullie wil ik bedanken voor de keren dat juUie mijn 
enthousiasme voor een gelukt experiment deelden, voor de keren datjuUie me spontaan werk 
uit de hand namen wanneer een onverwachte groeistuip van klonen en cellijnen ervoor lOrgde 
dat alle testen tegelijkertijd uitgevoerd moesten worden en voor het feit dat juUie wat 
structuur in mijn vaak chaotische werkwijze hebben gebracht. Nicolet, Cees, Fransisca, 
Nicole, Carla, Barbara, Paula, Ronella, Wendy, Cecile, en Sjors wil ik bedanken voor de 
gezellige labborrels, het invoeren van de droppot en vreemde theeen, en voor de vaak 
"Ieerzame" discussies. Ook Frans Claas, Egbert Bos en Aggie Balk wil ik bedanken voor hun 
interesse en positieve benadering van mijn werk als ook voor het nauwkeurig corrigeren van 
mijn artikelen. 
Meer nog dan naar aile anderen gaat mijn waardering uit naar ons marn en pap; het feit dat 
jullie altijd vierkant achter me staan en trots op me zijn ongeacht mijn prestaties en keuzes 
geeft mij de kracht om devolgende stap te wagen wetend dat ik altijd een plaats heb om naar 
terug te gaan. Richard, Sheila, en Dave, jullie waardeerden mijn werk vanuit een compleet 
andere hoek; een congres in de States ........ Levis, Ralph Lauren, en Disney! !!!. ... Bedankt! 
Ook mijn schoonouders wil ik via deze weg bedanken voor hun altijd aanwezige interesse. 
En als laatste, Pim. Pim, ik zou deze hele pagina weI vol kunnen schrijven met dingen 
waarom ik jouw waardeer en hoe je mij altijd weer helpt maar dat weet je allemaal al. 
Daarom wil ik slechts zeggen: "Pimmie, zander jou zijn de meeste dingen aanzienlijk minder 
de moeite waard". 
112 
